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ABSTRACT
This thesis describes the first randomized controlled trial on the ketogenic diet as a 
treatment for children with drug-resistant epilepsy. It asks two main questions. Firstly, 
are there clear benefits on seizure control in children treated with the ketogenic diet as 
compared with no additional treatment?; and secondly, is the classical ketogenic diet 
more efficacious than the medium chain triglyceride (MCT) ketogenic diet, as often 
claimed but not supported by scientific evidence? The trial also examines the 
tolerability o f the two diets, and their effect on growth.
145 children were randomized to receive the classical or MCT diet, either 
immediately or after a 3-month delay with no change in treatment (control group). 
Seizure frequency was assessed after 3 months, compared to that of controls. 
Efficacy and tolerability o f the two diets was compared at 3, 6 and 12 months. Growth 
was assessed during the study period. Clear guidelines on calculation o f both diets 
were developed, as was an electronic ketogenic calculator to reduce the burden o f 
time spent on recipe calculations.
Results show children on a ketogenic diet to have significantly reduced numbers o f 
seizures after 3 months, as compared to the control group. Despite increased ketone 
levels in classical diet children, there was no difference in efficacy between the two 
diets at 3, 6 or 12 months. There was no difference in gastro-intestinal tolerability; 
both diets caused increased cholesterol levels, but increased triglyceride levels were 
seen in the classical group only. Many children did show compromised growth during 
the study, but after 12 months, there was no significant difference in growth outcome 
between the two diets.
These results strongly support using the ketogenic diet in childhood epilepsy. 
Classical and MCT diets are comparable in efficacy, tolerability and growth 
outcomes; both protocols continue to have their place in the treatment o f this group o f 
children.
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CHAPTER 1 
THE KETOGENIC DIET IN CHILDHOOD EPILEPSY
Contents
1.1 Epilepsy -  background, definitions and epidemiology
1.2 Prognosis and treatment
1.3 Development o f  the ketogenic diet
1.4 The classical ketogenic diet
1.5 The medium chain ketogenic diet
1.6 Availability and efficacy o f  the ketogenic diet
1.7 Comparison o f  the classical and M CT ketogenic diets
1.8 Aims o f  this study
1.1 Epilepsy - background, definitions and epidemiology
Epilepsy is the most prevalent o f the serious neurological disorders. The 
name derives from the Greek verb ‘to be seized'. Historically, by definition the 
diagnosis has required at least two epileptic seizures. The most recent proposal by 
the International League Against Epilepsy (ILAE) and the International Bureau for 
Epilepsy (IBE) defines epilepsy as a ‘disorder of the brain characterized by an 
enduring predisposition to generate epileptic seizures and by the neurobiologic, 
cognitive, psychological and social consequences o f this condition' (Fisher et al, 
2005); at least one epileptic seizure is required for this definition. Seizure activity is 
caused by an abnormal and excessive discharge from the neurons in the brain, and 
manifests as alterations in sensation, behaviour, or consciousness, and in some cases, 
as purely electrical activity, discemable only on electroencephalography (EEG).
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Seizure types can broadly be divided into two groups -  those arising from a 
single location, or focus, within the brain, termed focal seizures, and those o f a more 
generalized nature. ILAE proposals for a new diagnostic scheme for people with 
epilepsy (Engel, 2001) include updated guidelines for seizure classification (see Table 
1 . 1 ).
Table 1.1 ILAE classification of epileptic seizure types (from Engel, 
2001)
Many types of epilepsy can be classified into syndromes, based on clinical 
features, EEG results, associated development and learning, and a range o f other 
factors such as family history, age of onset, and response to treatment. The 
classification proposed by the ILAE in 1989 further divided epilepsies into idiopathic.
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symptomatic, or cryptogenic, depending on the suggested cause of the disease 
(Anonymous, 1989). ‘Idiopathic’ generally refers to genetic syndromes with no 
associated brain pathology; ‘symptomatic’ epilepsies are the result o f a known brain 
disorder, and ‘cryptogenic’ epilepsies are the result o f a brain disorder that cannot be 
identified. Despite updated ILAE proposals for syndrome classification removing 
these labels (Engel, 2001), they are still widely used in clinical practice.
The overall incidence of epilepsy ranges between 40 to 70 per 100,000 per 
year in developed countries and 100 to 190 per 100,000 in developing countries 
(Guberman & Bruni, 1999). It is highest in early childhood and old age, with 50 -  
60% of epilepsy beginning before the age of 16 years. The prevalence of epilepsy is 
between 5 and 10 cases per 1000 persons (Bell & Sander, 2001); rates being 
influenced by the definition used for ‘active’ epilepsy (generally taken as one or more 
seizures in the previous five years).
1.2 Prognosis and treatment
A range of anti-epileptic medication is available for use in the treatment of 
seizures; this is usually commenced after presentation o f two or more unprovoked 
seizures. Literature reports on prognosis suggest approximately 70% of patients can 
achieve long-term remission from seizures (Annegers et al, 1979; Goodridge & 
Shorven, 1983; Cockerell et al, 1997; Sanders, 1993). In a study examining progress 
of 417 children with epilepsy over 8 years, Camfield et al (1997) reported that 61% of 
children who were taking one anti-epileptic medication in the first year o f treatment 
were seizure free at the end of the study period. 17% of children needed to have an 
additional medication; 42% of this group subsequently became seizure-free.
15
«
Medication is usually the first line o f choice in epilepsy treatment. However, 
there is a minority of individuals for whom this is unsuccessful, with continued 
seizure activity; this group is termed drug-resistant or intractable. This definition of 
intractability frequently refers to failure of at least two appropriate anti-epileptic 
medications, but has been much debated, particularly in the context of criteria for on­
going referral and treatment (Berg & Kelly, 2006). Intractability is of particular 
concern in children, where on-going seizure activity may impact on development. 
Although the seizure type can help in predicting prognosis, with focal seizures less 
likely to remit than generalized (Bell & Saunder, 2001), the specific epilepsy 
syndrome will be more predictive, and likely to indicate any associated neurological 
and mental morbidity (Shinnar, 1994) (see Table 1.2).
Table 1.2 Prognosis for seizure remission and/or neurological 
deterioration, based on syndrome type (from Guberman & Bruni, 
1999)___________________________ ________________________________
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Treatment options for patients with intractable epilepsy are more limited, and 
include surgery (suitable in only a minority of candidates), vagal nerve stimulation, 
and the ketogenic diet.
1.3 Development o f  the ketogenic diet
Earliest reports o f the effect o f starvation on epilepsy date back to the 5th 
century, when Hippocrates described a man whose seizures were cured by abstaining 
from all food and drink. Other renowned early physicians who advocated the role of 
diet in epilepsy were Galen and Avicenna. First reports in the medical literature were 
by Guelpa and Marie (1911), who described the cessation of seizures during complete 
fasting. This idea was not taken up until 1921, when Geyelin also reported the 
successful use o f fasting to treat epilepsy. He found that 20 out of 26 fasted patients 
had improved seizure control, two of who remained seizure free for more than a year. 
The arbitrary length o f fasting was 20 days, however only four had seizures after the 
tenth day without food. Geyelin was inspired by the work of an osteopath named 
Conklin (1922) who believed that epilepsy was caused by intoxication from the 
Peyer's patches o f the intestine and therefore advocated complete gut rest. Conklin 
fasted his patients for up to 25 days, and reported a 90% success rate in children under 
the age of 10 years, decreasing to 50% in adults. These observations sparked 
considerable clinical and research interest, and linked in with ongoing studies 
examining ketoacidosis and the disturbance in glucose metabolism that occurs in 
diabetes.
During fasting, the body passes through various phases o f hormonal and 
metabolic adaptation in an attempt to spare protein breakdown and to draw on the 
energy reserves of body fat. The muscles and other tissues progressively switch their
17
energy source from glucose to free fatty acids. B-oxidation of these fatty acids results 
in the formation of acetyl-CoA, and this can be converted into ketone bodies 
(acetoacetate and p-hydroxybutyrate), by a five-step pathway that takes place in liver 
mitochondria (see Figure 1.1). Ketone bodies, in contrast to fatty acids, are able to 
pass across the blood-brain barrier, and as their levels rise in the blood, will be 
increasingly utilized for energy by the brain, heart and muscle. They are converted 
back to acetyl CoA, which enters the tricarboxylic acid cycle. Blood levels of ketones 
will continue to increase during the first two weeks of starvation, until the brain 
becomes dependent on them for energy. Serum bicarbonate is also reduced, with a 
compensated metabolic acidosis.
Use of fasting to treat epilepsy had obvious clinical limitations, and it was 
therefore suggested by Wilder (1921) that a diet high in fat and low in carbohydrate 
might mimic the ketotic effect. A restriction o f dietary carbohydrate would limit 
glucose supply, and as fat is metabolized to ketone bodies, these would be used as the 
alternative fuel. Wilder went on to find that 50% of his patients at the Mayo Clinic 
had significant seizure control on this '“ketogenic" diet. Peterman (1925), a fellow 
worker at the clinic, reported further successful results in a group of 37 patients, with 
95% showing improvement when treated by the diet.
In 1927, Talbot and his co-workers were able to show that this ketogenic diet 
did cause similar biochemical changes to fasting. They introduced the idea o f an 
initial fast before commencing the diet, w ith a gradual build up of dietary fat over the 
following few days. The diet was subsequently shown to have a use in seizure control 
by many other workers (Helmholtz (1927), Lennox (1928), Me Quarrie & Keith 
(1929), Wilkins (1937)). It was widely used throughout the 1930s, and was found to 
be most successful in children, who produce and use ketones more rapidly, and have
18
fewer problems with compliance. Although there are a few reports in the literature of 
successful use of the diet in adults (Sirven et al, 1999), it is primarily used in 
childhood epilepsy.
Figure 1.1 Summary metabolic pathways of ketone body synthesis 
and oxidation
Synthesis Oxidation
-------------------  B -oxidation ---------------------
Fatty' Acids of fatty acids Acetyl Co A Tricarboxylic > Acid (TCA) cycle
AcetoacetylCoA thiolase Thiolase
ENERGY
LIVER 
MITOCHONDRIA
Acetoacetyl CoA
HMG CoA synthetase
HMG-CoA
3 -  ketoacyl CoA 
transferase
HMG CoA lysase
BRAIN, HEART 
& MUSCLE
Acetoacetate
Spontaneous 
decarboxylation /
3-hydroxybutyrate \  
\  dehydrogenase
3-hydroxybutyrate 
\  dehydrogenase
Acetone B-hydroxybutyrate
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The development o f new anticonvulsant medication at the end of the 1930’s 
detracted interest away from the ketogenic diet, but a realization that not all children 
do respond to medications, and concerns about their side effects, has maintained 
interest in alternative treatments, and there has been renewed research interest in the 
diet over the past ten years. The basic dietary principles remain the same as in early 
studies. Although uniquely characterized by the high fat content, and by the strict 
limitation o f carbohydrate and protein intake, there are two main types of ketogenic 
diet that have been developed, as described in the following sections.
1.4 The classical ketogenic diet
The early studies by Wilder and Peterman used a diet of lg  protein per kg 
body weight in children, with 10-15g carbohydrate daily, the remaining energy supply 
being from fat. They used primarily animal fats, in the form of butter, lard, and cream. 
The term “ketogenic ratio" was used to describe the ratio o f ketone producing foods in 
the diet (that is, dietary fat) to foods that reduced ketone production (that is, 
carbohydrate and protein). Seizure control was found to be optimal with a ratio o f 3 or 
more. This has led to the terminology of a 3:1 or 4:1 ketogenic diet, and is the basis of 
the classical diet that is used today. The ratio may be increased further for short 
periods in certain children in order to achieve optimal ketosis and seizure control. The 
carbohydrate intake is very limited on this diet, and protein is kept to a minimum to 
meet requirements, generally lg  per kg body weight daily.
1.5 The medium chain triglyceride ketogenic diet
Huttenlocher et al introduced a modification of the classical diet in 1971, 
using medium chain triglycerides (MCT) as an alternative fat source. The main 
constituents of MCT are the medium chain length octanoic and decanoic fatty acids,
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which are absorbed more efficiently than their long chain counterparts, and carried 
directly to the liver in the portal blood. This is in contrast to long chain fatty acids, 
which are incorporated into chylomicrons and transported via the thoracic duct 
through the lymph system to the left subclavian vein, where they exit into the 
circulation, and are carried via the peripheral tissues to the liver (Figure 1.2).
Figure 1.2. Differential medium and long chain fatty acid metabolism
Mucosal cell CirculationIntestine
Lymphatic
system
Chylomicron
Portal
blood
LCFA
MCFA
Peripheral
tissues
Left
subclavian
vein
LCFA = long chain fatty acids 
MCFA = medium chain fa tty acids
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Following hepatic tissue uptake, there are further differences between long and 
medium chain fat metabolism. Long chain fatty acids will be firstly bound to 
carnitine; this is necessary for their transport across the mitochondrial membrane, into 
the liver mitochondria where 13-oxidation and ketone body synthesis occurs. This 
carnitine shuttle system is not necessary for medium chain fatty acids, which will 
enter mitochondria directly.
These differences in MCT metabolism will facilitate more rapid and greater 
oxidation of medium chain fatty acids, resulting in a higher ketone yield per 
kilocalorie of energy provided than their long-chain counterparts. This increased 
ketogenic potential means that less fat would need to be incorporated in the diet, 
therefore more protein and carbohydrate could be allowed. Huttenlocher (1976) went 
on to show that a ketogenic diet providing 60% of energy from MCT was as effective 
as a 3:1 classical diet in producing ketosis and controlling seizures in 12 children with 
epilepsy. As the MCT diet allows more carbohydrate and protein, it may improve 
palatability and patient acceptance. However, frequent gastro-intestinal side effects 
are reported, primarily diarrhoea and abdominal discomfort due to the osmotic effects 
of the MCT. This can be reduced by temporarily lowering the amount o f MCT, and 
ensuring it is re-introduced gradually.
In view of concerns about these side effects, Schwartz et al (1989a) developed 
a modified MCT ketogenic diet, using both MCT and long chain fat, providing only 
30% of energy from MCT oil or emulsion and an extra 30% from saturated fats in the 
form of butter or cream; this became known as the John Radcliffe diet.
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1.6 Availability and efficacy o f  the ketogenic diet
Worldwide use of the ketogenic diet has increased dramatically since the early 
1990s. Although the largest numbers o f centres offering this treatment are in the 
United States, a recent survey reported ketogenic diet programs in 41 other countries, 
16 o f which had multiple centres (Kossoff & McGrogan, 2005). Most geographic 
regions were represented, with the exception o f the majority o f Africa and Central 
America. Although most of the larger centres in the United States currently use a 
classical protocol, European and worldwide ketogenic diet practice is more varied, 
with both classical and MCT diets being employed; the choice often being influenced 
with how easily such a diet fits in with local food choices. Both protocols are 
currently used within the UK; a postal survey of 250 British Dietetic Association 
Paediatric Group members was conducted in 2000 (Magrath et al, 2000). O f the 127 
replies, 22 centres were using the ketogenic diet. 13 used the classical protocol (59%), 
and 9 the MCT protocol (41%).
Despite increasing worldwide usage o f the ketogenic diet, and extensive recent 
media and internet coverage on the subject, many hospitals, even those specializing in 
paediatric neurology, are unable to provide the treatment for their paediatric patients 
with epilepsy. Nearly all centres in Europe report being limited by a lack o f dietetic 
time and resources (Kossoff & McGrogan. 2005). Neurologists are becoming more 
aware of the diet, but most continue to reserve its use until a child has failed a number 
of anticonvulsants; the main reasons for this reluctance being lack of dietetic 
resources, and uncertainty about efficacy (Hemingway et al, 2001b).
So does the ketogenic diet work? Many studies have reported excellent 
success rates in treating seizures in children with intractable epilepsy, and most health 
professionals working in this field can provide numerous anecdotal reports of success.
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It has also been used as a successful early therapy before epilepsy becomes intractable 
(Rubenstein et al, 2005). Lefevre & Aronson systematically reviewed 11 studies in 
2000 and concluded there was sufficient evidence to determine that the diet is 
efficacious in children with intractable epilepsy, although they were concerned about 
the lack of controlled trials. All 11 studies were observational, only 2 were 
prospective, one being a United States multi-centre trial. An updated review o f 14 
studies (Keene, 2006) made the same conclusion, but also found no prospective 
controlled studies. This problem was highlighted in a Cochrane review, which failed 
to find any randomized controlled trials on the ketogenic diet (Levy & Cooper, 2003), 
despite ILAE recommendations that such trials should be included among the 
required criteria for assessing efficacy and tolerability o f an antiepileptic agent 
(Anonymous, 1989). A randomized controlled trial is clearly necessary to validate the 
reported benefits of using the ketogenic diet in children with epilepsy. Positive results 
in such a trial would enable increased resources to be channeled into this area of 
work, and thus improve availability o f the diet for those children who need it.
/. 7 Comparison between the classical and M C T ketogenic diets
There have been many recent claims that the classical ketogenic diet is more 
efficacious in treating seizures than the MCT diet, mainly originating from centres in 
the United States. These cannot be backed by scientific evidence, as studies 
comparing the efficacy of the two types o f diet are very limited. Livingstone et al 
(1977) examined results on 600 patients following the classical 3:1 ketogenic diet and 
25 following the MCT diet, and concluded that only those on the classical diet 
responded. This was an uncontrolled study, with the difference in sample size o f each 
group being too large for statistical analysis. Berman (1978) also compared the two
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diets in a small, uncontrolled group o f children, using the 4:1 ratio for the classical 
diet, and concluded that the MCT diet was less effective.
Schwartz et al (1989a, 1989b) compared the clinical and metabolic effects of 
three types of ketogenic diet -  the classical 4:1 diet, the traditional MCT oil diet (60% 
energy as MCT), and the modified MCT diet (30% energy as MCT). 55 children and 
4 adults were studied. 15 patients received the classical diet alone, 22 received the 
MCT diet alone (including the four adults), 13 received the modified diet alone, and 
nine were given the MCT diet for at least 33 months, then changed to the classical 
diet. They found all three diets equally effective in controlling seizures in children 
under the age of 15 years. However the diets were chosen as deemed the most 
appropriate for the child and family in this study, and not randomized; therefore 
results could be influenced by substantial selection bias.
The classical diet can seem unpalatable due to such a high fat and low 
carbohydrate content. Fat sources would be butter, mayonnaise, margarine, oil, cream 
or a prescribable long chain fat supplement. Starchy foods such as cereals, bread, 
potato or rice are generally not allowed, the main carbohydrate sources being a 
limited portion of vegetables or fruit. Meat, fish, egg or cheese would provide protein 
at each meal, but it is difficult to include protein foods that contain additional sources 
of carbohydrate, such as sausages, fish fingers or milk. The MCT diet allows 
considerably more carbohydrate and protein, thus the incorporation of a wider range 
of food choices. This has led many to argue that it is easier to comply with, but the 
risk of gastro-intestinal side effects must be considered. Schwartz et al (1989a) found 
no problems with the fat content of the classical diet, however large amounts of MCT 
oil were unpalatable. For this reason, many centres using the MCT diet will use a
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modified protocol, although at this reduced level o f MCT, there may be problems 
obtaining adequate levels of ketosis.
1.8 Aim  o f  this study
In view of the lack of randomized trials comparing the classical and MCT 
ketogenic diets, and the lack of any controlled trials on either diet as a treatment for 
childhood epilepsy, a randomized controlled trial on these two dietary protocols was 
designed. The aim of this study was to conduct such a trial, and in particular to 
address the following questions.
Are there clear benefits in terms o f  seizure control in the group o f  children with 
epilepsy treated with a ketogenic diet as compared to a control group?
This will be examined by the randomization of children to an immediate or delayed 
start to one of the two diets, providing a group who act as their own controls, against 
which the efficacy o f the diets could be compared. Records o f seizure activity using a 
specially designed chart, EEG recordings, and documentation o f changes in anti­
epileptic medications will be used to assess efficacy. Chapter 3 evaluates the literature 
on efficacy of the ketogenic diet, and reports results o f this trial.
Is the classical ketogenic diet more efficacious than the M CT ketogenic diet in 
controlling seizures, as often claimed but not supported by scientific evidence?
This will be examined by randomization of children to either a classical or MCT 
protocol for the ketogenic diet. The methods described above will be used to assess 
efficacy. This subject is also discussed in chapter 3, where results are reported.
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How' do the classical and MCT ketogenic diets compare in terms o f  tolerability? 
Although it is often assumed that the increased carbohydrate provided by the MCT 
diet allows better tolerability and easier use, the gastro-intestinal side effects of MCT 
may cause problems. This question will be examined by comparing the tolerability o f 
the classical and MCT diets, using a parental questionnaire. Reasons for any early 
failures will be examined and other side effects that may occur on the diet also 
reported. Chapter 4 explores the literature on this subject, and reports results.
Does the restricted ketogenic diet affect grow th o f  children w ith epilepsy, and are 
there any differences betw een the classical or M CT diets?
In view of the risk of growth problems in children following a restricted diet, weight 
and height changes of children on both classical and MCT ketogenic diets will be 
closely monitored. Results are reported and discussed in chapter 5.
\\ hat conclusions can be draw n from this study and w here do w e go from  here ? 
Chapter 6 concludes the thesis and looks at where we may go from here. Although the 
primary' aim of the study was to conduct the randomized controlled trial as described, 
the results will also provide further information that will be important in the eventual 
development of national best practice guidelines for use o f the ketogenic diet.
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METHODOLOGY, DIETETICS AND THE DEVELOPMENT OF 
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2.1 Subjects and inclusion criteria
Subjects were children from the UK with a diagnosis of epilepsy who had been 
referred by their local consultant paediatrician to one of the two consultant paediatric 
neurologists heading the study. The majority of children were seen at Great Ormond 
Street Hospital. London, although a few children were recruited additionally from 
Central Middlesex Hospital, London, and the National Centre for Young People with 
Epilepsy, Lingfield (residential centre). Subjects had to fulfill the following inclusion 
criteria:
• Aged between 2 and 16 years
• At least 7 seizures weekly
• Tried at least 2 anti-epileptic medications
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• No previous treatment with the ketogenic diet
• Families or other carers understand the implications of the diet and are 
contactable for regular monitoring while at home
• No history of hyperlipidaemia or renal stones
• No enzyme deficiencies o f organic acid metabolism (all children screened by 
urine test).
2.2 Study design
Ethical permission for the study was obtained from the ethics committees for 
each of the three centres involved. Children were initially seen at a screening 
appointment by a paediatric neurologist, paediatric dietitian and nurse. An 
information sheet was sent out in advance o f this visit, and further details about the 
ketogenic diet and current study were explained at the appointment. Parents or carers 
of all children enrolled into the study were asked to give written consent before the 
child was randomized to receive either the classical or MCT ketogenic diet. 
Randomization was done at the time o f the clinic visit by a computer program that 
uses the minimization method to ensure a close balance between the treatment groups 
for three defined age groups (2-6 years, 7-11 years, 12-16 years), and for whether the 
child is at the residential centre or not. This program also randomized the children to 
either start the diet after a 4-week baseline period of seizure records, or to start the 
diet after that period and an additional 3 months of seizure records, with no change in 
treatment; this latter group acting as their own controls for this additional pre-diet 3 
month period. Subsequent to starting the diet, all children were reviewed as 
outpatients at 6 weeks, 3 months, 6 months and 12 months. Children were advised to 
follow the diet for at least 3 months, after this time the decision as to whether to
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continue or not was reviewed. Table 2.1 outlines the investigations that were 
performed at each time point. Children were also closely monitored by telephone 
between clinic visits. The study design is illustrated in figure 2.1.
Table 2.1 Investigations performed at each clinic visit
Investigation 6 weeks 3months 6months 12 months
Review by Doctor V V V ✓
Review by Dietitian V v s
EEG V V s
Blood tests V V s
Urine test V V s
Height/weight V V s
Parental questionnaire V V V
Figure 2.1 Study design
CLASSICAL DIET
Subject entry to 
study and —  
randomization
MCT DIET
Screening visit D ie t-  12 month v
1 I I____
4 weeks .............................
Controls
12 weeks
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2.3 Calculation o f  a ketogenic diet -  an introduction
A paediatric dietitian with specialist ketogenic diet experience (the author) 
calculated the classical and MCT diets. The calculation of a ketogenic diet can be 
divided into four steps as shown below:
• Step 1 - determining the energy prescription
• Step 2 -  determining the dietary prescription by calculating amounts o f the 
macronutrients fat, protein and carbohydrates
• Step 3 - translating the dietary prescription into meals, using recipes or food 
exchanges.
• Step 4 -  prescribing necessary supplements to ensure nutritional requirements 
are met.
At the outset of this study, I wanted to be clear and consistent as to how each of these 
steps was to be approached for both types o f diet. Although there are a couple o f texts 
on the subject that are widely used among dietitians practicing in the field (Shaw & 
Lawson, 1994, 2001, 2007; Freeman et al, 2000), at present there is still limited 
information available for dietitians in the UK to turn to if needing advice. This is 
particularly a problem with regard to the MCT diet, as much of the literature on the 
ketogenic diet is produced from the USA, and relates to the classical diet only. As the 
two diets formed the two treatment arms of the randomized trial, it was important to 
define exactly what constituted each diet, and keep within the defined parameters. 
This is more of an issue when dealing with this dietary trial, than if comparing two 
drug treatments, as it is an important component of a ketogenic diet not to be a fixed 
prescription, but to be modified as needed over the course o f treatment. Any one, or 
often more, of the above four steps would need to be changed on a regular basis, with 
the aim of improving seizure control, ketosis, growth, acceptance or tolerance. I
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needed to define not only how the two diets were going to be initially calculated, but 
also the parameters within which their prescriptions could be modified if necessary, 
while the child still clearly remained on the treatment arm he or she had been 
randomized to. The process by which this was achieved for each of these four steps 
will be examined separately.
2.4 Determining the energy prescription
Recommendations for classical ketogenic diet calculations agree a moderate 
energy restriction is of benefit in ketosis and seizure control (Eaton, 1994; Freeman et 
al, 2000). This prescription varies according to the age of the child, however 
approximately 75% of the recommended intake for the child's age and ideal weight is 
frequently suggested. A figure of 75kcal per kg body weight has been quoted (Eaton, 
1994), decreasing as the child gets older, to 40 - 50 kcal per kg by ages 11 years and 
older (Freeman et al, 2000). The only currently available textbook recommendation 
for energy prescription on the MCT diet suggests that this should be calculated using 
the UK recommended amount o f energy for a child's age (Eaton, 1994), which is 
considerably more calories than would be given for a comparable classical diet. A 
literature review on the MCT diet suggests conflicting reports regarding energy 
prescriptions (see Table 2.2). It is o f interest that the original paper on the two diets 
(Huttenlocher, 1976) did not distinguish between the classical or MCT protocol in 
terms of total daily energy prescription.
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Table 2.2. Summary of studies reporting MCT ketogenic diet treatment
A uthors No Age range
(yrs=years,
mo=months)
Energy prescription Diet prescription Translating 
into meals
Berman, 1978 18 2-17 yrs 60-75cal/kg 19% CHO, 10% protein, 11% LCT 
fat in foods, 60% MCT
Not stated
Clark & 
House, 1978
13 Not stated RDA (UK) 60% MCT, 40% food lOOkcal and 
50kcal
Huttenlocher 
et al, 1971
12 2.5-16 yrs R D A (U SA ) 19% CHO, 10% protein, 11% LCT 
fat in foods, 60% MCT aimed for
Protein, 
carbohydrate 
and fat 
exchanges
Huttenlocher 
et al, 1976
18 18 m o-18 yrs io w  m aintenance’ 
(75kcal/kg)-increased as 
needed
18% CHO, 10% protein, 12% LCT 
fat in foods, 60% MCT
Not stated
Mak et al, 
1999
13 3 yrs -  13 yrs 110% o f recommended 
daily requirem ent (Tawain)
1.5-2g protein/kg/day, < 19%CHO, 
MCT 65-70%, fat in food not less 
than 10%
Not stated
Ross et al, 
1985
9 3 mo -13 yrs ‘recommended total 
calories for age’ (USA)
‘Protein l-1.5g/kg, remaining energy 
in 3:1 ratio o f  fat.CHO, with 60% o f 
total energy as M CT’= approx 5-8% 
protein, 12% CHO and 80% fat (60% 
MCT; 20% LCT)
Not stated
Schwartz et al, 
1989
55
children 
and 4 
adults
20 under 5 yrs; 25 
aged 5-10 yrs; 9 
aged 11-15 yrs, and 
5 aged 15-54 yrs
R D I(U K ) 19% CHO, 10% protein, 11% LCT 
fat in foods, 60% MCT 
M odified diet (n=l 3) — 19% CHO, 
10% protein, 30% MCT, 41% LCT
Protein and 
carbohydrate 
exchanges 
used
Sills et al, 
1986
50 2-15 yrs ‘assessed on individual 
basis by dietitan’
60% MCT aimed for Not stated
Trauner et al, 
1985
17 12mo -  13 yrs ‘total calorie needs 
calculated’ -  energy intake 
gradually increased to 
approx 150% o f needs (nec 
to prevent weight loss)
60% MCT, 15% protein, 15% CHO, 
10% fat
Not stated
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The problem with applying clear numeric guidelines regarding energy 
prescription is that it does not allow for individual variation. Energy requirements will 
be influenced by seizure activity, physical activity, recent growth trends, current 
weight and height, and any relevant medication. For this reason, all children entering 
the study were individually assessed. Weight and height were plotted using a 
computer growth package (Cole TJ, Pan. H. lmsGrowth: an Excel add-in to convert 
measurements to Z-scores), and any recent trends noted. A 4-day food diary was 
analysed on the computer for each child (Compeat Pro v5.8) to provide an estimation 
o f pre-diet calorie intake. Initial prescription was based on an average between this 
pre-diet intake, and recommendations from Johns Hopkins for energy requirements on 
the ketogenic diet (Freeman et al, 2000), but taking into account weight and height 
(both current and recent trends), UK requirements (Department o f Health, 1991), 
physical activity levels, seizure activity and medications. As no literature evidence 
was found for increased energy allowance on the MCT diet, no difference was made 
between the two diets in determining the prescription.
Modifications to energy prescriptions were needed during the course o f 
follow-up as part o f dietary fine-tuning; these were generally applied in increases or 
decreases o f lOOkcal increments, and waiting at least 2 weeks before any further 
changes were applied. 50kcal increments were used in children with a very low daily 
energy prescription, for example, the very young or non-ambulant.
2.5 Calculating the dietary prescription
Step 2 involves the calculation of a dietary prescription, based on amounts o f the 
macronutrients fat, protein and carbohydrate. A classical ketogenic diet is based on a 
ratio of fat to carbohydrate and protein, generally 3:1 or 4:1. In a 3:1 diet, 87% o f the
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energy is provided by fat, in a 4:1 diet this increases to 90%. Fat source is long chain, 
usually from foods such as butter, mayonnaise, margarine, oil, cream, or a 
prescribable fat supplement. Protein intake is based on minimum requirements for 
growth (World Health Organisation, 1985; Dewey, 1996), and is generally provided 
by a portion of meat, fish, egg or cheese at each meal. Due to the limited carbohydrate 
allowance, it is difficult to include protein foods that contain additional sources o f 
carbohydrate, such as sausages, fish fingers or milk. Starchy foods such as cereals, 
bread, potato or rice are generally not allowed, the main carbohydrate sources being a 
limited portion of vegetables or fruit.
Johns Hopkins provides an excellent formula for calculating the classical diet 
(Freeman et al, 2000), this is widely employed throughout the world; this formula was 
used to calculate all classical ketogenic diets for this study. Most children required a 
4:1 ratio diet to achieve the necessary ketosis and seizure control; children who 
needed to lose weight and the very young only needed a 3:1 ratio. Adjustments to 
ketogenic ratio, made to fine tune study children on classical ketogenic diets, were 
done by increases or decreases in 0.5 increments, and kept within a range between 2:1 
and 5:1.
When calculating the MCT ketogenic diet, the first step is to determine the 
percentage o f total energy to be provided from the MCT fat. Although studies 
reported in the literature generally employ the traditional 60% energy MCT diet (see 
table 2.1), the author is familiar with many centres in UK that use the modified (John 
Radcliffe) version of 30% energy MCT. Both protocols have limitations, the former 
often resulting in tolerance problems; the latter a poor ketosis. The energy value o f the 
MCT is an unresolved issue. Current European Union guidelines state that the 
standard conversion factor for fat o f 9 kcal per gram should be used (Anonymous,
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1990), however most studies on the MCT diet have used the widely accepted lower 
value of 8.3 kcal per gram. More recent work suggests an even lower value of 7 kcal 
per gram is more accurate (Ranhotra et al, 1995).
The remaining energy in the MCT diet is provided from carbohydrate, protein 
and long chain fat. The original diet as devised by Huttenlocher provided 10% energy 
as protein, 18-19% energy as carbohydrate, and the remaining 11-12% as saturated fat 
from foods. Other studies have used different breakdowns of macronutrient energy 
supply for the MCT diet, as illustrated in table 2.1, notably as low as 12% 
carbohydrate (Ross et al, 1985). The John Radcliffe modified diet has a remaining 
energy breakdown of 19% carbohydrate, 10% protein, 30% long chain fat with an 
additional 11% fat from foods (Schwartz et al, 1989a).
A problem for many dietitians using the MCT diet, in particular those with 
limited experience, is that these figures are taken as fixed values, and not fine tuned as 
needed to suit the individual concerned. For this current study, a starting level o f 45% 
energy from MCT was used when calculating the MCT diets, in order to provide a 
balance between gastro-intestinal tolerance and adequate ketosis. This was increased 
up to a maximum of 60% energy MCT, or reduced to a minimum of 30% energy 
MCT as needed during dietary fine-tuning; generally using increments or decrements 
of 5% energy. The resulting increase or decrease in energy was usually balanced by a 
reduction or increase in the amount o f long chain fat. to maintain overall calorie 
content of the diet. In view of the lack o f updated European Union guidelines, the 
original value of 8.3kcal per gram MCT was used. Carbohydrate was started at 15% 
o f energy; a figure of 18-19% energy was considered slightly too high to achieve 
adequate ketosis. This was reduced to a lowest value of 12% if necessary during fine- 
tuning. Reduction of carbohydrate to improve ketosis was only done if an increase in
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MCT were not possible due to poor tolerance. Protein was usually started at 10% 
energy; up to 12% was needed in older non-ambulant children with very low energy 
requirements, in order to meet estimated protein requrements. The remaining starting 
energy provided from long chain fat was therefore usually 30%.
2.6 Translating the dietary prescription into meals
Having calculated a ketogenic dietary prescription, step 3 is to turn this into 
meals (and snacks if required) that will suit the individual child. The 4-day pre-diet 
food diaries gave an indication of a child's food preferences and eating patterns over 
the day, this was also discussed during a pre-diet telephone consultation with parents 
or carers, and was used as a basis for ketogenic meal plans wherever possible, within 
the constraints of the dietary restrictions. Many children with seizures actually have a 
preference for high fat foods prior to commencing the diet (Amari et al, 2007).
When administering a classical diet, the dietitian will use the dietary 
prescription to calculate a range of meal and snack recipes, all o f which will be in the 
prescribed dietary ratio and exact amounts for the individual child. Parents or carers 
will then follow these recipes, weighing out all food, usually to the nearest one-gram 
increment. The conversion of a dietary prescription to recipes has traditionally 
involved time-consuming hand calculations, although a couple o f computer 
calculation programs are available from the USA, using American food values. These 
were not appropriate for a UK based project; therefore prior to starting the study, I 
developed a computerized calculation program for UK ketogenic diet recipes. The 
development and evaluation of the program is discussed later in this chapter.
The increased carbohydrate and protein allowance on the MCT ketogenic diet 
means a much wider range of foods can be incorporated. This diet has traditionally
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been administered by using food exchange (or choice) lists as opposed to exact meal 
calculations, either separate carbohydrate and protein exchanges (usually lOg and 6g 
respectively), or calorie exchanges (for example, 50kcal or lOOkcal). Three studies 
reported use of exchanges; none report using exact recipe calculations (see table 2.1). 
Although this more flexible system makes the diet easier to calculate, there are two 
main problems with its use. It can cause an uneven distribution of carbohydrate, 
protein and fat over the day, leading to fluctuations in ketone levels, and it can lead to 
inaccuracy in calculations. For example, a protein intake thought to be 10% of total 
energy will actually be higher unless the low biological value protein provided from 
carbohydrate exchanges is also included, and if the energy provided from ‘fat in 
foods' is only an estimation, it could vary greatly within a persons diet and between 
people. These problems with the MCT diet will be compounded in many centres by 
the frequent inclusion o f a ‘free’ vegetable list, the omission of MCT from some 
snacks or meals, and the less accurate weighing of food exchanges (using five-gram 
rather than one-gram increments).
Although the impact of these problems on seizure control is undetermined, it 
was considered extremely important to use a tightly controlled MCT diet protocol for 
this current study. In comparing the efficacy and tolerability o f two ketogenic diets, 
the use o f a stricter MCT regime that was free from any of these potential problems 
would allow  ^ a more rigorous testing o f the original idea behind the MCT diet -  that 
using MCT to replace long chain fat increases ketosis, and so allows more 
carbohydrate and protein without reducing efficacy. A different approach to the 
exchange system was therefore devised. This used exchange lists for carbohydrate 
(lOg), protein (6g), and long chain fat (5g). The carbohydrate exchanges provided an 
average o f 1.5g of protein each, which was included into the calculations, and the
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protein exchanges were fat-adjusted to give an average o f 3g of long chain fat per 
exchange. When teaching parents or carers, exchanges were structured over the day 
by specifying numbers for each meal, with an exact amount of MCT fat to balance the 
carbohydrate and protein in the meal. Snacks were generally given as recipes, 
containing a prescribed amount o f MCT. This method allowed a more careful balance 
of fat (both MCT and long chain) to carbohydrate and protein over the whole day, 
while still using a system of exchanges rather than recipes. All food was weighed to 
one-gram increments, and all vegetables were included in the carbohydrate 
calculation, and chosen from a specially designed fruit and vegetable exchange list. 
This list was used for both classical and MCT diets. The exchange lists for 
carbohydrate, protein, fat and fruit and vegetables are included with other developed 
dietetic resources in the appendix.
The source o f MCT was traditionally MCT oil, as used by Huttenlocher et al 
(1971, 1976). Sills et al (1986) first reported use of an alternative MCT emulsion 
(Liquigen); this improved tolerance and is now used by most centres that follow an 
MCT ketogenic diet protocol. For the current study, Liquigen was used as the initial 
MCT source; this can be mixed into milk for drinks or cooking, and also used in 
recipes. Finding acceptable ways to incorporate MCT into the diet is the key to good 
compliance; children who refused milk-based drinks often needed an additional 
prescription for MCT oil, as this can be used in smaller volumes for cooking.
Children who are unable to take the ketogenic diet orally can safely have their 
diet prescription translated into a suitable enteral feed, to be given either via 
gastrostomy or naso-gastric tube. This has been shown to be safe and effective in a 
small study (Hosain et al, 2004). Prescribable dietary products can be used to 
implement both classical and MCT diets. In the current study, a couple o f extra
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products were made available for use from Scientific Hospital Supplies. Ketocal, a 
complete 4:1 ratio powdered formula, was used as the base product for all classical 
diet enteral feeds. Ketoflex, a protein, vitamin, mineral and trace element source, was 
used for the MCT diet enteral feeds, combined with Liquigen and carbohydrate and 
long chain fat sources. Since study completion, Ketocal has been made available on 
prescription in the UK.
2.7 Prescribing necessary supplements
Step 4 involves prescribing necessary supplements to ensure a child's 
ketogenic diet is nutritionally adequate. After reviewing the available products and 
nutritional requirements of each age group, a supplementation protocol was drawn up 
for the study (see Table 2.3) There are no UK published guidelines on supplementing 
ketogenic diets, however this protocol is similar to that used by most UK centres 
practising the diet, with the exception o f the additional magnesium supplementation 
on the classical diet, and essential fatty acid supplementation on the MCT diet. A 
magnesium supplement was considered necessary in view of the dietary restrictions, 
as the amount provided by Forceval Junior (paediatric vitamin and mineral 
supplement, see Table 2.3) is well below requirements. Magnesium deficiency is 
unlikely to be a problem on the MCT diet due to increased cereal and vegetable 
content. Essential long chain fatty acid deficiency is unlikely, but could be a risk in 
children on the MCT diet receiving 60% energy from MCT, due to the very small 
amount of long chain fat that would be allowed. Enterally fed children had full 
supplementation provided by the Ketocal or Ketoflex product used in their feed.
42
Table 2.3. Supplements used for classical and MCT ketogenic diets
Supplem ent C lassical Diet M CT Diet
General Forceval Junior -  1 capsule daily ages 2-10 years 
2 capsules daily ages 11-16 years
Calcium Sandocal 400 -  1 X lOmmol tablet 
daily
Requirements depend on dietary 
intake. Vi - 1 X Sandocal 400 daily 
if needed
Other Magnesium glycerophosphate -  XA - 
1 X 4mmol tablet daily (commenced 
after 3 months on diet)
2ml walnut oil daily as essential 
fatty acid source (commenced 
after 3 months on diet)
2.8 Initiating the ketogenic diets
On commencing this study, a protocol of outpatient initiation, without a fast or 
fluid restriction, was established. All families attended the hospital for a full initiation 
day of outpatient education prior to commencing the ketogenic diet. At this initiation 
visit, baseline haematology and biochemistry blood tests were done, and urine 
samples were taken to check for haematuria. All children on topiramate had a baseline 
renal ultrasound performed to exclude pre-diet renal calculi. Diets were started at the 
beginning of a week, to avoid complications occurring over the weekend, and during 
the first two weeks on the diet families had daily telephone contact with an 
experienced ketogenic dietitian or nurse (often more frequently for the first few days). 
On-going regular telephone contact was maintained as needed.
Both classical and MCT ketogenic diets were initiated using a gradual step­
wise protocol. Classical diet children were commenced on full calories at a 2:1 ratio 
for the first 2-3 days. This was achieved by adding a prescribed amount of extra 
orange juice to 4:1 ratio recipes at each meal and snack; this was then slowly reduced 
to increase the ratio to 3:1. as tolerated. After a further few days, the orange juice was
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stopped, leaving the child on a 4:1 ratio diet, if  tolerated. All incremental orange juice 
reductions were made after discussion with the dietitian or nurse, and with close 
monitoring o f ketone levels and tolerance. MCT diet children were commenced on the 
full prescription of carbohydrate, protein and fat from foods, but with a very small 
amount o f MCT. The MCT was built up to the full prescription in daily increments 
over 10 days, again depending on ketone levels and tolerance. Fluids were not 
restricted on either diet, however children who drank large amounts were advised to 
keep to the recommended daily amounts for their age group.
2.9 Development and evaluation o f  EKM
Prior to starting the study, the need for a computer calculation program 
relevant to the UK was identified, to allow the highly prescriptive and time- 
consuming ketogenic diet recipe calculations to be performed quickly and easily. No 
such programs were currently available for use with UK food values, and the aim of 
such a program would be to reduce the burden o f time for dietitians involved in this 
area o f work.
The original idea was based on Microsoft Excel software, using a simple 
spreadsheet with inputted food values. This idea was then used to design a stand-alone 
program, not dependant on Excel, working in conjunction with a software engineer 
(MicroMan2000 Ltd), who had previously designed a well-used dietetic feed 
calculation program. Electronic Dietetic Manager (EDM). The new ketogenic diet 
recipe calculation program was named Electronic Ketogenic Manager (EKM). Once 
the dietitian has calculated a dietary prescription, EKM enables recipes to quickly be 
planned and adapted, using McCance & Widdowson 6th Edition Food Composition 
data. Parents can also use it to plan meals, based on a prescription given to them by
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the dietitian. EKM was designed to be available free, and is obtained by download 
from the internet. There were initial concerns about such a program being misused by 
parents without any dietetic or medical supervision. In order to be sure that it is used 
appropriately it was decided to only allow parents to download after email permission 
has been obtained from the dietitian managing their diet. It is of note that the 
programs of similar nature produced in the USA are available on the internet and do 
not include any such supervisory checks. The timescale for program development is 
given in table 2.4.
Table 2.4 Timetable for development of EKM
Time Action
December 2001 
-  February 2002
Design of simple ketogenic diet calculation spreadsheet using 
Microsoft Excel software, first used February 2002, used for all 
study diets calculated until February 2004
February 2004 First meeting with software engineer (MicroMan2000 Ltd) 
regarding development o f a stand-alone program
February - 
September 2004
Program design and development, used alongside Excel version 
for study diets. Licensing agreement with Institute o f Chemistry, 
to enable a one-off purchase o f McCance & Widdowson 6th 
Edition Food Composition data; this enabled program to be 
available free to users.
September 2004 Draft windows version of EKM ready. Initial evaluation by 2 
dietitians and 2 parents after Vi day training session.
11th November 
2004
Official release o f EKM at ketogenic diet conference (Institute of 
Child Health)
In February 2005, 3 months after program launch, an initial questionnaire was 
sent out by email to the first users o f EKM (4 dietitians and 3 parents), all o f who had 
been using the program for at least one month. This questionnaire asked about ease of 
use, whether there had been any problems, how the program compared with their 
previous method of meal planning, and whether they would use it on a regular basis to 
calculate ketogenic diet meals.
45
Six of the 7 respondents (86%) reported finding EKM easy or very easy to 
use, one dietitian initially found it more difficult. When asked about any problems, 3 
dietitians reported having some computer compatibility problems that resolved with 
help; the other 4 respondents had no problems. All respondents said that the program 
was much better than their previous methods o f calculating recipes, and that they 
would use the program on a regular basis; the dietitians finding that it was much 
easier than hand calculating ketogenic recipes, and the parents enjoying the freedom 
of calculating their own meals, working alongside their dietitian. These initial pilot 
questionnaire results were encouraging, although the survey was limited by small 
sample size. Users generally found it easy to use and it reduced the time taken to 
calculate a ketogenic diet.
A survey of EKM users in March 2006 showed that by this time 104 people 
had downloaded the program for use: 51 dietitians and 53 parents. At a recent 
international ketogenic diet conference in November 2007, many countries other than 
the UK reported using EKM. The on-going aim is that more dietitians working in this 
area will use EKM as a resource; by freeing up dietetic time this will hopefully allow 
more children with severe epilepsy to try this treatment.
2.10 Development o f other dietetic resources
A range o f other written information was produced to give to parents or carers 
on the initial education visit. This included a parents illness information sheet, 
information on how to measure ketones, and separate information sheets for classical 
and MCT diets, including example recipe ideas. This written information is included 
in the appendix to chapter 2.
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APPENDIX -  DIETETIC RESOURCES
1. Fruit and vegetable exchange lists
2. Carbohydrate, protein and fat exchange lists
3. Classical and MCT diet general information sheets
4. Illness information sheet
5. Measuring ketones information
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Exchange Lists for Fruit and Vegetables
FRUIT
Weights are given for raw fruit (not dried), fruit stewed without sugar, or fruit canned 
in natural juice. As there are individual variations in the carbohydrate content of the 
different fruits within a group, try and vary choices. If you find that one type o f fruit 
is being used very regularly then discuss this with the dietitian as the overall ratio of 
your diet may need to be checked.
10% fruit - these contain an average o f lOg carbohydrate per lOOg. Use the amount 
prescribed for each meal:
Apples
Apricots Kiwi fruit
Cherries Nectarines
Damsons Paw-paw
Peaches Plums
Pears Watermelon
Pineapple
Canned fruit cocktail (in natural juice)
Oranges, including mandarin, satsuma and tangerine
Lower Carbohydrate fruits (approx 6 XA %) - these contain an average of 6 Vz g 
carbohydrate per lOOg. Use 1 Vi times the amount prescribed for each meal:
Blackberries
Blackcurrants
Blueberries
Grapefruit
Lemons
Gooseberries
Loganberries
Melon - canteloupe, honeydew, galia
Raspberries
Redcurrants
Strawberries
Cranberries
Higher carbohydrate fruits (approx 15%) - these contain an average o f 15g 
carbohydrate per lOOg. Use 2/3 o f the amount of fruit prescribed for each meal:
Mango
Grapes
Lychees
Banana - contains approx 23g carbohydrate per lOOg. Use 1/3 o f the amount of fruit 
prescribed for each meal.
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VEGETABLES
Weights are given for raw (R) or cooked (C) vegetables. 'Cooked' refers to boiling or 
steaming. Try and vary choices due to individual variations in carbohydrate and 
protein content within a group. If one type o f vegetable is being used at most meals 
discuss this with the dietitian to enable checking o f the overall diet ratio.
Group 1 vegetables - these contain moderate amounts o f carbohydrate and protein. 
Use the amount prescribed for each meal.
Beetroot - R
Sprouts - R or C 
Onion - R 
Turnip - R 
Mangetout - R or C 
Beansprouts - R 
Okra -  R or C 
Cauliflower -  R
Carrots - R or C 
French beans - R or C 
Swede - R
Red or yellow pepper - R or C 
Cabbage/spring greens - R 
Butternut squash -  R or C 
Broccoli -  R
Group 2 vegetables - these contain lower amounts o f carbohydrate and protein. Use 
twice the amount of vegetable prescribed for each meal.
Asparagus - R or C Aubergine - R
Runner beans - R or C Broccoli - C
Cabbage/spring greens - C Cauliflower - C
Courgette - R or C 
Leeks - R or C 
Marrow - R 
Radish - R 
Spring onion - R 
Tomato - R or canned 
Watercress - R 
Celeriac -  R or C
Green pepper - R or C 
Turnip - C 
Pumpkin - R or C 
Spinach - R or C 
Swede - C 
Curly kale -  R or C 
Chicory - R 
Fennel - R
Group 3 vegetables - these are very low* in carbohydrate. Use four times the amount of 
vegetable prescribed for each meal.
Celery - R or C 
Cucumber - R 
Lettuce - R 
Mustard & cress - R 
Marrow - C 
Mushroom -  R 
Fennel - C
Rhubarb - although actually a fruit, this is very low in carbohydrate, so can be used in 
group 3 vegetable amounts. It may be particularly useful if your child is constipated.
Other vegetables
There are a few other vegetables that are much higher in carbohydrate and/or protein, 
so cannot be included in the exchange lists. These include potato, baked beans, peas, 
yam, plantain and parsnip. Small amounts o f these vegetables can be calculated into 
the diet separately by the dietitian if necessary.
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lOg Carbohydrate exchanges for MCT ketogenic diet
Rice and pasta 
12g rice (dry weight)
33g boiled rice
13g pasta or noodles (dry weight)
50g boiled pasta
Breads and crackers 
24g wholemeal bread 
22g white bread
18g white French stick or pitta bread
21 g granary bread
23g chapatti (without fat)
20g white burger buns 
23g croissants or muffins 
17g hot cross buns 
23g Scotch pancakes 
19g scones or teacakes 
14g rye crispbread 
15g cream crackers
Breakfast cereals 
21 g All Bran 
14g Branflakes 
14g Fruit and fibre 
1 lg Cornflakes 
15g Puffed wheat 
15g Ready brek 
1 lg  Rice krispies 
14g Shredded wheat 
13g Shreddies 
13g Weetabix
13g porridge oats (dry weight)
Baking
13g flour (plain/self-raising)
1 lg  cornflour
17g pizza base eg. Sainsbury's thin and 
crispy (ready to cook)
Miscellaneous
70g tinned spaghetti in tomato sauce 
170g tinned tomato soup 
1 OOg tinned vegetable soup
Snacks 
18g cheddars 
16g twiglets
17g tortilla chips or wheat crunchies 
19g potato crisps 
13g ice cream cup comets
High carbohydrate vegetables 
(raw or cooked weight)
58g potato- without skin
30g chips
39g roast potato
28g yam
35g plantain
38g sweetcom, canned
80g parsnip
Fruits
150g of melon, grapefruit, raspberries, 
strawberries, loganberries, 
blackberries, blackcurrants or rhubarb
lOOg of apple, apricot (not dried), 
cherries, kiwi, orange, tangerine, 
satsuma, mandarins (including tinned) 
pear (including tinned), peach 
(including tinned), plums, pineapple, 
nectarine.
65g of grapes, mango, gooseberries 
fruit cocktail tinned in juice, pineapple 
tinned in juice
43g of banana
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6g Protein exchanges for MCT ketogenic diet (fat-adjusted)
Fish
22g tuna, tinned in oil
26g boiled prawns with an extra 3g oil or 4g butter, margarine or mayonnaise 
lOg dried prawns with an extra 3g oil or 4g butter, margarine or mayonnaise 
30g white fish with an extra 3g oil or 4g butter, margarine or mayonnaise (eg. cod, 
coley, plaice, haddock, halibut, whiting)
30g smoked mackerel
35g pilchards tinned in tomato sauce
30g salmon (raw or steamed weight)
24g smoked salmon with an extra 2g oil or 3g butter, margarine or mayonnaise
25g tinned salmon
25g sardines, tinned in oil
33g sardines, tinned in tomato sauce
Meat
26g raw beef meat
20g grilled beef steak
20g roast beef
30g raw lamb meat
20g grilled lamb steak or chops
21 g roast lamb
28g raw pork meat with an extra 2g oil or 3g butter, margarine or mayonnaise 
19g roast pork with an extra 2g oil or 3g butter, margarine or mayonnaise 
30g raw mince (either beef, lamb or pork)
27g raw chicken meat or turkey meat with an extra 3g oil or 4g butter, margarine or 
mayonnaise
19g grilled chicken breast with an extra 3g oil or 4g butter, margarine or mayonnaise
20g roast chicken breast with an extra 2g oil or 3g butter, margarine or mayonnaise
19g roast turkey with an extra 2g oil or 3g butter, margarine or mayonnaise
30g raw liver
36g raw bacon
25g grilled bacon
25g boiled gammon
33g ham with an extra 2g oil or 3g butter, margarine or mayonnaise 
23g corned beef 
29g salami
Cheese 
24g cheddar
47g cottage cheese (not low fat)
23g Edam 
30g brie 
26g stilton
Other
1 small egg (approx 50g)
43g quom
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Foods that give both carbohydrate and protein exchanges
•  70g fruit fromage frais = 1 carbohydrate exchange and XA protein exchange
•  120g Muller Light yoghurt = 1 carbohydrate exchange and 1 protein exchange
• 60g baked beans with an extra 3g oil or 4g butter, margarine or mayonnaise =
1 carbohydrate exchange and XA protein exchange
• 60g fish cakes OR fish fingers = 1 carbohydrate exchange and 1 protein 
exchange
•  40g sausage = XA carbohydrate exchange and 1 protein exchange
5g Fat exchanges for MCT ketogenic diet
6g butter - any type o f butter, eg. Anchor, Country Life, supermarkets own
brand
5g oil - a vegetable oil, such as olive or sunflower is recommended
6g mayonnaise - Heilmans (jar), or alternative full fat
8g margarine - For example. Flora. Not low fat spreads.
lOg double cream - any type, including UHT.
20g Philadelphia full fat cream cheese -  maximum once daily as a fat exchange
12g mascarpone cheese -  maximum once daily as a fat exchange
30g avocado pear - maximum once daily as a fat exchange
7g walnuts, macadamia nuts or brazil nuts - maximum once daily as a fat exchange
9g almonds or peanuts - maximum once daily as a fat exchange
52
The MCT Ketogenic Diet
This diet contains a prescribed amount o f medium chain triglyceride (MCT). This is a 
special type of fat, which helps the body produce ketones. It is usually given in the 
form of an emulsion called Liquigen, however MCT oil can also be used if necessary. 
These products are available on prescription for use in this diet.
The diet is also made up o f a prescribed amount o f other fat, protein and carbohydrate. 
The daily amounts of these nutrients have been carefully calculated on an individual 
basis, and it is therefore important that the recipes are followed exactly.
The MCT ketogenic diet allows adequate protein to meet requirements, however the 
carbohydrate content is lower than normal diets. The carbohydrate in the diet will be 
provided by starchy foods only, as sugar and sugary foods are not allowed on this diet.
You have been given a choice o f meal recipes (see separate sheets) for initial use, 
based on your child's food preferences. The dietitian can adapt these and add new 
foods as needed, however, all changes should be discussed with her, as they will need 
to be carefully calculated into the diet.
Food should be weighed to the nearest lg, as specified in the recipes, lg  of liquigen or 
milk is the same as lm l, however you will probably find it easier to weigh rather than 
measure these liquids.
All meals and snacks will contain a significant proportion of oil, butter, mayonnaise 
or double cream, or a combination of these fat sources. The recipes do not specify 
which of these should be used, however have been based on the following products:
Oil - a vegetable oil, such as olive or sunflower is recommended 
Butter - any type o f butter, eg. Anchor, Country Life, supermarkets own brand. 
Margarine - this is slightly lower in fat than butter and may be less palatable in 
large quantities, however, provides a healthier balance of fatty acids. The type 
used will be specified in the recipes.
Mayonnaise - Heilmans (jar)« or alternative full fat.
Double cream - any type.
All meals and snacks will also contain a prescribed amount of Liquigen. This can be 
included in the diet by mixing with milk (for drinks and on cereal), using in cooking, 
or making up as a sugar-free jelly. The amounts of milk or other ingredients needed to 
combine with the liquigen are carefully calculated, and included in your recipes.
Once a bottle of liquigen has been opened, it should be kept in the refrigerator.
Free foods
There are no free foods on this diet, except as specified in the list below.
Drinks Tea and coffee (no milk or sugar, acceptable sweeteners only)
Water, including mineral. Flavoured waters can be used if only contain 
a trace of carbohydrate, eg. Tesco still flavoured mineral waters.
Diet fizzy drinks - check that carbohydrate content is less than 
O.lg/lOOml
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Sugar free squash - check the label as some low sugar products still 
contain significant amounts o f carbohydrate. Aim for a carbohydrate 
content o f 0.6g or under per 100ml of undiluted drink, or 0.1 g per 
100ml diluted drink.
(different manufacturers choose to label drinks in different ways)
Some suggestions are:
• Sainsbury's - no added sugar whole orange, orange, lemon and pineapple, 
lemon, lemon & lime or blackcurrant drinks. Low price no added sugar orange 
drink *
• Tesco's - low sugar whole lemon squash, whole grapefruit squash, or whole 
orange squash. Value low calorie apple and blackcurrant, lemon or orange 
drinks*
• Safeway no added sugar lemon, orange or strawberry drinks. Safeway savers 
no added sugar apple and blackcurrant or orange drinks.*
• Asda no added sugar orange and lemon drinks. Asda Smartprice no added 
sugar orange, lemon or apple & blackcurrant drinks.*
* Information correct at Dec 2003 -  do check label again in case of changes.
Sweeteners Saccharin is the best choice eg. Sweetex or hermesetas tablets. Avoid 
sweeteners containing sucrose, fructose, glucose, lactose, sortbitol or 
maltodextrin. Aspartame can be used in moderation. Avoid powdered 
sweeteners, eg. Candarel, as these contain significant amounts o f 
maltodextrins.
Flavourings Salt, pepper, herbs and spices.
Pure food essences and colourings
Vitamin and mineral supplementation
This diet is not nutritionally complete. A supplement will need to be taken daily - 
please see details on your diet sheet.
Medicines and toothpaste
These should be sugar-free if possible. Check with your pharmacy, doctor or the 
ketogenic diet team if you are uncertain.
Toothpaste should be sugar free if possible. Suitable types are Colgate baking soda 
toothpaste and Arm & Hammer baking soda toothpaste (available in supermarkets).
Initiating the diet
Liquigen should be introduced into the diet slowly - please see the plan on your diet 
sheet for building up the amount.
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The Classical Ketogenic Diet
The ketogenic diet is very high in fat, and low in carbohydrate. The carbohydrate will 
be provided by a limited amount o f starchy foods only, such as fruit and vegetables, as 
sugar and sugary foods are not allowed on this diet. The diet is also low in protein, 
however provides an adequate amount for growth. The daily amounts of these 
nutrients have been carefully calculated on an individual basis, and it is therefore 
important that the recipes are followed exactly.
You have been given a choice o f meal recipes (see separate sheet) for initial use, 
based on your child's food preferences. The dietitian can adapt these and add new 
meals as needed, however, all changes should be discussed with her, as they will need 
to be carefully calculated into the diet. Food should be weighed to the nearest lg, as 
specified in the recipes.
All meals will contain a high proportion o f oil, butter, margarine, mayonnaise or 
double cream, or a combination of these fat sources. The recipes do not specify which 
of these should be used, however have been based on the following products:
Oil - a vegetable oil, such as olive or sunflower is recommended 
Butter - any type of butter, eg. Anchor, Country Life, supermarkets own brand. 
Margarine - this is slightly lower in fat than butter and may be less palatable in 
large quantities, however, provides a healthier balance o f fatty acids. The type 
used will be specified in the recipes if wanted.
Mayonnaise - Heilmans (jar), or alternative full fat.
Double cream - any type.
Free foods
There are no free foods on this diet, except as specified in the list below.
Drinks Tea and Coffee (no milk or sugar, acceptable sweeteners only)
Water, including mineral. Flavoured waters can be used if only contain 
a trace of carbohydrate, eg. Tesco still flavoured mineral waters.
Diet fizzy drinks - check carbohydrate content is below O.lg/ 100ml 
Sugar free squash - check the label as some low sugar products still 
contain significant amounts of carbohydrate. Aim for a carbohydrate 
content of 0.6g or under per 100ml o f undiluted drink, or O.lg per 
100ml diluted drink.
(different manufacturers choose to label drinks in different ways)
Some suggestions are:
• Sainsbury's - no added sugar whole orange, orange, lemon and pineapple, 
lemon, lemon & lime or blackcurrant drinks. Low price no added sugar orange 
drink *
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• Tesco's - low sugar whole lemon squash, whole grapefruit squash, or whole 
orange squash. Value low calorie apple and blackcurrant, lemon or orange 
drinks*
• Safeway no added sugar lemon, orange or strawberry drinks. Safeway savers 
no added sugar apple and blackcurrant or orange drinks.*
• Asda no added sugar orange and lemon drinks. Asda Smartprice no added 
sugar orange, lemon or apple & blackcurrant drinks.*
• Information correct at Dec 2003 -  do check label again in case of changes.
Sweeteners Saccharin is the best choice eg. Sweetex or hermesetas tablets. Avoid 
sweeteners containing sucrose, fructose, glucose, lactose, sortbitol or 
maltodextrin. Aspartame can be used in moderation. Avoid powdered 
sweeteners, eg. Candarel, as these contain significant amounts o f 
maltodextrins.
Flavourings Salt, pepper, herbs and spices.
Pure food essences and colourings
Vitamin and mineral supplementation
This diet is not nutritionally complete. A supplement will need to be taken daily, as
specified on your diet sheet.
Medicines and toothpaste
These should be sugar-free if possible. Check with your pharmacy, doctor or the
ketogenic diet team if you are uncertain.
Toothpaste should be sugar free if possible. Suitable types are Colgate baking soda
toothpaste and Arm & Hammer baking soda toothpaste (available in supermarkets).
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How to manage illness while on the ketogenic diet
You may notice that ketone levels drop if your child becomes unwell. This is quite 
common, and caused by a combination o f factors, such as the infection itself and 
decreased physical activity. Although we would aim to maintain ketosis during illness 
if possible, it is far more important for your child to get well again.
At times of illness, if you are concerned about you child, it is important to contact 
your local doctor or ketogenic diet specialists. However the following guidelines give 
some general advice on how to manage illness while your child is following a 
ketogenic diet.
Vomiting or diarrhoea
• Stop the diet, and use Dioralyte until vomiting has settled. It is extremely 
important to maintain an adequate fluid intake at this time, so drinks should be 
offered frequently as tolerated. Clear sugar-free liquids such as water, sugar-free 
fizzy drinks and sugar-free squash could be used instead if preferred in older 
children, however if the symptoms continue for over 24 hours, Dioralyte should 
be used, as this will replenish the body's electrolyte levels. If your child is being 
fed by gastrostomy or nasogastric ketogenic feeds, these should be stopped, and 
Dioralyte or water used in place o f the feeds, ensuring an adequate fluid intake.
• Watch carefully for signs of low blood sugar and /or excess ketosis during this 
time. If there is no improvement in 24 hours, your local doctor should be 
contacted.
• When your child has stopped vomiting, re-introduce the diet. This should be done 
slowly. If your child is not able to take solid foods, the ketogenic milkshake recipe 
can be offered in small sips throughout the day. This may need to be initially 
diluted with water or dioralyte if there are problems with tolerance due to 
continued diarrhoea. The amount of milkshake given can slowly be increased, and 
then replaced with meals once appetite has returned. It does not matter if the 
correct amount o f milkshake for the day cannot initially be completed, however 
during this time of building the diet back to normal it is essential to maintain an 
adequate fluid intake with other sugar-free drinks.
• When reintroducing meals, start with half the usual amounts for the first day or 
two. If your child is unable to complete meals, mix the meal constituents together, 
so that the food eaten is in the correct ratio of fat to protein and carbohydrate. If 
your child is unable to tolerate the full-fat meals due to continued diarrhoea or 
vomiting, it may be necessary to reduce the fat in the diet for a couple o f days. 
Use half the prescribed amount o f cream, butter, oil and/or mayonnaise at each 
meal for a day, and slowly increase this back to normal over the next couple of 
days as tolerated. If you are using Liquigen (MCT diet only), the amount used 
may also need to be reduced by half, and then built back up to full strength over 2- 
3 days. If diarrhoea is a continuing problem, the Liquigen may need to be 
introduced at a quarter strength and built up to the full amount over 4-5 days - this 
can be discussed with the dietitian.
• When reintroducing gastrostomy or nasogastric ketogenic feeds, initially use half 
strength for 24-48 hours, then gradually build up to full strength as tolerated over 
a few days.
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Fever
• Use sugar free paracetamol or suppositories at the correct dose for your child.
• Maintain an adequate fluid intake by offering sugar free fluids without restriction. 
If your child will eat as usual, then the diet can be maintained. However, you may 
prefer to use the milkshake recipe - this can be sipped throughout the day.
• It is important to contact your local doctor, as you would normally, if you are 
worried about your child's health.
• Any other medication, such as antibiotics, should be sugar-free if possible.
Constipation
• Discuss this with your dietitian as some dietary changes may be possible
• Lactulose can be used as a stool softener and so can Fybogel. These products have 
very limited absorption into the body, so are unlikely to interfere with the diet.
Seizures
• If your child is unwell with worsening o f seizures, check the ketones in the urine 
and contact your local paediatric team
• Emergency treatment can be given as normal, eg. rectal diazepam
• If taken to hospital a glucose infusion should be avoided (unless in exceptional 
circumstances - see below). Your child can have normal saline and other types of 
infusion. The nurses will monitor your child's blood sugar.
Low blood sugar
Many children on the diet have lower blood sugars than they would on normal diets. 
This is not a problem unless symptoms develop. Symptoms of low blood sugar 
include sweating, becoming cold and clammy, jittery, confused or aggressive. This is 
rare, but if they do occur, should be treated immediately by giving a drink that 
contains carbohydrate, such as a sugar containing (non-diet) fizzy drink or fresh fruit 
juice. Start with 1 - 2 tablespoons. However, if these symptoms do develop, you 
should also contact your local doctor, as it will be important to monitor blood glucose 
levels and provide further treatment. If hospital admission is needed, a glucose 
infusion may be required.
Excess ketosis
Occasionally ketone levels can become too high. This may occur after a change in the 
diet, or during illness. The signs of this are rapid, panting breathing, increased heart 
rate, facial flushing, irritability, vomiting and unexpected lethargy.
If your child seems to be showing these symptoms, give 1 - 2 tablespoons of fresh 
fruit juice or a sugar-containing fizzy drink. If the symptoms have not improved after 
15-20 minutes, this should be repeated, and your local doctor contacted immediately. 
It may be necessary to alter the diet ratio if ketone levels are persistently excessive.
If you are very worried about your child's health, phone your local doctor or call 
for an ambulance.
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Instructions for ketone measurement with Ketostix
Ketones need to be measured morning and evening, at roughly the same 
times each day.
What you will need;
-Good lighting in the room.
-A bottle of test strips-Ketostix.
-A watch that measures seconds.
-A clean container or cotton wool balls to collect urine.
Testing urine
1. Collect urine in a clean, dry container.
2. Remove one test strip from the bottle and replace the lid.
3. Dip the test strip into the urine (or stream of urine) and remove 
immediately.
4. Remove excess urine on the test strip by shaking.
5. Wait 15 seconds and read the test strip by comparing with the 
colour chart.
6. Record result.
Testing ketones from nappies
1. Place a cotton wool ball in the nappy prior to the time of testing.
2. When the nappy is wet remove the cotton wool.
3. Squeeze the cotton wool onto the test strip, so that the urine makes the 
test strip wet.
4. Wait 15 seconds and read the test strip.
5. Record result.
We are aiming for large levels of ketones (8 -16 mmols/L).
However levels will vary depending on the dilution of the urine.
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CHAPTER 3 
EFFICACY OF THE KETOGENIC DIET
Contents
3 .1 Introduction
3.2 Methodology
3.2.1 Assessment o f  primary outcome -  diet efficacy
3.2.2 Sample size calculation
3.2.3 Statistical analysis
3.3 Results
3.3.1. Trial overview
3.3.2. Comparison between diet and control group
3.3.3. Comparison between classical and M CT diet groups after 3 months
3.3.4. Comparison between classical and M CT diet groups after 6 and 12
months
3.3.5. Analysis by seizure syndrome
3.3.6. Ketosis and seizure control
3.4 Discussion
3.1 Introduction
Efficacy of an anti-epileptic treatment will be assessed by its ability to produce 
seizure freedom, or a reduction in seizure frequency and/or severity. This can be done 
by using records o f seizure numbers, by using an additional graded system for records 
o f seizure severity, by assessing the EEG, and by monitoring anti-epileptic medication 
use, both regular and emergency. A widely accepted measure of an efficacious anti­
epileptic treatment is one that reduces seizure frequency by more than 50%. Previous 
ketogenic diet studies in children have used percentage response rates to present 
results, based on records of actual seizure numbers, with categories of seizure free, 
greater than 90% reduction and greater than 50% reduction. Studies are summarized 
in Table 3.1.
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Study & location No Ages (yrs) Diet type Seizure free >90% decrease > 50% decrease
Berman, 1978 (IJSA) 18 2-17 M CI 1 /1 8 (6 % ) N ot stated 6 /1 8 ( 3 3 % )
C oppola  et al. 2002  (Italy) 56 1-23 Classical 4:1 Not stated Not stated 37.5%  at 3 mo  
26 .8%  at 6 mo  
17.9% at 12 mo
DiMario & Holland. 2002  (U S A ) 24 1-15 Not stated 4/24  (17%) at 6 mo  
4/24  (17%  at 12 m o
Not stated 
Not stated
13/24 (54% ) at 6 mo  
7/24 (29% ) at 12 mo
Lreeman et al. 1998 (U S A ) 150 1-16 Classical 3:1 4:1 4 /1 5 0  (3%) at 3 mo  
5 /1 5 0 ( 5 % )  at 6 mo  
1 1 /1 5 0 (7 % ) at 12mo
5 0 /150  (33%) at 3 mo  
48 /1 5 0  (32%) at 6  mo  
4 1 /1 5 0 ( 2 7 % )  at 12 mo
8 9 /1 5 0 ( 6 0 % )  at 3 mo  
7 7 /1 5 0  (51%) at 6 mo  
7 5 /1 5 0 ( 5 0 % )  at 12 mo
Hassan et al. 1999 (Canada) 52 Not stated 
mean 5.5
Classical 4 :1(49)  
M odified M C T (3)
6 /52  (11 .5% ) Not stated 35/52  (67.3%)
Hopkins & Lynch. 1970 (Australia) 34 1-13 Classical 3:1 3/34  (8.8%) Not stated N ot stated
Huttenlocher et al. 1971 (U S A ) 12 2 .5 -16 MCT 4 /1 2 ( 3 3 % ) Not stated N ot  stated
Huttenlocher,  1976 (U S A ) 18 1.5-18 M C I 4 /1 8 ( 2 2 % ) 1 0 /1 8 (5 6 % ) 1 6 /1 8 (8 9 % )
Janaki, 1976 (India) 15 0-30 Classical 4:1 3/15 (20%) Not stated 15/15 (100%)
Kankirawatana et al. 2001 (Thailand) 35 0 .2-13 Classical  4:1 5/35 (14%) at 3 mo  
4/35 (11%) at 6 mo  
3/35 (9%) at 12 mo
15/35 (43%) at 3 mo  
12/35 (34%) at 6 mo  
8/35 (23% ) at 12 mo
17/35 (49%) at 3 mo  
15/35 (43%) at 6 mo  
10/35 (29%) at 12 mo
Kang et al. 200 5  (Korea) 199 0.5-17 .5 Classical 4:1 70 /1 9 9  (35% ) at 3 mo  
6 6 /1 9 9  (33%) at 6 mo  
5 0 /1 9 9 ( 2 5 % )  at 12 mo
N ot stated 123/199 (62%) at 3 mo  
1 1 5 /1 9 9 (5 8 % )  at 6 mo  
8 2 /1 9 9 ( 4 1 % )  at 12 mo
Katyal et al, 2 0 0 0  (U S A ) 48 Not stated Classical 3:1 - 5 : 1 Not stated 16/48 (33%) 30 /48  (63%) at 45  days
Kinsman et al. 1992 (U S A ) 58 1-19.6 Classical 4:1 N ot  stated 17/58 (29%) 22 /58  (38%)
Mackay et al, 2005  (Australia) 26 2.3-13 .2 Classical.  3:1-4.2:1 4 /2 6 ( 1 5 % ) 5 /2 6 (1 9 % ) 7/26  at 3 m o (27%)  
4/26  at 6 m o (15%)  
8/26  at 12 mo (31%)
Mak et al. 1999 (Taiwan) 13 3-13 M CI None 5/13 (38%) 7/13 (54%)
Maydell et al. 1999 (U S A ) 143 0 .3-9 Classical 4:1 21 /143  (15%) at 3 mo  
24/143  (17%) at 6 mo  
23/143  (16% ) at 12 mo
43/143  (30%) at 3 mo  
4 1 /143  (29%) at 6 mo  
38/143  (27%) at 12 mo
59/143  (41%) at 3 mo  
60/143  (42%) at 6 mo  
54/143  (38% ) at 12 mo
Ross et al, 1985 (U S A ) 9 0 .25-13 MCT 2/9 (22% ) at 10 w eeks N ot  stated 6/9  (66%) at 10 w eeks
Schwartz et al. 1989a (UK ) 59 <5 - > 1 5 Classical 4:1 (15), MC T (22),  
modified  M C I'(13),  M ixed (9)
N ot  stated 26/63  studies on 55 children  
(41%)
51/63 studies on 55 children 
(81%)
Sills  e ta l ,  1986 (U K ) 50 2-15 M C I 8 /5 0 ( 1 6 % ) 12/50 (24%) 2 2 /50  (44%)
Trauner, 1985 (U S A ) 17 1-13 M C I 5 /1 7 ( 2 9 % ) Not stated 1 0 /1 7 (5 9 % )
V in ing  et al. 1998 (U S A  multicentre) 51 1-8 Classical  4:1 6/51 (12%) at 3 mo  
6/51 (12%) at 6 mo  
5/51 (10%) at 12 mo
13/51 (25%) at 3 mo  
15/51 (29% ) at 6 mo  
11/51 (22% ) at 12 mo
28/51 (54%) at 3 mo  
27/51 (53%) at 6 mo  
20/51 (40%) at 12 mo
Table 3.1 Efficacy of the ketogenic diet -  a review of the literature
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When interpreting this table, it is important to note that the values for 
proportions that fall into each of the three categories of seizure free, greater than 90% 
reduction, and greater than 50% reduction, are given as a percentage of the number of 
children starting the diet, not as a percentage o f those who were still on the diet at 
each time point. Authors vary in their choice o f denominator; standardization for this 
table allows more accurate comparisons between studies. It must also be noted that 
the category of greater than 90% reduction will include the seizure free children, and 
the greater than 50% reduction category will include the seizure free and greater than 
90% reduction group. Some studies do not state how long individuals were on the diet 
when results were reported. Where possible, the table gives results after 3, 6 and 12 
months on the diet. The majority o f studies reported use of the classical diet, those 
using the MCT version tended to have considerably smaller sample sizes.
Despite the number o f studies reporting successful use of the ketogenic diet, 
there are concerns about the quality o f the evidence base to support its claims of 
efficacy. The studies in Table 3.1 are all based on clinical series of patients, with 
either retrospective analysis o f data or assessment of outcomes, or designed as 
prospective observational clinical trials; none were randomized or controlled. There 
have also been no randomized trials comparing the two diet protocols, despite 
frequent anecdotal claims that the classical diet may be more efficacious. Recent 
ILAE treatment guidelines for evidence-based analysis of anti-epileptic drug efficacy 
(Glauser et al, 2006) rate studies into four classes o f evidence, based on criteria 
adapted from the American Academy of Neurology (Edlund et al, 2004) scoring 
systems. A class 1 efficacy study will be a randomized controlled trial, in a 
representative population, with a primary efficacy outcome, > 48 week treatment 
duration, > 24 weeks of efficacy data, a double blind design, and no forced study exit
due to treatment-emergent seizures. Appropriate statistical analysis must be applied, 
and either superiority demonstrated, or the study must have a sample size sufficient to 
show non-inferiority o f no worse than a 20% relative difference in efficacy. A class II 
study will meet all the above criteria except with treatment duration of > 24 weeks but 
< 48 weeks, and no demonstration o f superiority, with a sample size allowing non­
inferiority with a 21-30% difference in efficacy to be shown. A class III study will be 
a randomized controlled trial not meeting the above two criteria, and a class IV study 
will provide evidence from non-randomized, prospective, controlled or uncontrolled 
studies. Current evidence for use o f the ketogenic diet is all based on class IV studies: 
it is clear that more appropriate studies designs are needed to further evaluate its 
efficacy.
There is also a need to compare use o f the two types of ketogenic diet. The 
only previous study to examine this question, in 55 children and 4 adults using either 
a classical, MCT, or modified MCT ketogenic diet, reported no statistically significant 
difference in short term clinical effects (Schwartz et al, 1989a): 22 of the 24 (92%) 
individuals using the classical diet had a greater than 50% seizure reduction, and 29 of 
the 39 (74%) individuals using either the MCT or modified MCT diet had a greater 
than 50% seizure reduction. However this study was non-randomized, and results 
were obtained after only 3 weeks; there are no other data comparing the two diets on 
either a short or longer-term basis.
A frequently asked question is whether certain types o f seizure or syndrome 
will respond better to ketogenic diet treatment? It was traditionally thought to be most 
successful in treating patients with myoclonic or atonic seizures, or the mixed seizures 
seen in Lennox-Gastaut syndrome, however Freeman et al (1998) found no significant 
difference in efficacy between different types of seizure, including those o f a focal
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nature. Maydell (2001) also reported benefit in children with focal seizures; although 
there was a tendency for improved outcome in the generalized rather than focal 
seizure group, differences were not significant. In a study comparing children who 
showed a dramatic early response to diet treatment with a control group of 
unsuccessful children. Than et al (2005) found the absence of complex partial seizures 
in the early responders to be the only significant difference. Kang et al (2005) 
reported seizure outcomes for children with infantile spasms, Lennox-Gastaut 
syndrome, and nonspecific partial seizures (n=54) to be similar to each other, with no 
difference in outcome between the different seizure types presenting as part o f the 
Lennox-Gastaut syndrome. To make a statistical comparison, the authors defined two 
outcome groups, favourable (>50% seizure reduction and continued diet beyond 12 
months) and unfavourable (<50% seizure reduction and stopped diet before 12 
months); there was no difference between children defined as having a symptomatic 
or cryptogenic etiology to their epilepsy, or between those whose pre-dominant 
seizure type was generalised or partial, although the partial seizure group and those 
with a symptomatic etiology were more likely to relapse after completing their 
treatment with the diet. Other seizure syndromes where good efficacy has been 
documented include infantile spasms (Kossoff et al, 2002b), severe myoclonic 
epilepsy of infancy (Caraballo et al, 2005), tuberous sclerosis complex (Kossoff et al, 
2005), and myclonic astatic epilepsy (Oguni et al, 2002; Kilaru & Bergqvist, 2007),
The aim of this study was to conduct the first randomized controlled trial on 
the ketogenic diet, addressing two main questions:
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1. Are there clear benefits in terms o f seizure control in the group o f children 
with epilepsy treated with a ketogenic diet as compared to a control group (no 
additional treatment)?
2. Is the classical ketogenic diet more efficacious than the MCT ketogenic diet in 
controlling seizures, as often claimed but not supported by scientific evidence.
3.2 Methods
3.2.1 Assessment o f  primary outcome -  diet efficacy
The primary outcome of the study was a change in seizure activity. This was
assessed by the following methods.
a) Parental/carer recording of seizures using specially designed charts (See appendix 
to chapter 3). Epilepsy syndrome was diagnosed where possible according to the 
latest diagnostic scheme proposed by the ILAE (Engel, 2001). Seizures were 
classified into 6 categories for recording (absence, myoclonic, atonic, tonic, tonic- 
clonic and focal). At the initial hospital consultation, a description of the child's 
seizures was discussed with a consultant paediatric neurologist, who then advised 
as to how they should be categorized for subsequent recording. Seizures were 
recorded daily for the 4 week baseline period, during the additional 3 months prior 
to starting the diet for the group acting as controls, and throughout the time a child 
was on the diet. The 28 days prior to a time point were used to calculate total 
seizure numbers at that time point, and mean daily seizure numbers were then 
calculated. These were expressed as a percentage of the mean daily seizure 
numbers during the 4-weeks prior to a child starting the diet (this was the 4 week 
baseline period for non-controls, and the last 4 weeks of the control period for the 
control group). Defined time points for assessment and analysis were 3 months, 6
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months and 12 months on the diet. An additional time point at the end o f the 3- 
month control period was used in the group acting as controls; mean daily seizure 
numbers over the last 4 weeks o f this period were compared with those in the 4 
week baseline period.
b) Anti-epileptic medication use was documented prior to starting the diet. After the 
initial 3 months of dietary treatment, during which medication was not changed, 
the aim was to progressively reduce medication dosages in children who were 
doing well in terms of seizure reduction.
A secondary outcome was to examine ketosis. Parents were asked to 
document urinary ketones twice daily. Blood samples were taken where possible from 
all children following a ketogenic diet at their outpatient clinic visits (before starting 
the diet and after 3, 6 and 12 months). Serum p-hydroxybutyrate and acetoacetate 
levels were measured in the hospital laboratories.
3.2.2 Sample size calculation
This trial was designed as comparative; the hypothesis being tested was that the 
classical diet might be more efficacious than the MCT diet as a treatment. Using a 
null hypothesis that the two diets were not significantly different in their effect on 
seizure control, and defining 25% as the minimum outcome difference o f clinical 
importance, the sample size formula for comparing two means gave a necessary 
sample of 47 per diet group, allowing detection of a difference significant at 5% with 
a power of 90%. This was based on an expected outcome range of mean percentage of 
baseline seizures from 0 -  150% (standard deviation o f 37.5%). This sample would 
allow detection of a 25% or more difference in mean percentage o f baseline seizures
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in the MCT diet group as compared to the classical diet group; any difference greater 
than this would be regarded as clinically significant.
3.2.3 Statistical analysis
Analysis for this thesis was based on total numbers of daily seizures; the more 
detailed subdivision into the six individual types, with subsequent changes in pattern 
of seizure activity, is not included. Statistical analyses were performed on the 
efficacy data as outlined below, in order to answer the following questions:
1. Was there a significant difference in efficacy between diet and control groups? 
The unpaired t test was used to compare mean percentage of baseline seizure numbers 
after 3 months between children on a ketogenic diet and those acting as controls. For 
this analysis, only the diet data from the children who were not controls was used, to 
avoid any bias in the diet data provided by the control children resulting from the 
additional delay in commencing treatment. Multiple linear regression was used to 
examine the association between whether a child was on the diet or a control, and 
their percentage of baseline seizures, taking into account sex and age group (three age 
groups were defined, as for the initial randomization (2-6 years, 7-11 years, 12-16 
years). Cut off points of greater than 50% and 90% seizure reduction were applied, 
and the Fishers exact test used to examine differences between diet and control groups 
in relation to these cut off points.
2. How did the classical and M CT ketogenic diets compare in terms o f  efficacy? 
The unpaired t test was used to compare mean percentage of baseline seizure numbers 
in the classical and MCT diet groups after 3, 6 and 12 months. Data was provided 
from all children, both those who had started the diet after only 4-week baseline, and
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those who had an additional 3-month control period before starting. Multiple linear 
regression was used to examine the association between which ketogenic diet a child 
was following, and their percentage o f baseline seizure numbers, taking into account 
sex and age group. Cut off points o f greater than 50% and 90% seizure reduction were 
applied, and the Fishers exact test used to examine differences between the two diet 
groups in relation to these cut off points. In children who continued the diet for 12 
months, linear regression was used in each child separately to determine the gradient 
of the line of best fit o f their serial values of percent baseline seizure numbers (3, 6 
and 12 months). The resulting gradient value was used to represent the overall change 
in seizure numbers in that child over the 12-month period. The unpaired t-test was 
used to compare the mean gradient o f the line of best fit between the two diet groups. 
The number of children who had their medication dosage reduced after 3 months 
treatment was also compared between the two diet groups using the Fishers exact test.
3. Was there any difference in efficacy according to epilepsy syndromes?
A number o f syndrome groups were defined, and children allocated to one o f these 
groups. The mean percentage of baseline seizure numbers was calculated for each 
syndrome group separately. Where possible, children were also categorized into two 
broad classifications of symptomatic generalized or symptomatic focal epilepsy, to 
allow a comparison of mean percentage of baseline seizure numbers between these 
two groups, using the unpaired t-test. In children who completed 12 months of 
treatment, this test was also used to compare the mean gradient of the line of best fit 
between symptomatic generalized and symptomatic focal groups.
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4. Was there any difference in ketosis between the two diet groups, and did this 
correlate with dietary efficacy?
The unpaired t test was used to compare mean P-hydroxybutyrate and acetoacetate 
levels in the classical and MCT diet groups at baseline, and after 3, 6 and 12 months. 
Spearman's correlation coefficient was used to examine the association between a 
child's p-hydroxybutyrate and acetoacetate levels at each time point (3, 6 and 12 
months), and their percentage of baseline seizures at that time.
SPSS software version 13 was used for all statistical analysis.
3.3 Results
3.3.1 Trial overview
Recruitment for the study commenced December 2001, and closed July 2006. This 
thesis is based on results collected by the end of 2007. Figures 3.1 and 3.2 illustrate 
the flow of children through each stage of the study.
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Figure 3.1 Flow o f children through the trial -  diet V control
Assessed for eligibility 
(n= 150)
Excluded (n=5: 2 did not 
meet inclusion criteria, 3 
refused to participate)
Enrollment
Randomized (n=145)
Allocated to a ketogenic diet without 
control period (n= 73)
Received dietary treatment 
(n=65)
Did not receive treatment (n=8:
5 changed mind, 1 seizures improved, 
2 diagnosis changed)
Allocation
Lost to follow-up (n=0)
Discontinued intervention (n=10: 
6 poor tolerance, 3 parental 
unhappiness, 1 increased seizures)
Follow-Up
Analyzed (n=54)
Excluded from analysis as 
inadequate data (n=l)
Analysis
Allocated to control period before 
diet start (n=72)
Received control period intervention 
(n=64)
Did not receive intervention, ie did 
not start control period (n= 8: 5 
changed mind, 1 died, 1 seizures 
improved, 1 diagnosis changed)
Lost to follow-up (n=0)
Discontinued intervention (n=0, 
all who started control period 
completed the 3 mo data 
collection)
Analyzed (n= 49)
Excluded from analysis as 
inadequate data (n=15)
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Figure 3.2 Flow o f children through the trial -  classical V M CT diet
Enrollment
Randomized (n=T45)
Assessed for eligibility 
(n= 150)
Excluded (n=5: 2 did not 
meet inclusion criteria, 3 
refused to participate)
Allocated to classical diet 
(n=73)
Received dietary treatment 
(n=61)
Did not receive treatment (n=12:
7 changed mind, 1 died, 1 seizures 
improved, 3 diagnosis changed)
Lost to follow-up (n=0)
Discontinued treatment (n:= 10:
4 poor tolerance, 2 parental
unhappiness, 4 increased
seizures)
Analyzed (n=45)
Excluded from analysis as 
inadequate data (n=6)
Follow-Up
Analysis
Allocation
Allocated to MCT diet 
(n=72)
Received dietary treatment 
(n=64)
Did not receive treatment (n=8:
3 changed mind, 3 seizures improved, 
2 unable to travel so treated locally 
outside of trial)
Lost to follow-up (n=0)
Discontinued treatment (n=15:
10 poor tolerance, 4 parental 
unhappiness, 1 increased seizures)
Analyzed (n=49)
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The analysis was limited to those children from whom seizure data was available at 
the given time points. An ‘intention to treat’ analysis was not possible, as seizure data 
was not available on the other children not remaining on the diet. Baseline 
demographic characteristics o f children randomized to, and included in the final 
analysis, o f each of the study groups are given in tables 3.2 and 3.3.
Table 3.2 Baseline characteristics of children allocated to each study 
group and included in final analysis - diet V control
Diet group Control group
Allocated Included in Allocated Included in
to study final to study final
group analysis group analysis
3 II^ 4 (n=54) (n=72) (n=49)
Boys 38 (52.1%) 30 (55.6%) 38 (52.8%) 25 (51.0%)
Girls 35 (47.9%) 24 (44.4%) 34 (47.2%) 24 (49.0%)
Aged 2-6 yrs 37 (50.7%) 28 (51.9%) 29 (40.3%) 20 (40.8%)
Aged 7-11 yrs 27 (37.0%) 20 (37.0%) 32 (44.4%) 20 (40.8%)
Aged 12-16 yrs 9(12.3% ) 6(11.1% ) 11 (15.3%) 9(18.4% )
Table 3.3 Baseline characteristics of children allocated to each study 
group and included in final analysis -  classical V MCT diet
Classical diet group MCT diet group
Allocated Included in Allocated Included in
to study final to study final
group analysis group analysis
(n=73) (n=45) (n=72) (n=49)
Boys 40 (54.8%) 26 (57.8%) 36 (50.0%) 25 (51.0%)
Girls 33 (45.2%) 19(42.2%) 36 (50.0%) 24 (49.0%)
Aged 2-6 yrs 32 (43.8%) 21 (46.7%) 34 (47.2%) 24 (49.0%)
Aged 7-11 yrs 31 (42.5%) 16(35.5%) 28 (38.9%) 20 (40.8%)
Aged 12-16 yrs 10(13.7%) 8(17.8% ) 10(13.9%) 5 (10.2%)
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At the time of study entry, 6 children were on no epilepsy medications, 20 children 
were on one medication, 53 children on two medications, 54 children on three 
medications, 11 children on four medications, and one child on five medications. 
Children had a mean of 11.6 seizures daily (10.1 in control group v 13.3 in diet group; 
9.9 in classical diet group v 13.3 in MCT diet group). Eight children were recruited 
from the residential centre; all others attended the hospital as outpatients while living 
at home. Of the residential centre group; one never started the diet due to parental 
circumstances, three stopped before 3 months (one intolerance, one parental 
unhappiness and one increased seizures), and two stopped at 3 months due to limited 
efficacy. Only two continued beyond 3 months of treatment.
3.3.2. Comparison between diet and control groups
Table 3.4 shows results for percentage o f baseline seizure numbers after 3 months in 
the diet and control groups. This is illustrated in Figure 3.3.
Table 3.4 Percentage of baseline seizure numbers after 3 months in 
diet and control groups
Percent baseli 
Diet group 
(n=54)
ne seizures (%)
Control group 
(n=49)
Mean 62.01 136.93
95% confidence interval for mean 49.63 -74 .38 105.17- 168.68
Median 47.65 106.25
Standard deviation 43.34 110.56
Range 0.00 -  200.00 28.21 -5 7 5 .0 0
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Figure 3.3 Percentage of baseline seizure numbers in diet and control
groups
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The difference between the mean percentage baseline seizures in diet and control 
groups was 74.92% (95% confidence interval of difference 42.43 -  107.40). This 
difference was highly significant (p=0.000). Although data distribution is clearly 
skewed, with a number of outliers, and a digression between mean and median values 
for both groups, this difference remained at the same highly significant level when 
additionally tested using non-parametric methods (Mann-Whitney U). Removal of 
outliers before analysis lowered the mean difference to 44.05% (95% confidence 
interval of difference 25.46 -  62.64), but this remained highly significant (p=0.000). 
Using a linear regression model to take into account the sex and age group of the 
child, the difference between the mean percentage baseline seizures in diet and control 
groups increased slightly to 76.63% (95% confidence interval of difference 44.37 -
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108.89): this was still highly significant (p=0.000). Although the wide confidence 
intervals represent the data to be compatible with a broad range of clinical scenarios, 
it is clear from these results that the ketogenic diet group had a significantly better 
outcome in terms of efficacy than the control group.
Table 3.5 shows the numbers o f children in each group achieving a greater 
than 50% or 90% seizure reduction after 3 months, using numbers of children actually 
started on either a ketogenic diet, or the control period, as denominators. This is 
significantly greater in the diet group at the 50% cut off level, but non-significant at 
the 90% level.
Table 3.5. Numbers of children in each group achieving 50% and 
90% seizure reduction after 3 months, based on numbers who 
actually started their allocated intervention
Numbers achieving cut off points
Diet group 
(n=65)
Control group 
(n=64)
p value
Greater than 90% 
seizure reduction 5 (7.7%) 0 0.0577
Greater than 50% 
seizure reduction 28 (43.1%) 4 (6.3%) <0.0001
3.3.3. Comparison between classical and M CT diet groups after 3 months
Table 3.6 shows results for percentage o f baseline seizure numbers after 3 months in 
the two diet groups. This is illustrated in Figure 3.4.
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Table 3.6 Percentage of baseline seizure numbers after 3 months in
classical and MCT diet groups
Percent baseli 
Classical diet group 
(n=45)
ne seizures (%)
MCT diet group 
(n=49)
Mean 66.50 68.85
95% confidence interval for mean 52.29 -  80.73 51.77-85.93
Median 58.14 58.12
Standard deviation 47.34 59.47
Range 0.00 -  200.00 0.00- 385.71
Figure 3.4 Percentage of baseline seizure numbers after 3 months in 
classical and MCT diet groups
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The mean percentage of baseline seizure numbers after 3 months was 2.45% lower in 
the classical diet group (95% confidence interval of difference -19.80 -  24.29). This 
difference was not significant (p=0.834). Figure 3.4 shows the data had one extreme 
outlier in the MCT diet group, on reanalysis excluding this outlier; the mean
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percentage o f baseline seizures in the MCT diet group fell to 62.25% (standard 
deviation 37.83%). This was 4.26% lower than the classical diet group (95% 
confidence interval of difference 13.34 -  21.85), and still non-significant (p=0.632). 
Using a linear regression model to take into account the sex and age group of the 
child, the difference between the mean percentage baseline seizures in the two diet 
groups increased very slightly to 3.45% (95% confidence interval of difference -19.22 
-  26.11), still non-significant (p=0.763). These results show that after 3 months of 
ketogenic diet treatment, there was no difference in terms of efficacy between the 
classical or MCT diet protocols.
Table 3.7 shows the numbers o f children in each diet group achieving a greater 
than 50% or 90% seizure reduction after 3 months, using the numbers of children 
started on either of the ketogenic diets as denominators. There was no significant 
difference between the two groups at either 90% or 50% cut off level.
Table 3.7. Numbers of children in each diet group achieving 50% and 
90% seizure reduction after 3 months, based on numbers who 
actually started their allocated intervention
Numbers achieving cut off points
p valueClassical diet group 
(n=61)
MCT diet group 
(n=64)
Greater than 
90% seizure 
reduction
5 (7.8%) 2(3.1% ) 0.2656
Greater than 
50% seizure 
reduction
18(29.5%) 21 (32.8%) 0.7043
After 3 months of treatment, 26 children on the classical diet and 27 children on the 
MCT diet were able to have their anti-epileptic medication dose reduced (p= 0.841).
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3.3.4. Comparison between classical and M CT diet groups after 6 and 12 months
Fewer numbers of children provided seizure data at 6 and 12 months, due in part to 
children discontinuing diet treatment, and in part to unavailable data for analysis. 
Table 3.8 gives numbers of children providing data for analysis at each time point and 
reasons why some data was unavailable.
Table 3.8. Flow of children through the study after 3 months
Numbers of children
Classical diet MCT diet
Discontinued diet after 3 month follow up 9 11
Moved away after 3 month follow up 1 0
Data available for 6 month analysis 30 34
Discontinued diet after 6 month follow up 5 5
Discontinued diet after 9 months treatment 1 1
Data available for 12 month analysis 22 25
Data unavailable at 6 and 12 months 5 4
O f the 45 children on the classical diet who had seizure data analysed at 3 months, 9 
discontinued treatment after the 3 month follow up visit (20%); of the 49 children on 
the MCT diet who had seizure data analysed at 3 months, 11 discontinued treatment 
after the 3 month follow up visit (22.4%). Reasons for discontinuation at this point 
were based on limited efficacy, the psychosocial costs of following the strict dietary 
regime outweighing the benefit seen in terms of seizure reduction. A further 10 
children (5 on each diet) discontinued for the same reason after the 6 month follow 
up, and 2 more after 9 months. By 12 months, 32 children out of the original 94 who 
provided 3-month data (34%) had stopped treatment. Data was unavailable for 9 
children who had completed 12 months of treatment, but failed to keep adequate 
records.
Table 3.9 shows results for percentage of baseline seizure numbers after 6 
months in the two diet groups. This is illustrated in Figure 3.5.
Table 3.9 Percentage of baseline seizure numbers after 6 months in 
classical and MCT diet groups
Percent baseli 
Classical diet group 
(n=30)
ne seizures (%) 
MCT diet group 
(n=34)
Mean 48.53 67.62
95% confidence interval for mean 32.40 -  64.67 45.86-89.39
Median 37.51 62.05
Standard deviation 43.21 62.36
Range 0 -1 6 0 .5 3 0 -300 .00
Figure 3.5 Percentage of baseline seizure numbers after 6 months in 
classical and MCT diet groups
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The mean percentage of baseline seizure numbers after 6 months was 19.09% lower 
in the classical diet group (95% confidence interval of difference -8.08 - 46.25). This 
difference was non-significant (p=0.165). Data distribution appears skewed, with 
some digression between mean and median values, especially in the classical diet 
group, however a similar significance level was seen when an additional non- 
parametric test was applied (Mann-Whitney £/, p=0.213). There were two extreme 
outliers in the MCT diet group, on reanalysis excluding these outliers; the mean 
percentage of baseline seizures in the MCT diet group fell to 55.01% (standard 
deviation 35.87%). This was 6.47% higher than the classical diet group (95% 
confidence interval of difference 13.65 - 26.60), (p=0.522).
Using a linear regression model to take into account the sex and age group of 
the child, the difference between the mean percentage baseline seizures in the two diet 
groups at 6 months remained very similar at 19.25% (95% confidence interval of 
difference -8.44 -  46.94), still non-significant (p=0169). These results show that 
although after 6 months of ketogenic diet treatment the classical protocol does appear 
to show slight superiority in terms of efficacy there was no statistically significant 
difference in seizure reduction between the classical or MCT diets.
Table 3.10 shows the numbers of children in each diet group achieving a 
greater than 50% or 90% seizure reduction after 6 months, using the numbers of 
children started on either of the ketogenic diets as denominators. There were no 
significant differences between the two diet groups in numbers of children achieving 
either greater than 50% or greater than 90% seizure reduction.
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Table 3.10. Numbers of children in each diet group achieving 50% 
and 90% seizure reduction after 6 months, based on numbers of 
children who actually started their allocated intervention
Numbers achieving cut off points
p valueClassical diet group 
(n=61)
MCT diet group 
(n=64)
Greater than 
90% seizure 
reduction
6 (9.8%) 4 (6.3%) 0.524
Greater than 
50% seizure 
reduction
18(29.5%) 14(21.9%) 0.413
Table 3.11 shows results for percentage of baseline seizure numbers after 12 
months in the two diet groups. This is illustrated in Figure 3.6.
Table 3.11 Percentage of baseline seizure numbers after 12 months in 
classical and MCT diet groups
Percent baseli 
Classical diet group 
(n=22)
ne seizures (%) 
MCT diet group 
(n=25)
Mean 40.83 53.16
95% confidence interval for mean 24 .08-57 .57 30.42-75.91
Median 36.55 31.29
Standard deviation 37.77 55.10
Range 0 -1 2 3 .7 2 0 -1 9 6 .5 2
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Figure 3.6 Percentage of baseline seizure numbers after 12 months in
classical and MCT diet groups
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The mean percentage of baseline seizure numbers after 12 months was 12.34% lower 
in the classical diet group (95% confidence interval o f difference -15.81 -  40.47). 
This difference was non-significant (p=0.382). Although this mean percentage was 
lower in the classical diet group, the median was lower in the MCT group. Using a 
linear regression model to take into account the sex and age group of the child, the 
difference between the mean percentage baseline seizures in the two diet groups at 12 
months remained similar at 12.53% (95% confidence interval of difference -16.09 -  
41.14), non-significant (p=0.382). These results show that although after 12 months of
8 2
ketogenic diet treatment there were no significant differences between the two 
protocols.
Table 3.12 shows the numbers of children in each diet group achieving a 
greater than 50% or 90% seizure reduction after 12 months, using the numbers of 
children started on either o f the ketogenic diets as denominators. There were no 
significant differences between the two groups at the 50% or 90% cut off level.
Table 3.12. Numbers of children in each diet group achieving 50% 
and 90% seizure reduction after 12 months, based on numbers of 
children who actually started their allocated intervention
Numbers achievin g cut off points
p valueClassical diet group 
(n=61)
MCT diet group 
(n=64)
Greater than 
90% seizure 
reduction
7(11.5% ) 7(10.9%) 1.000
Greater than 
50% seizure 
reduction
13 (21.3%) 16(25%) 0.676
The overall change in percentage o f baseline seizure numbers for individual children, 
during the course o f the 12-month study period, was plotted for the two diets 
separately (Figure 3.7).
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Figure 3.7. Overall change in percentage baseline seizure numbers 
over 12 months in children on the classical and MCT ketogenic diets
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Although these graphs allow visualisation of overall trends, it is difficult to see any 
clear patterns without more detailed statistical analyses. In children who completed 12 
months of dietary treatment, the use of a gradient of the line of best-fit technique 
allowed a value to be assigned to each individual; this value representing their overall 
pattern of change in seizure frequency during the 12 months. Summary gradient data 
for each diet group was then analysed (Table 3.13). Although there is considerable 
variation between individuals in their pattern of change in seizure frequency, both diet
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groups as a whole appear similar: the mean difference in gradient between the 
classical and MCT groups was -1.025 (95% confidence interval of difference -3.360 
-  1.310); this was not significant (p=0.381).
Table 3.13 Summary gradient of best-fit line data in classical and 
MCT diet children completing 12 months of treatment
Gradient o 
Classical diet group 
(n=22)
* best-fit line
MCT diet group 
(n=25)
Mean -4.10 -3.08
95% confidence interval for mean -5.48 - -2.73 -4.97- -1.18
Median -4.35 -4.68
Standard deviation 3.10 4.59
Range -7 .9 6 -4 .2 8 -8.21 -8 .8 8
3.3.5. Analysis by seizure syndrome
Syndrome groups were defined to assess how efficacy varied across the different 
seizure syndromes. Table 3.14 shows the numbers of children randomized to each of 
the study groups subdivided by seizure syndrome.
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Table 3.14. Numbers of children allocated to study groups, by 
syndrome
Numbers allocated to each study group
Diet v control Classical v MCT
Syndrome diagnosis Diet
group
(n=73)
Control
group
(n=72)
Classical
group
(n=73)
MCT
group
(n=72)
Symptomatic generalised 
(unspecified)
11 11 8 14
Symptomatic focal:
- focal (no brain abnormality specified)
- multifocal (no brain abnormality 
specified)
- structural brain malformation 
(including tuberous sclerosis)
9
5
15
7
9
12
9
8
13
7
6
14
SMEI (severe myoclonic epilepsy of 
infancy)
2 5 3 4
Lennox-Gastaut syndrome 7 7 6 8
West syndrome (Infantile spasms) 6 5 8 3
Myoclonic absence epilepsy 4 3 4 3
Myoclonic epilepsy (unspecified) 2 6 5 3
Myoclonic astatic epilepsy 4 4 1 7
Atypical absence epilepsy 1 2 2 1
Childhood absence epilepsy 2 0 0 2
Degenerative conditions 3 0 3 0
Early myoclonic encephalopathy 0 1 1 0
ESESS (electrical status epilepticus of 
slow sleep)
2 0 2 0
Due to the small numbers in the last five groups, these were excluded from the 
syndrome analysis. Table 3.15 shows the mean percentage of baseline seizures after 3,
6 and 12 months in each of the remaining syndrome groups, based on the numbers o f 
children from whom data was available for analysis at each of the time points.
Table 3.15. Mean percentage of baseline seizures at 3, 6 and 12 
months in defined syndrome groups
Mean (SD) percentage baseline seizure numbers 
at each time point (number of children in each 
group providing data at that time point)
3 months 6 months 12 months
Symptomatic generalised 
(unspecified)
73.23% (53.87) 
(n = ll)
68.10% (36.82) 
(n=7)
73.46% (89.84) 
(n=2)
Symptomatic focal:
- focal (no brain abnormality 
specified)
74.70% (40.42) 
(n=12)
63.20% (40.51) 
(n=8)
23.85% (17.76) 
(n=4)
- multifocal (no brain abnormality 
specified)
92.15%( 109.05) 
(n = ll)
86.08% 
(129.25) (n=5)
50.42%
(n=l)
-structural brain malformation 
(including tuberous sclerosis)
67.34% (33.55) 
(n=18)
47.49% (41.96) 
(n=9)
25.15% (29.07) 
(n=7)
SMEI 77.61% (32.0) 
(n=5)
64.15% (51.91) 
(n=3)
0%
(n=l)
Lennox-Gastaut syndrome 50.50% (34.89) 
(n = ll)
40.57% (29.52) 
(n=10)
60.67% (64.84) 
(n=9)
West syndrome 72.82% (68.09) 
(n=6)
44.98% (26.67) 
(n=4)
58.49% (51.10) 
(n=4)
Myoclonic absence epilepsy 54.94% (19.39) 
(n=4)
87.84% (12.33) 
(n=3)
77.60% (7.91) 
(n=2)
Myoclonic epilepsy (unspecified) 58.68% (23.72) 
(n=8)
71.93% (85.20) 
(n=6)
66.56% (53.11) 
(n=6)
Myoclonic astatic epilepsy 58.21% (65.98) 
(n=4)
3.5% (4.95) 
(n=2)
7.31% (10.33) 
(n=2)
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The numbers in each group providing data at 3, 6 and 12 months were too 
small for between-group statistical analysis: a between-group comparison of the mean 
gradients o f the best fit lines in children completing 12 months was also not possible 
due to small numbers.
Two additional categories were defined: all seizure syndrome groups that 
could be grouped together as being symptomatic generalised in origin, and all seizure 
syndrome groups that could be grouped together as being symptomatic focal in origin. 
Of the 125 children who started dietary treatment, 114 were able to have their seizures 
broadly classified in this way (62 symptomatic generalised, 52 symptomatic focal); 
not all seizure syndromes could be included. Table 3.16 shows the mean percentage of 
baseline seizures after 3, 6 and 12 months in these two groups: there were no 
significant differences at 3 and 6 months, the difference at 12 months was just 
significant.
Table 3.16. Mean percentage of baseline seizures at 3, 6 and 12 
months in symptomatic generalised and symptomatic focal groups
Time point
Mean (SD) percent 
time point (numbei 
dal
age baseline seizure 
* of children in eacli 
ta at that time point
numbers at each 
group providing
t)
Symptomatic
generalised
Symptomatic
focal
p value
3 months 59.62% (44.31) 
(n=44)
76.15% (63.29) 
(n=41)
0.164
6 months 58.40% (45.82) 
(n=32)
61.97% (68.03) 
(n=22)
0.819
12 months 61.73% (54.57) 
(n=24)
26.82% (24.55) 
(n=12)
0.043
In the children who completed 12 months of treatment, the mean gradients o f the line 
o f best fit o f their serial percentage of baseline seizure values were compared. This 
was significantly lower in the symptomatic focal group (-5.51) than in the
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symptomatic generalised groups (-2.16; p=0.022); the focal group therefore showing a 
more significant trend in seizure reduction over the 12 months.
3.3.6. Ketosis and seizure control
Table 3.17 and Figure 3.8 show the serum p-hydroxybutyrate levels in the children on 
the classical and MCT ketogenic diets at each time point. The mean level was higher 
in the classical diet group after 3, 6 and 12 months of treatment; this was significant at 
3 and 6 months only. However, there was a wide range in individual values, with the 
highest level at all time points on the diet seen in a child on the MCT diet.
Table 3.17. Serum p-hydroxybutyrate levels in children on classical 
and MCT ketogenic diets
Time
(months)
p-hydroxybutyrate level (mmol/1)
Mean ± SD (range), (no of children from whom data
available)
p value
Classical diet MCT diet
0 0.08 ±0.13 0.07 ±0.67 0.596
(<0.05 -  0.86) (<0.05 -  0.46)
(n=42) (n=49)
3 4.21 ± 1.73 2.71 ± 1.70 0.000
(0.11 -7 .3 2 ) (0.05 -  8.22)
(n=42) (n=45)
6 4.21 ± 1.44 2.76 ± 1.81 0.001
(1 .10 -6 .84 ) (0 .15 -6 .87 )
(n=32) (n=37)
12 4.24 ± 1.69 3.37 ±2.81 0.224
(1.05 -  8.28) (0.05 -9 .6 5 )
(n=22) (n=22)
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Figure 3.8. Serum p-hydroxybutyrate levels in children on classical
and MCT ketogenic diets
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Table 3.18 and Figure 3.9 show the serum acetoacetate levels in the children on the 
classical and MCT ketogenic diets at each time point. The mean level was 
significantly higher in the classical diet group after 3, 6 and 12 months, although there 
was again a wide range in values during the course of the study.
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Table 3.18. Serum acetoacetate levels in children on classical and
M CT ketogenic diets
Time
(months)
Acetoacetate level (mmol/1)
Mean ± SD (range), (no of children from whom data 
available)
p value
Classical diet MCT diet
0 0.041 ±0.030  
(0.030-0.192) 
(n=34)
0.063 ± 0.088 
(0.008-0.570) 
(n=42)
0.169
3 1.182 ±0.501 
(0 .033- 1.949) 
(n=37)
0.696 ± 0.475 
(0.0028 -  2.004) 
(n=39)
0.000
6 1.255 ±0.453  
(0.183-2.180) 
(n=31)
0.596 ±0.382 
(0.079-1.648) 
(n=32)
0.000
12 1.263 ±0.692  
(0 .195-2.485) 
(n=2»
0.709 ± 0.485 
(0 .095- 1.806) 
(n=21)
0.005
Figure 3.9. Serum acetoacetate levels in children on classical and 
MCT ketogenic diets
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The correlation between ketone levels and seizure control was examined for all 
children on a ketogenic diet, using Spearman’s correlation coefficient (Table 3.19). 
This was significant for both ketone bodies at 3 months, but not at 6 and 12 months.
Table 3.19. Correlation of serum ketone levels with percentage of 
baseline seizure frequency
Time Correlation with percentage of baseline seizure frequency
(months) P-hydroxybutyrate Acetoacetate
Correlation
coefficient
p value Correlation
coefficient
p value
3 -0.238 0.036* -0.312 0.009**
6 -0.058 0.673 -0.204 0.147
12 0.158 0.366 0.187 0.297
* significant at p<0.05 level 
** significant at p<0.01 level
3.4. Discussion
This study on the use o f two ketogenic diets in childhood epilepsy is an 
important first o f its kind, with no other randomized or controlled trials to date being 
done on the ketogenic diet, despite a number o f other prospective and retrospective 
studies (table 3.1). Our results have clearly shown the benefits of the diet in treating 
children with intractable seizures, as compared to a control group with no additional 
treatment. Despite a wide range in percentage of baseline seizures after 3 months in 
both groups, the difference between the two means was highly significant. Seizures in 
the 54 diet children who did not act as controls fell to a mean of 62% of baseline, and 
increased to 137% of baseline in the control group. Significance was also seen when 
using the more widely accepted cut off point of greater than 50% seizure reduction.
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The use of cut off points allows a comparison with other ketogenic diet studies 
employing the same levels. 43% of our 65 non-control diet children who actually 
started their allocated intervention had a greater than 50% seizure reduction after 3 
months; 8% had a greater than 90% seizure reduction. When the group of 94 children 
who provided diet data for analysis was looked at as a whole, results were very 
similar (41% and 8% respectively).
Analysis by seizure syndrome after 3 months shows children with Lennox- 
Gastaut and the myoclonic epilepsies to have the best outcomes on the diet, although 
statistical comparisons were not possible due to the small numbers in each group. 
When children with seizures of symptomatic generalised origin were compared to 
those of symptomatic focal origin, the 3 and 6-month results show the former group to 
have a better outcome; this was reversed by 12 months. However, the numbers 
remaining on the diet in the focal group were smaller; 24 of the 62 symptomatic 
generalised children who started the diet (38%) were still on treatment at 12 months, 
compared to 12 o f the 52 symptomatic focal children (23%). O f the five children who 
stopped the diet before 3 months due to increased seizures, two had epilepsy o f a 
symptomatic generalised and three o f a symptomatic focal origin.
On comparing our 3-month efficacy results with the literature, it can be seen 
that results in our children on the diet achieving greater than 50% reduction are 
similar to those reported by Coppola et al (2002), Kankirawatana et al (2001), and 
Maydell et al (1999) in their groups o f 56, 35, and 143 children respectively, who had 
been on the classical diet for 3 months. The USA multicentre study (Vining et al, 
1998) found 54% of children to have a greater than 50% seizure reduction after 3 
months, and the two largest studies (Freeman et al, 1998; Kang et al, 2005) both
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reported just under two thirds o f those starting the diet to have greater than 50% 
seizure reduction after 3 months; all using the classical protocol.
The main difference between our results and other studies is that other groups 
report a much higher number o f children, within the greater than 50% cut off group, 
who actually have a greater than 90% reduction. 19-56% of children are reported to 
have a greater than 90% seizure reduction after 3 months on the diet in previous 
studies (table 3.1); the two with the largest number of children (Freeman et al, 1998; 
Kang et al, 2005) reporting 33% and 43% respectively. Why could our results show 
this inferior difference? One possibility is at the study selection stage. The scarce 
nature o f ketogenic diet services in the UK, and the lack of medical awareness about 
the treatment, have meant that it is often viewed as a last resort after everything else 
has failed. The children referred to our trial therefore had very severe intractable 
epilepsy, usually having explored many other treatment options over a number of 
years. Inclusion criteria required at least seven seizures weekly, and having tried at 
least two anticonvulsant medications. In fact, at the time of study entry, our children 
had a mean o f 12 seizures daily. 53 children (37%) were on two medications, 54 
children (37%) on three medications, 11 children (8%) on four medications, and one 
child on five medications. Minimum seizure numbers for entry into the two other 
larger studies were lower; at least two seizures weekly (Freeman et al, 1998), or four 
seizures monthly (Kang et al, 2005) Although both these studies required children to 
have tried at least two (Freeman et al, 1998), or three (Kang et al, 2005) 
anticonvulsant medications, the inclusion o f children with considerably lower 
numbers of seizures at baseline could have resulted in improved outcomes; this may 
go some way in explaining the discrepancy in results from our study. In addition, our 
study did not include children less than two years of age; there is some evidence that
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this age group may respond more favourably than older children (Kossoff et al 2002b, 
Nordli et al 2001).
Critics of the MCT diet protocol (Freeman et al, 2000) may argue that our 
results were negatively influenced by including children on both diets, that the 
superior outcomes seen in other studies were due to use of the classical protocol 
alone. However, the studies reported in Table 3.1 do include the use of both protocols, 
albeit the MCT in much smaller numbers. Our results do not show the classical diet to 
be significantly better in terms o f efficacy outcome. At 3 months, a wide range in 
percentage of baseline seizures was seen in both classical and MCT groups, however 
the two means (67% and 69% respectively) were not significantly different; indeed 
after exclusion of one extreme outlier in the MCT group, this mean fell to 62%. There 
were also no significant differences between the groups in the numbers achieving 
greater than 50% and 90% seizure reduction, or reducing medication dose after 3 
months.
Results after 6 and 12 months also do not show significant differences 
between the classical and MCT diet. 20 children discontinued the diet after their 3- 
month follow-up due to limited efficacy (9 classical and 11 MCT, in total 16% of 
those starting one of the two diets); a further 10 discontinuing after their 6-month 
follow-up (5 each diet, in total 8% of those starting one of the two diets). Nine 
additional children were unable to provide their 6 and 12-month data for analysis. 
Although 6-month results show the 30 children in the classical diet group to have a 
slightly better outcome, with a 19% lower mean percentage of baseline seizures, this 
was not statistically significant, and was reduced to only 6% by removal of the outlier. 
At 12 months, the classical diet again appeared to be slightly superior, with a 12% 
lower mean percentage of baseline seizures, but this was not statistically significant.
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There were no significant differences between the groups in the numbers achieving 
greater than 50% and 90% seizure reduction at 6 or 12 months. The use of a gradient 
o f line of best fit of serial measures in children who completed 12 months of dietary 
treatment is recommended as the appropriate statistical methodology for this type of 
data (Matthews et al, 1990); allowing a mean gradient to be obtained for the two diet 
groups, and thus a statistical comparison of overall change in seizures to be made 
between the groups. The mean gradient in the 22 classical diet children was more 
negative than in the 25 MCT children, indicating more of a reduction in percentage of 
baseline seizures over the 12 months, however this was not significant. Although a 
larger sample size would have been beneficial, these results do not support the 
hypothesis that the classical diet is significantly better in terms of seizure control. It is 
not possible from this study however to conclude equal effectiveness. This would 
require an equivalence study design as opposed to a comparative study design, which 
would require a much larger sample size (Jones et al, 1996), only achievable by using 
a multi-centre study design, run over many years.
In our study, mean levels o f p-hydroxybutyrate and acetoactetate in the blood 
were significantly higher in the classical diet group, although all diets were fine-tuned 
with the aim o f children achieving a high level of urinary ketones (8-16mmol per 
litre), and very high blood ketone levels were found in certain individuals on both 
diets. The increased ketosis in the classical diet group could be expected, as the MCT 
diet allows more carbohydrate, with a lower total fat level because of the highly 
ketogenic nature of the MCT. The increased dietary carbohydrate, especially if daily 
distribution is not carefully controlled, may adversely affect the state of high ketosis 
seen in ketogenic diet children. Schwartz et al (1989b) also found significantly higher 
blood ketone body levels in their classical diet group during 24-hour blood profiles
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measured 3 weeks after starting the diet; no significant difference was seen between 
the MCT and modified MCT groups, despite the different level of MCT fat in these 
two protocols.
The relationship between seizure control and ketosis is still unclear. Whereas 
some authors suggest ketones must be at a sufficient level to achieve seizure control 
(Gilbert et al, 2000; Huttenlocher, 1976), the link between ketosis and seizure control 
has been questioned (Bough et al, 2000; Cunnane, 2004). A recent randomized study 
comparing the 3:1 and 4:1 classical diets in 76 children found the higher ratio diet to 
have significantly greater anti-epileptic efficacy, however there were no significant 
differences in the P-hydroxybutyrate levels between the two groups (Seo et al, 2007). 
Some animal models have shown ketone bodies to exert direct anticonvulsant action, 
but p-hydroxybutyrate is thought to be less important than acetoacetate (Likhodi & 
Burnham, 2004), and acetone suggested as the most important of the ketone bodies 
(Kalapos, 2007; Gasior et al, 2007). Our results did show some correlation between 
seizure control and ketosis, however this was only at 3 months. A clear linear 
relationship may not actually exist; other ketosis-induced metabolic changes may be 
more important in seizure control.
A number of hypotheses on mechanism of action have emerged over the past 
few years. One involves the effect of the diet on cerebral energy metabolism; with 
failure to meet brain energy needs contributing to the initiation and spread of epileptic 
activity (Nordli & DeVivo, 2004). The ketogenic diet will increase brain energy 
reserves by bypassing less efficient glycolysis pathways, and maximizing 
tricarboxylic acid cycle function. This may influence seizure activity by increased 
production of inhibitory neurotransmitters, improved ability to buffer the extra­
cellular milieu, or alteration of resting membrane potential ((Nordli & DeVivo, 2004).
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The reduction in glycolytic energy supply may activate ATP-sensitive potassium 
channels, which may regulate seizure threshold (Schwartzkroin, 1999; Bough & Rho, 
2007). Fructose-1,6-bisphosphate, important in shifting glucose metabolism away 
from glycolysis, may also have a role (Lian et al, 2007).
An alternative hypothesis is the alteration of brain amino-acid handling. 
Utilization of ketone bodies as a brain substrate will alter metabolism of glutamate, an 
important excitatory neurotransmitter. Reduced transamination of glutamate to 
aspartate increases glutamate availability for synthesis of the main inhibitory brain 
neurotransmitter, gamma amino butyric acid (GABA), both directly, and via 
glutamine production (Yudkoff et al, 2004). A hypothesis by Cullingford (2004) is the 
involvement of metabolic adaptations to the diet, mediated at the molecular level by 
sensor mechanisms. The fatty-acid activated transcription factor peroxisome 
proliferator-activated receptor a  (PPARa), activated by ketogenesis, may be important 
in the anti-epileptic effects of the diet, by influencing neurotransmitter metabolism. 
Other researchers have suggested the role of neuropeptides and norepinephrine. 
Anticonvulsant neuropeptides, galanin and neuropeptide Y, which are stimulated by 
nutrients in the gut, especially fats, are regulated by energy states, and may mediate 
action of the ketognic diet (Weinshenker, 2004), with increased levels being released 
in the brain (Tabb et al, 2004). It has also been suggested that calorie restriction alone 
may underlie the anticonvulsant mechanism of the diet; this reduced seizure 
susceptibility in mice independent of any changes in ketosis (Greene et al, 2003).
Polyunsaturated fatty acids have been shown to be more ketogenic than 
saturated fats or oils (Fuehrlein et al, 2004), and a diet enriched in the essential fatty 
acids linoleate and a-linolenate more ketogenic than other long chain fats or oils 
(Cunnane, 2004). The ketogenic diet has also been shown to raise plasma levels of
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free fatty acids released from adipose tissue (Cunnane et al, 2004). Could these 
essential fatty acids be directly protective against seizures? If so, could this explain 
some of the anecdotal differences between the two dietary protocols that have been 
previously reported? The MCT protocol has a theoretical risk of being considerably 
lower in essential long chain fatty acids due to the large percentage o f fat energy 
provided by the MCT; in contrast, many classical diets will contain much higher 
amounts, particularly if aiming for a healthier balance of fatty acids within the overall 
fat provision. Despite limited information in the literature, in our trial, children on the 
MCT diet were supplemented with essential fatty acids if continuing beyond 3 
months, to ensure no risk of low intakes. Clearly more investigation needs to be done 
into these specific requirements on the MCT diet.
There are a number of limitations in the data analysis for this study. Total 
numbers of daily seizures were used, despite more detailed records being kept of 
numbers of six individual seizure types. A more complex seizure sub-group analysis 
is aimed for in the future, yielding more detailed results on how different seizure types 
may respond. Absences seizures are included in the current analysis; however, these 
are difficult to record accurately without accompanying 24-hour EEG data. The 
analysis also was based only on the daily seizures in the 28 days before each time 
point, and did not take into account the numbers over the whole of the 3 or 6-month 
period; this is hoped for at the time of a full seizure sub-type analysis. The use of 
parental or carer seizure records will run the risk of subjective errors; it is hoped that 
even if present, within-person recording would be consistent over the study period. 
However it is likely that recording improves with practice over a period of time. The 
fact that percentage of baseline seizures increased to 137% after 3 months in the 
control group supports this theory; this may have led to an underestimation of the
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benefit of the diet over time. Analysis of the EEG results will be independent o f any 
subjective errors, and would be expected to correlate closely with clinical outcome, as 
seen in the largest study on the diet to data (Kang et al, 2005). However, early results 
on 48 children from our study suggest this may not be the case (Mills et al, 2006), 
with EEG being a poor indicator o f apparent seizure response. Further results are 
awaited.
The scientific weight o f this study would also have been improved by an 
intention to treat analysis. This was not possible, as the children who either did not 
start treatment, or who dropped out before 3 months did not keep on-going seizure 
records. It would have been very difficult for these parents or carers to have 
motivation to continue records, but in retrospect, inclusion of this data would have 
been preferable.
Our study showed a high non-start and drop out rate. After initial outpatient 
assessment, 145 children were randomized into the trial. Twenty subsequently did not 
start the treatment, for a variety o f reasons; in five children this decision was made 
after the diet had been calculated and a comprehensive education program completed. 
In 25 additional children, the treatment was terminated before the 3-month trial 
period. Although in many cases this was due to intolerance or increased seizures, six 
children were withdrawn because of parental unhappiness with the necessary dietary 
restrictions. Of the initial 145, only 100 (69%) actually completed 3 months on the 
diet. A further six did not complete seizure records as instructed; data was available 
for analysis on 94. This high non-start and drop out rate was difficult to predict, but 
has important implications for the careful use of scarce dietetic resources because of 
the time consuming nature of initial ketogenic calculations and monitoring. Although 
it has been suggested that non-medical reasons for discontinuing the diet are as
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common as medical reasons (Lightstone et al 2001), no other literature on the 
ketogenic diet has reported similar results prior to diet start or in the early stages of 
treatment.
The use of a randomization process to allocate children to one of the two 
dietary regimens, and to either control or non-control, using a minimizing method to 
account for age group and treatment location, will avoid any selection bias between 
the study groups. The minimizing process did not control for gender; there were a 
greater proportion of boys than girls in the diet group as compared with the control 
group, and in the classical group as compared with the MCT group; there is no 
evidence that this would have any influence on seizure control. The study would be 
improved by a double blind randomization process, as recommended by Glauser et al 
(2006) for all Class I or II scientific evidence. It would have been impossible to blind 
the parents, carers or child receiving treatment, due to the nature of this being a 
prescribed diet that closely involved their co-operation. Most families were fully 
aware of the different types o f diet, and what type of food intake they included, 
usually before even being seen at the initial assessment clinic. In this study, the 
dietitian prescribing the diets was also very involved in data collection, so would be 
unable to be blinded. An improvement, that was not possible due to study resources, 
would have been to have an independent person, who was blinded as to group 
allocation, doing all the data collection and analysis.
Despite these limitations, this study has been clearly able to demonstrate in a 
randomized controlled trial that the ketogenic diet is efficacious in treating children 
with intractable epilepsy, and that both classical and MCT protocols can be used with 
success in this group.
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APPENDIX
Table A3.1. Seizure recording charts -  seizure types
Seizure type Description
1 Absence/atypical absence
2 Myoclonic
3 Atonic
4 Tonic
5 Tonic-clonic
6 Partial
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Table A3.2. Seizure recording charts -  daily m onitoring
Seizure monitoring
Week..................  Start Date
Date Day Seizure Type Ketones Comments
1 2 3 4 5 6 AM PM
Sun
Mon
Tues
Wed
Thurs
Fri
Sat
Total
Week  Start Date
Date Day Seizure Type Ketones Comments
1 2 3 4 5 6 AM PM
Sun
Mon
Tues
Wed
Thurs
Fri
Sat
Total
1 0 3
Table A3.3. Efficacy data recorded for all children
Study
no
Diet
(1=classical
2=mct)
Sex
(1=male
2=female)
Control Age
group
Centre
(H=hospital
(Presidential)
Syndrome
1 2 2 Y 2 H Unspec symp gen
2 2 1 N 1 H Unspec symp multifoc
3 1 2 Y 1 H SMEI
4 2 1 Y 2 H Lennox-Gastaux
5 1 1 N 1 H Infantile spasms
6 2 2 N 2 H Structural brain malf
7 1 1 Y 3 H Lennox-Gastaux
8 1 2 Y 2 H Myoclonic absence
9 2 2 Y 2 H Unspec symp gen
10 2 2 Y 3 R Lennox-Gastaux
11 1 1 N 1 H Infantile spasms
12 1 1 N 1 H Degenerative
13 2 2 N 2 R Myoclonic absence
14 1 1 Y 2 H Unspec symp gen
15 2 1 N 1 H Unspec symp gen
16 1 2 Y 3 H Myoclonic unspec
17 1 1 N 1 H Structural brain malf
18 2 1 N 2 H Myoclonic astatic
19 1 1 Y 2 H Structural brain malf
20 2 2 Y 1 H Structural brain malf
21 1 1 N 2 H Lennox-Gastaux
22 2 2 Y 2 H Structural brain malf
23 2 1 N 1 H Structural brain malf
24 2 2 Y 3 H Myoclonic astatic
25 2 1 N 2 H Myoclonic absence
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Syndrome No. of % baseline seizures
group baseline Control 3 mo 6 mo 12 mo
drugs
Symp gen 2 106.3 29.41 117.65.
Symp focal 2 155.1 300.
3 170 129.41.
Symp gen 3 95.71 68.66 69.9 196.5
Symp gen 3 39.67 42.59 32.78
Symp focal 2 136.14 140.59.
Symp gen 1 209.2 11.28 8.89 0
Symp gen 2
Symp gen 2 155.3.
Symp gen 3 151.2 47.95 71.85 42.06
Symp gen 3 5.35 51.82 123.7
4
Symp gen 4
Symp gen 2 192.3 107.14.
Symp gen 3
Symp gen 2 100 56.1 60.98 52.44
Symp focal 2
o
13.87 6.03 1.57
Symp focal
Z
2 108.9. 15.08
Symp focal 2 76.83 30.76 4.21
Symp gen 2 24.73 13.44 40.32
Symp focal 2 96.8 90.46.
Symp focal 3 48.74 61.78 70.37
1 62.97.
Symp gen 3 70.84 74.46.
Gradient of best 
fit of serial 
seizure data
8.882
-4.585
-6.904
-3.747
4.279
-3.194
-6.871
-7.077
-8.208
-3.789
-1.439
26 1 1 N
27 1 2 Y
28 1 2 Y
29 1 1 N
30 2 1 Y
31 1 1 Y
32 2 2 Y
33 1 1 N
34 1 2 Y
35 2 1 N
36 2 1 Y
37 2 2 Y
38 2 2 N
39 2 1 N
40 1 1 N
41 1 1 Y
42 2 2 N
43 1 1 Y
44 2 2 N
45 1 2 N
46 1 1 N
47 2 1 Y
48 1 2 Y
49 2 2 Y
50 1 2 Y
51 1 1 N
52 2 1 Y
53 2 2 N
54 2 2 N
55 1 1 N
H Unspec symp multifoc
H Unspec symp gen
R Lennox-Gastaux
H Structural brain malf
H Unspec symp multifoc
R Structural brain malf
R Unspec symp multifoc
H Lennox-Gastaux
H Unspec symp multifoc
H Unspec symp gen
H SMEI
H Lennox-Gastaux
R Unspec symp gen
H Lennox-Gastaux
H Lennox-Gastaux
H Unspec symp focal
H Unspec symp focal
H Infantile spasms
H Structural brain malf
H Infantile spasms
R Atypical absence
H Myoclonic astatic
H Myoclonic absence
H Unspec symp multifoc
H Early myoclonic enceph
H ESES
H Myoclonic unspec
H Lennox-Gastaux
H Structural brain malf
H Unspec symp gen
1
2
3
2
1
3
3
1
1
1
2
1
3
2
1
2
1
1
1
1
2
1
1
2
1
3
1
1
3
2
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Symp focal 2 79.41
Symp gen 3 109.3
Symp gen 3
Symp focal 3
Symp focal 2 56 385.71
Symp focal 2 41.58 61.29
Symp focal 2
Symp gen 3 125.7
Symp focal 2 496.6
Symp gen 2 4.74 79.09.
0 60.67 72.22.
Symp gen 3 233.2 46.83 67.18 31.29
Symp gen 2 142.48.
Symp gen 2 13.56 12.29 0
Symp gen 3 30.3 18.18 54.55
Symp focal 1 28.21
Symp focal 1 40.82
Symp gen 
Symp focal 
Symp gen
0
3
2 200
Symp gen 3 112.43 88.16.
4 116.1
Symp gen 1 68.3 54.99 98.77 83.19
Symp focal 3 81.93 132
Symp gen 2 575 7.14 23.37.
Symp gen 3
Symp gen 1 214.5 96.62 238.89 158
Symp gen 3 46.56 16.82 137.3
Symp focal 3 59.26
Symp gen 2 26.5 18.36 9.93
-4.683
-6.937
-2.684
-0.167
6.388
3.934
-6.398
56 2 1
57 1 2
58 2 1
59 1 2
60 1 1
61 1 2
62 1 1
63 2 2
64 2 1
65 2 2
66 2 1
67 2 2
68 1 1
69 2 1
70 1 1
71 1 1
72 1 2
73 2 1
74 2 1
75 1 2
76 2 1
77 1 2
78 1 2
79 1 1
80 1 2
81 1 1
82 2 1
83 2 1
84 1 1
85 2 2
Y 1 H
Y 1 H
Y 1 H
N 2 H
Y 2 R
Y 1 H
N 3 H
N 3 R
Y 2 H
N 2 H
N 2 R
N 1 H
Y 1 H
Y 3 H
N 1 H
N 3 H
Y 2 H
N 2 H
N 1 H
N 1 H
Y 2 H
N 2 H
N 2 H
N 1 H
N 1 H
Y 2 H
N 1 H
Y 1 H
Y 2 H
Y 1 H
Unspec symp gen 
Unspec symp multifoc 
Structural brain malf 
Unspec symp focal 
Myoclonic unspec 
Myoclonic unspec 
SMEI 
Unspec symp focal 
Myoclonic unspec 
Myoclonic astatic 
Unspec symp focal 
Lennox-Gastaux 
Infantile spasms 
Structural brain malf 
Infantile spasms 
Structural brain malf 
Atypical absence 
Myoclonic absence 
SMEI 
Myoclonic astatic 
Atypical absence 
Unspec symp focal 
Structural brain malf 
Myoclonic unspec 
Structural brain malf 
SMEI 
Myoclonic astatic 
SMEI 
Myoclonic unspec 
Unspec symp focal
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Symp gen 3
Symp focal 4 57.33
Symp focal 2 178.3
Symp focal 3
Symp gen 3 93.48
Symp gen 2 93.72
0
Symp focal 3
Symp gen 3
3
Symp focal 3
Symp gen 3
Symp gen 2 128.7
Symp focal 1 100
Symp gen 2
Symp focal 3
Symp gen 0
Symp gen 1
2
2
Symp gen 3 113.4
Symp focal 2
Symp focal 1
Symp gen 2
Symp focal 2
1
2
2 294.1
Symp gen 2
Symp focal 3 81.06
54.11 0.74 50.42
93.59.
35.07 21.71 0
58.14.
57.75 47.01 43.75
83.2 103.2.
31.67 0.91 18.9
29.31 19.83 26.29
43.36 45.76 44
83.67 72.96.
66.29 90.29 72
0 0 0
12.85. 0
91.26 112.24.
90.48.
46.3 2.84 0
15.98 7.01 14.61
52 84.
38.17 21.5 26.17
93.46 103.74 42.99
-3.884
-7.462
-4.119
-5.943
-5.062
-3.698
-1.529
-6.667
-6.74
-7.962
-5.804
-5.309
-4.664
86 2 1 N
87 1 2 Y
88 1 1 Y
89 2 2 N
90 2 2 Y
91 2 2 N
92 1 2 Y
93 2 2 N
94 2 1 Y
95 2 1 Y
96 1 2 N
97 1 1 Y
98 1 2 N
99 2 2 N
100 2 1 Y
101 1 2 Y
102 1 1 N
103 2 2 N
104 1 1 Y
105 2 1 Y
106 1 2 Y
107 2 1 Y
108 1 2 N
109 2 1 N
110 1 2 N
111 2 2 N
112 1 1 Y
113 2 1 Y
114 2 2 Y
115 1 1 N
H Infantile spasms
H Unspec symp focal
H Unspec symp focal
H Myoclonic unspec
H Structural brain malf
H Structural brain malf
H Unspec symp multifoc
H Infantile spasms
H Unspec symp gen
H SMEI
H Unspec symp gen
H Infantile spasms
H Unspec symp focal
H Unspec symp gen
H Myoclonic astatic
H Infantile spasms
H Structural brain malf
H Unspec symp focal
H Unspec symp focal
H Unspec symp gen
H Structural brain malf
H Infantile spasms
H Unspec symp gen
H Structural brain malf
H Unspec symp multifoc
H Unspec symp gen
H Unspec symp focal
H Structural brain malf
H Unspec symp gen
H Unspec symp gen
1
2
1
1
1
2
2
1
2
1
1
1
2
1
1
1
1
2
1
2
2
1
2
3
1
2
3
3
2
2
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Symp gen 3 82.48.
Symp focal 0
Symp focal 3 84.78 163.04.
Symp gen 2
Symp focal 2 82.33
Symp focal 3
Symp focal 
Symp gen
4
1
38.32
Symp gen 3 119.1
3 118.1
Symp gen 2
Symp gen 4 135
Symp focal 1
Symp gen 3
3 121.7
Symp gen 2
Symp focal 3
Symp focal 2
Symp focal 
Symp gen
3
1
444
Symp focal 1 87.25
Symp gen 
Symp gen
1
2
Symp focal 3
Symp focal 1
Symp gen 1
Symp focal 0 100
Symp focal 2 36.71
Symp gen 3 156.6
Symp gen 3
40.54 62.31 100.1 1.35
71.87.
28.57 42.86 61.14 -1.834
41.84 10.28
37.29 10.57 6.04 -7.114
113.21 100 137 2.792
51.2 5.24 0 -8.08
72.12 74.94 71.41 -1.893
125 46
41.61 64.54
70.7.
29.48 55.97.
61.26 32.43 26.13 -5.868
82.78.
56.63 45.41 23.69  
.103.0
-5.822
83.35 117.30 0.898.
77.48.
24.14 24.14.
62.89 73.88.
43.86 23.17.
116 1 2
117 1 1
118 2 2
119 2 1
120 2 1
121 1 2
122 1 2
123 2 1
124 1 1
125 1 1
126 2 2
127 2 1
128 2 1
129 1 1
130 2 2
131 1 2
132 2 2
133 1 1
134 2 2
135 2 2
136 1 1
137 1 2
138 1 2
139 1 2
140 1 1
141 2 2
142 1 1
143 2 2
144 1 2
145 2 1
N 1 H
N 1 H
N 1 H
Y 1 H
Y 1 H
N 2 H
N 2 H
N 1 H
Y 2 H
Y 2 H
N 1 H
N 3 H
Y 2 H
Y 3 H
N 2 H
Y 2 H
Y 2 H
N 1 H
N 1 H
Y 2 H
N 2 H
Y 2 H
N 2 H
Y 1 H
N 1 H
Y 1 H
Y 2 H
Y 2 H
N 3 H
N 2 H
Degenerative 
Structural brain malf 
Unspec symp gen 
Unspec symp gen 
Structural brain malf 
Degenerative 
Unspec symp focal 
Lennox-Gastaux 
Unspec symp gen 
Lennox-Gastaux 
Childhood absence 
Childhood absence 
Unspec symp focal 
Structural brain malf 
Unspec symp focal 
Unspec symp multifoc 
Lennox-Gastaux 
ESES  
Unspec symp multifoc 
Myoclonic astatic 
Myoclonic absence 
Unspec symp multifoc 
Unspec symp multifoc 
Structural brain malf
Unspec symp gen 
Unspec symp gen 
Myoclonic absence 
Unspec symp multifoc 
Structural brain malf 
Structural brain malf
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4
Symp focal 4
Symp gen 4
Symp gen 3 58.12. .22.00 -5.926.
Symp focal 4
3
Symp focal 3 75.76 113.64.63.06 -2.344.
Symp gen 2 96.61 81.36.93.94 -0.600.
Symp gen 2
Symp gen 3
1
2
Symp focal 1
Symp focal 2 59.87 113.83.
Symp focal 2 74.4.
Symp focal 3 121.7.
Symp gen 3
Symp gen 3 3.52.
Symp focal 4 61.59.40.64 .26.60 -5.759.
3 50 146.15.
Symp gen 3 27.62.62.86 .
Symp focal 2 87.87 18.5.
Symp focal 2 2.07 2 .07.0 .00 -6.706.
Symp focal 3
.100.6
Symp gen 2 175.61.160.53 6 -1.527.
Symp gen 2
Symp gen 1
Symp focal 5 196 0.00.0 .00 .0.00 -6.667.
Symp focal 3 101.54.
Symp focal 2 22.69.59.44 .
Table A3.4. Blood ketone levels recorded for all children from whom  results available
idy no. Diet Beta-hydroxy butyrate (mmol/l) Acetoacetate (mmol/l)
(1=classical, 0 mo 3 mo 6 mo 12 mo 0 mo 3 mo 6 mo 12 mo
2=met)
1 2 0.07. 5.79.
2 2 0.05 0.58 3.27 1.76 0.036 0.277 1.230 0.826
3 1 5.60 3.21. 1.561 1.512.
4 2 0.05 1.93 2.20 4.83 0.030 0.652 0.605 1.311
5 1 0.19 6.48 5.25 6.06 0.031 1.949 1.866 1.728
6 2 0.05 1.54 2.64. 0.030 0.487 0.675.
7 1 0.86 5.88 5.55 3.66 0.192 1.349 1.229 0.676
10 2 0.05 1.04 2.40 2.16 0.008 0.256 0.805 0.536
11 1 0.05 2.58 4.86 4.05. 1.618 1.852 1.711
14 1 0.05 0.11 0.045 0.099.
16 1 0.05 3.50 4.17 3.27 0.030 1.170 1.454 1.233
17 1 0.05 3.96 3.36 3.60 0.030 1.098 1.433 1.170
19 1 0.05 4.48 3.81 1.42 0.034 1.155 1.172 0.359
20 2 0.05 1.68 2.42 4.32 0.031 0.793 0.631 0.966
21 1 0.05 4.29 4.28 4.59 0.030 1.046 1.222 0.431
22 2 0.05 1.21 0.030 0.481.
23 2 0.05 6.48 4.48 6.06 0.030 1.040 0.675 0.851
25 2 0.05 0.90 1.17. 0.030 0.524 0.432.
26 1 0.05 3.57 0.033 1.560.
30 2 0.05 2.70 0.030 0.684.
31 1 0.05 1.57 0.030
33 1 0.05 6.88 0.030 1.229.
35 2 0.05 2.88 3.21. 0.047 0.620.
36 2 0.05 0.05 0.032 0.030.
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37 2 0.21 4.92 6.87
38 2 0.05 0.96.
39 2 0.05 3.03 3.30
40 1 0.07 6.85 6.63
42 2 0.06 3.81.
45 1 0.08 3.45.
46 1 0.05 4.35 4.95
48 1 0.05 3.66 5.70
49 2 0.05 1.62.
50 1 0.05 5.37 5.10
51 1 0.05 3.24 2.22
52 2 0.05 2.23.
53 2 0.05 3.33 2.31
54 2 0.05 1.70.
55 1 0.08 3.99 1.99
57 1 3.27
59 1 0.15 6.60 4.98
60 1 0.05 1.27.
61 1 0.05. 5.19
62 1 0.05 4.53.
64 2 0.13 4.41 3.02
66 2 0.05. 2.46
67 2 2.03 1.99
71 1 0.05 3.20 3.96
73 2 0.07 6.48 3.70
75 1 0.05 6.63 6.84
76 2 0.05. 0.51
77 1 0.05 6.90 2.50
79 1 0.05 1.84.
80 1 0.05 2.76 3.48
9.20
8.28
5.22
1.05
9.65
1.87
4.23.
5.25
0.10
2.38
0 . 86 .
3.99
0.88
0.078 1.974 1.164
0.030.
0.055 0.671 0.586.
0.039 1.276 1.453.
0.035 0.622.
0.110 0.615.
0.070 1.202 1.313.
0.034 1.155.
0.085 0.122.
0.037 1.238 1.872
0.032 1.561 1.012.
0.043 0.509.
0.062 0.923 0.615.
0.030 0.406.
0.034. 0.564
1.434
0.030 1.850
0.673.
1.618
0.031. 1.646.
0.039 1.204.
0.030 1.017 0.602.
0.036 0.552 0.773.
0.234 0.079
0.030 1.031 0.952.
0.057 2.004 0.981.
0.031 1.882 1.561 .
0.090. 0.130
0.030 1.116 1.094.
0.033 0.033.
0.050. 1.495
1.806
1.444
0.260
1.288
0.615
1.418
1.774
0.143
0.180
1.249
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82 2 0.46 2.79 6.39.
83 2 0.09 3.66 3.90.
84 1 0.05 1.50.
85 2 0.05 4.59.
86 2 0.07 4.74.
88 1 0.05 4.08.
89 2 0.05 2.88 5.80
90 2 0.12 1.80.
91 2 0.05 2.28 4.08.
92 1 0.05 3.22 2.25.
93 2 0.05. 0.38.
94 2 0.06 2.43 1.06
95 2 0.06 8.22.
97 1 0.05 4.59 5.70
98 1 0.05 3.99 2.04.
99 2 0.11 2.04 4.80.
100 2 0.05 3.09.
101 1 0.05 7.32 5.79.
103 2 0.05 0.76 0.15
109 2 0.31
110 1 0.10 2.49 1.10
112 1 0.05 4.77.
113 2 0.05 1.39.
114 2 0.05 3.21 0.40
115 1 0.05 4.65 4.44
122 1 2.65.
123 2 0.05 2.19 3.18
130 2 0.06 2.24 1.89
132 2 0.05 1.42.
133 1 0.28.
0.211
0.074
1.227
1.225.
1.648
0.038
0.030
0.447 
0.691 . 
1.228. 
1.120.
0.867
5.88 0.038.
0.067.
0.035 0.648.
1.317
0.030.
1.215 0.962
0.37 0.031 0.776 0.452
6.88 0.045 1.701.
6.27 0.030 1.905 1.312
0.038 0.176 0.207
0.043
0.059
0.030.
0.502
0.028.
0.391
1.205
0.05 0.057 0.171 0.116
0.34. 0.096
2.75 0.030
0.030
0.632
0.825.
0.183
2.94. 0.990 0.198
4.92. 1.935 1.198
3.51. 0.643
1.62 0.030 0.427 0.489
1.86.
0.108
0.480
0.484.
0.632
4.08.
0.265
1.124
0.162
0.139
1.110
1.809
0.095
0.180
0.195
0.859
2.150
1.135
0.484
0.600
1.719
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134 2 0.05 2.12 2.38
135 2 0.05 1.16 1.59
136 1 0.05. 5.43
137 1 3.93.
138 1 0.05 6.69 4.77
139 1 0.05 4.20 3.33
140 1 0.05 3.60 3.09
141 2 0.22 1.10.
143 2 0.05 4.32 1.68
144 2 3.75
145 2 0.05. 0.57
151 2 0.05 3.96 5.52
152 2 4.26.
153 2 0.05. 1.24
154 1 0.05 5.50 5.43
155 2 1.39
4.35 0.041. 1.017
0.030 0.294 0.303
3.42 0.030 0.905
1.338.
2.180
6.25 0.030.
4.38. 1.875 1.131
5.07 0.030
0.570
1.225 
0.301.
1.267
1.82. 1.035 0.269
3.55.
0.030.
0.620
0.111
0.162.
0.667.
1.458.
0.515
0.303
1.012
0.616
2.485
2.350
0.453
0.981
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CHAPTER 4 
TOLERABILITY OF THE KETOGENIC DIET
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4.1 Introduction
The recording of how the classical and MCT ketogenic diets are tolerated is an 
important part o f the assessment o f their role in the treatment of children with drug- 
resistant epilepsy. A diet may be extremely efficacious in seizure control, but if a 
child has problems with tolerance that cannot be resolved by either dietary changes or 
additional treatments, they may be unable to continue on the regime for any length of 
time. Although many tolerance problems will manifest themselves while the diet is 
being commenced or during the first few weeks, other complications may be later in 
onset.
The ketogenic diet has traditionally been initiated during an inpatient stay in 
hospital, after an initial period of fasting, and often a fluid restriction. This has been 
challenged in recent studies, all involving the classical diet (Table 4.1).
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Table 4.1 Sum m ary o f studies com paring ketogenic diet (KD) initiation protocols
Authors No Age Study Design In/outpatient 
diet initiation
Initiation protocol* Results
Wirrell et 
al, 2002
14 1.0 yrs 
-  16.8
yrs,
mean = 
63 mo
General 
retrospective 
review , all non­
fasted
6 outpatients, 8 
inpatients
Full calories, starting at 1:1 - 2 : 1  ratio 
KD, increasing to 3:1 -  4:1 ratio KD over 
3-4 days
N o f l u i d  restriction or fasting
-Tim e to ketosis (inpatient data only) sam e as other 
reported results o f  fasted children  
-E fficacy similar to other reported results o f  fasted 
children
-N o problem s with outpatient initiation
Kim et al 
2004
124
(fasting  
= 83, 
non 
fasting 
= 41)
Fasting, 
mean =
5.3 yrs; 
N on­
fasting, 
mean =
5.3 yrs
Comparative 
retrospective 
review , com paring 
fasted and non­
fasted groups
A ll inpatients Fasted group: fast until good ketosis, then 
Day 1= 1/3 4:1 ratio KD, Day 2 = 2/3 4:1 
ratio ketogenic diet; Day 3 = full 4:1 ratio 
KD
Non-fasted: Full calories, Day 1=1 / 3  
high fat diet, 2/3 normal diet; Day 2 = 2/3 
high fat diet, 1/3 normal diet; Day 3 =4: 1  
ratio KD
N o fluid restriction
-E fficacy -  no significant difference between groups 
-N o significant difference in tim e to seizure 
reduction or significant ketosis 
-Tolerability and com plications -  fasted group 
significantly more dehydrated
V aisleb et 
al, 2004
54 22 mo -  
12 yrs, 
mean = 
6.6  yrs
Comparative 
retrospective 
review, all non­
fasted, comparing  
in- and out-patient 
initiation groups
37 outpatients 
17 inpatients
Full calories, starting at 1.1:1 ratio KD, 
increasing to 4:1 ratio KD in 5 
incremental steps as tolerated 
N o fluid restriction or fasting
-N o significant difference in adverse effects on initiation  
-Outpatient group increased Tong-term ’ adverse effects 
-N o significant difference in seizure control or cognitive  
improvement
Bergqvist 
et al, 2005
48 (24  
fasted, 
24
gradual
start)
1 -14 yrs Random ized  
controlled trial, 
com paring fasted 
and gradual diet 
initiation groups
All inpatients Fasted group: Fast until good ketosis (up 
to 48 hrs), then Day 1= 1/3 4:1 ratio KD, 
Day 2 = 2/3 4:1 ratio KD; Day 3 = full 
4:1 ratio KD
Non-fasted: Full calories, Day 1=1. 1  
ratio KD, Day 2= 2.1 ratio KD, Day 3=  
3.1 ratio KD, Day 4=  4.1 ratio KD  
Fluid intake based on standard guidelines
-E fficacy -  equivalent betw een 2 protocols 
-G ood ketosis -  quicker in fasted group, no difference by 
end o f  initiation
-A dverse events -  milder in non-fasted group 
-Overall tolerance -  better in non-fasted group
Rizutti et 
al, 2007
46 1.5-17
yrs
Prospective, non­
randomized, 
com paring in-and 
out-patient groups
23 in-patients 
23 out-patients
In-patients: fasted for 24  hours, then 4:1 
ratio KD
Out-patients: 2:1 ratio KD for lOdays, 
then full diet
-E fficacy and transient com p lication s- no difference 
betw een protocols
-1 year fo llow  up, no differences in adverse events or 
m etabolic profile
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Three studies involved a retrospective data review (Wirell et al, 2002; Kim et al, 
2004; Vaisleb et al, 2004); two were prospective, one of which was a randomized 
controlled trial (Berquist et al, 2005). No differences in dietary efficacy or overall 
achievement of ketosis were reported between fasted and non-fasted children, and 
between those initiated in hospital or at home. In some studies using a non-fasting 
protocol was associated with improved tolerance and fewer adverse effects. One study 
did note increased unspecified long term adverse effects in the outpatient group 
(Vaisleb et al, 2004); the authors had no explanation for this, but the long term nature 
o f any problems occurring would make this unlikely to be related to any differences in 
the initiation protocol, but rather due to the random nature of such events.
There have been many reports of gastro-intestinal intolerance in children 
following the ketogenic diet. Vomiting, diarrhoea, and abdominal discomfort are 
frequently reported in children using the MCT protocol, thought to be due to the faster 
digestion and absorption of this type of fat (Figure 1.2). Studies reporting use o f the 
MCT diet are shown in table 4.2; many do report tolerance problems, in some cases 
occurring in up to half of children being initiated onto the diet. These problems are 
not unique to the MCT diet. In a study of 129 children using the classical protocol, 
Kang et al (2004) reported diarrhoea in 33% and vomiting in 28% of patients during 
the first four weeks of treatment. Only 3% reported constipation, although this could 
be more of a problem on the classical diet, due to the very low carbohydrate and high 
fat intake, and in some cases, low fluid intake. A systematic review of 27 papers that 
listed adverse events in a total o f 1066 children on the diet (Keene, 2006) found a 
lower incidence of gastro-intestinal problems: vomiting was reported in 5.5% and 
diarrhoea or constipation in 1.9%. In this review, only 3 children were reported to be 
on the MCT diet, and 3 of the 27 papers did not state which dietary protocol was used.
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Study, year and 
location
No Age range Percent MCT in diet GI Tolerance
Berman, 1978 
(USA)
18 2-17 years 60% Not stated
Clark & House, 
1978 (UK)
13 NS 60% A problem in some, resolved by slow introduction of oil
Huttenlocher et 
al, 1971 (USA)
12 2.5-16 years 60% aimed for 5 children -  diarrhoea, cramps, vomiting, nausea
Huttenlocher et 
al, 1976 (USA)
18 18mo-18 years 60% Not stated
Mak et al, 1999 
(Tawain)
13 3yrs2mo -  13 yrs 65-70% Diarrhoea (38.5%), abdominal cramps (15.4%), 
nausea/vomiting (15.4%)
Ross et al, 1985 
(USA)
9 3 m o-13 years 60% Loose stools (1), vomiting (1)
Schwartz et al, 
1989a (UK)
55 children 
and 4 adults
20 under 5 yrs; 25 
aged 5-10 yrs; 9 
aged 11-15 yrs, and 
5 aged 15-54 yrs
60% or 30% in ‘modified 
diet (n=13)
Nausea, vomiting, abdominal discomfort in approx half of 
patients while establishing diet
Sills et al, 1986 
(UK)
50 2-15 years 60% aimed for 44 tolerated diet; 24 tolerated 60% MCT, 18 tolerated 50- 
58% MCT, 2 tolerated 45% MCT. Diarrhoea/abdominal 
pain worse if MCT given without food
Trauner et al, 
1985 (USA)
17 12mo -  13 years 60% MCT 3 unable to tolerate due to diarrhoea, vomiting nd 
abdominal pain. Many of the 17 had bulky, loose stools.
Table 4.2 Studies reporting MCT diet treatment and tolerance
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Other reported side effects are less common. Haematological disturbances 
have been seen in children following the ketogenic diet, both impaired neutrophil 
function (Woody et al, 1989), and alterations in platelet function, with an increased 
tendency to bleeding (Berry-Kravis et al. 2001). There have been many reports in the 
literature of raised serum cholesterol and triglyceride levels in children following the 
ketogenic diet (Dekaban, 1966; Chesney et al. 1999;Vining, 1996; Delgado et al, 
1996; Kwiterovitch, 2003; Keene, 2006), although other studies have not found this to 
be a problem (Schwartz et al, 1989b; Couch et al. 1999). Other isolated reported 
problems include cardiac complications (Best et al, 2000), pancreatitis (Stewart et al, 
2001; Kang et al, 2004; Lyczkowski et al, 2005), selenium deficiency (Bergqvist et al, 
2003), and fatal propofol infusion syndrome (Baumeister et al, 2004)
Renal stones have been frequently reported in about 5% of children on the diet 
(Hertzberg et al, 1990; Furth et al, 2000; Kielb et al, 2000; Freeman et al. 1998; 
Sampath et al, 2007), and can be a particular problem in children undergoing 
concomitant anti-convulsant therapy with carbonic anhydrase inhibitors such as 
topiramate (Kossoff et al, 2002a). There are also concerns about the increased risk of 
metabolic acidosis in children on topiramate who commence the ketogenic diet; large 
decreases in bicarbonate levels have been reported in this group (Wilner et al, 1999; 
Takeota et al, 2002), and close monitoring is needed, especially during diet initiation.
Using the ketogenic diet with concomitant sodium valproate therapy may 
cause other problems. In one report o f five children who developed serious adverse 
events while on the diet (Ballaban-Gill et al, 1998), the complications were suggested 
to be due to interactions with valproate in four of the individuals. However, in a 
larger retrospective study of 71 children, Lyczkowski et al (2005) found no significant
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difference in adverse-event profiles between the valproate group and non-valproate 
group.
An important part o f this randomized controlled trial on the ketogenic diet was 
to investigate the tolerability o f the classical and MCT protocols. The results of this 
aspect of the study are presented in this chapter.
4.2 Methods
All children taking part in this study were commenced on either a classical or 
MCT ketgenic diet. The initiation protocol for this study has already been discussed 
(Chapter 2). Diets were started at home under close telephone supervision, without 
fasting or fluid restriction. Both classical and MCT protocols were initiated using a 
gradual step-wise protocol; with an expectation of reaching the full prescription 
within about 10 days of treatment. Problems with dietary tolerance on commencement 
were all documented carefully in patient study notes. If any problems did occur, the 
step-wise incremental increases in either diet ratio (classical diet) or MCT amount 
(MCT diet) were slowed down to try and alleviate the problem, and maintain the child 
on dietary treatment.
The aim was for all children to try the diet for a minimum of three months; 
any drop-outs before this time point were documented, and adverse events noted. At 
3, 6 and 12 months, children were reviewed at the hospital, and any adverse events 
documented. Parents or carers of all children were asked to complete a questionnaire 
at each of these time points, to record any incidence of gastro-intestinal problems. 
This questionnaire also enquired about hunger or taste problems, lack of energy and 
any changes in alertness, awareness or responsiveness (see appendix to chapter 4).
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Repeat blood samples were also taken for routine haematology and biochemistry, 
including cholesterol and triglycerides.
Statistical analysis:
• The Fishers exact test was used to compare the results of this parental/carer 
questionnaire between the two diet groups
• To examine differences in blood cholesterol and triglyceride levels between 
children on the classical and MCT diets, mean levels were compared at 3, 6 
and 12 months using the unpaired t-test. Within person changes from baseline 
to each of the time points were compared between the two diets using paired t- 
tests. Differences in the number o f children on each diet defined as having 
high levels of either cholesterol or triglycerides at each of the time points, as 
defined by age-appropriate ranges set by the Great Ormond Street Hospital 
laboratory, were compared using the Fishers exact test.
SPSS software version 13 was used for all statistical analysis.
4.3 Results
Tolerability results were examined in three different time frames. Firstly, 
problems occurring during the initial commencement and early build up of a diet; 
secondly, problems that occurred after establishment onto the full dietary prescription, 
but could not be resolved adequately, resulting in withdrawal from the study; thirdly, 
problems related to tolerance and side effects occurring at 3, 6 and 12 months, which 
did not directly cause study withdrawal.
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4.3.1 Problems during diet commencement
61 children started a classical ketogenic diet, and 64 children started a MCT 
ketogenic diet (Figure 3.2), all o f which were commenced at home. Five o f these 
children stopped the diet within the first week, before being established on the full 
diet prescription (table 4.3). Two classical diet children had dramatically increased 
seizure activity (one symptomatic multifocal, on medications valproate and 
vigabatrin, and one symptomatic generalized (unspecified), on medications 
lamotrigine and clobazam). One MCT diet child had severe diarrhoea (symptomatic 
generalized (unspecified), on keppra), one had extreme drowsiness (symptomatic 
focal (unspecified), on topiramate, keppra and clobazam), and one had severe 
vomiting (symptomatic generalized (unspecified), on keppra, topiramate, lamotrigine 
and clobazam). These numbers are too small for statistical comparisons
Table 4.3. Withdrawals during the first week of treatment.
Classical diet MCT diet
Increased seizures 2 0
Diarrhoea 0 1
Extreme drowsiness 0 1
Vomiting 0 1
In addition, during the first few days of the study, two classical diet children 
attended their local hospital (one needed an admission) because o f symptoms relating 
to excess ketosis and acidosis. Both children had Lennox-Gastaut syndrome, and both 
were on topiramate, one in combination with gabapentin, and one in combination with 
clobazam and lamotrigine.
121
4.3.2 Withdrawals before 3 months
Table 4.4 shows other study withdrawals occurring before the recommended 
3-month trial of dietary treatment. Three further children reported greatly increased 
seizure activity resulting in study withdrawal, two on the classical diet (one structural 
brain abnormality, on tegretol, and one atypical absence, no medication), and one on 
the MCT diet, (symptomatic multifocal, on medications valproate and 
oxycarbemazepine). Two further MCT diet children had severe diarrhoea (one 
tuberous sclerosis, on topiramate, valproate and vigabatrin, and one SMEI, on 
phenytoin and stiripentol), and one classical diet child had severe constipation 
(structural brain abnormality, on topiramate, lamotrigine and clobazam). Despite use 
of medications to help in all three cases, the diet was discontinued.
Table 4.4. Other diet withdrawals before 3 months
Classical diet MCT diet
Increased seizures 2 1
Diarrhoea 0 2
Constipation 1 0
Textural food problems 0 1
Parental unhappiness 2 4
Behavioral food refusal 3 4
Other withdrawals before three months were one child who had pre-existing problems 
with certain food textures which worsened while on the MCT diet, two classical and 
four MCT diet children who were withdrawn by parents who were unhappy with the 
dietary restrictions, and three classical and four MCT diet children who had 
behavioural feeding problems. Again, these were pre-existing and were worsened by 
dietary treatment. Statistical comparisons of these other withdrawals before 3 months 
between the two diets were not possible due to small numbers.
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4.3.3 Questionnaire results at 3 months
Questionnaire data was available from 47 classical diet children and 42 MCT 
diet children at 3 months. Results showed no significant differences in reported side 
effects between the two diets except increased reports of lack of energy on the 
classical protocol (table 4.5). In addition, 15 of the 47 classical diet children (32%) 
and 11 of the 42 MCT diet children (26%) needed medication for constipation after 3 
months on diet treatment (p=0.643).
Table 4.5. Reported side effects of the classical and MCT diets at 3 
months
Side effect Numbers (%) reported to have side effects P value
Classical diet 
(n=47)
MCT diet 
(n=42)
Vomiting 13 (28%) 11 (26%) 0.876
Diarrhoea 7(15%) 6(14%) 1.000
Abdominal pain 5(11%) 8(19%) 0.369
Constipation 21 (45%) 14(33%) 0.288
Lack of energy 17(36%) 6(14%) 0.028*
Hunger 12 (26%) 14(33%) 0.487
Taste problems 10(21%) 7(17%) 0.603
* significant atp<0.05 level
The questionnaire also asked about changes in alertness, awareness and 
responsiveness. After 3 months on a diet, 39 o f the classical diet group (83%) and 32 
of the MCT diet group (76%) were reported to have improved alertness (p=0.443); 39 
of the classical diet group (83%) and 30 of the MCT diet group (71%) were reported 
to have improved awareness (p=0.214); and 39 of the classical diet group (83%) and 
31 of the MCT diet group (74%) were reported to have improved responsiveness 
(p=0.313). Three of the MCT diet group (7%), but none of the classical diet group 
were reported to have a reduction in alertness (p=0.101); two of the MCT diet group 
(5%) but none of the classical diet group were reported to have a reduction in
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awareness (p=0.220); and one o f the classical diet group (2%) and 2 of the MCT diet 
group (5%) were reported to have a reduction in responsiveness (p=0.600). O f the 
total 71 children who were reported as having improved alertness, only 34 (48%) had 
over 50% reduction in baseline seizure numbers at this time point; o f the total 69 
children who were reported as having improved awareness, only 33 (48%) had over 
50% reduction in baseline seizure numbers at this time point; and of the total 70 
children who were reported as having improved responsiveness, only 36 (51%) had 
over 50% reduction in baseline seizure numbers at this time point.
4.3.4 Questionnaire results at 6 months
At 6 months, questionnaire data was available from 25 classical diet children 
and 32 MCT diet children. There were no significant differences in reported side 
effects between the two diets (table 4.6). In addition, 11 of the 32 classical diet 
children (34%) and 10 of the 25 MCT diet children (40%) needed medication for 
constipation after 6 months on diet treatment (p=0.784).
Table 4.6. Reported side effects of the classical and MCT diets after 6 
months
Side effect Num bers (% ) reported to have side effects P value
Classical diet 
(n=25)
M CT diet 
(n=32)
Vomiting 9 (36%) 7 (22%) 0.373
Diarrhoea 1 (4%) 4(13% ) 0.372
Abdominal pain 2 (8%) 4(13% ) 0.686
Constipation 12 (48%) 13 (41%) 0.602
Lack of energy 2 (8%) 5(16% ) 0.450
Hunger 6 (24%) 6(19% ) 0.747
Taste problems 4(16% ) 11 (34%) 0.141
At 6 months, 21 of the classical diet group (84%) and 27 of the MCT diet 
group (84%) were reported to have improved alertness (p= 1.000); 22 of the classical
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diet group (88%) and 26 of the MCT diet group (81%) were reported to have 
improved awareness (p=0.717); and 21 o f the classical diet group (84%) and 26 of the 
MCT diet group (81%) were reported to have improved responsiveness (p= 1.000). 
One of the classical diet group (4%) and one of the MCT diet group (3%) were 
reported to have a reduction in alertness (p= 1.000); no children in either group were 
reported to have a reduction in awareness; and one of the classical diet group (4%) 
and one of the MCT diet group (3%) were reported to have a reduction in 
responsiveness (p= 1.000). O f the total 48 children who were reported as having 
improved alertness, 30 (63%) had over 50% reduction in baseline seizure numbers at 
this time point; of the total 48 children who were reported as having improved 
awareness, 29 (60%) had over 50% reduction in baseline seizure numbers at this time 
point; and of the total 47 children who were reported as having improved 
responsiveness, 28 (60%) had over 50% reduction in baseline seizure numbers at this 
time point.
4.3.5 Questionnaire results at 12 months
At 12 months, questionnaire data was available from 20 classical diet 
children and 23 MCT diet children. There were significantly more reports of vomiting 
in the classical diet group, but no significant differences in other reported side effects 
between the two diets (table 4.7). Eight of the 20 classical diet children (40%) and 9 
of the 23 MCT diet children (39%) needed medication for constipation after 12 
months (p= 1.000).
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Table 4.7. Reported side effects of the classical and MCT diets after 
12 months
Side effect Numbers (% ) reported to have side effects P value
Classical diet 
(n=20)
MCT diet 
(n=23)
Vomiting 9 (45%) 3(13%) 0.039*
Diarrhoea 2(10%) 4(17%) 0.669
Abdominal pain 2(10%) 4(17%) 0.669
Constipation 9 (45%) 9 (39%) 0.763
Lack of energy 2(10%) 3 (13%) 1.000
Hunger 5 (25%) 4(17%) 0.711
Taste problems 3 (15%) 5 (22%) 0.704
* significant atp<0.05 level
At 12 months, 22 of the classical diet group (96%) and 17 of the MCT diet 
group (85%) were reported to have improved alertness (p=0.324); 22 of the classical 
diet group (96%) and 17 of the MCT diet group (85%) were reported to have 
improved awareness (p=0.324); and 22 of the classical diet group (96%) and 17 of the 
MCT diet group (85%) were reported to have improved responsiveness (p=0.324). 
Two of the classical diet group (10%) but none of the MCT diet group were reported 
to have a reduction in alertness (p=0.210); one of the classical diet group (5%) but 
none of the MCT diet group were reported to have a reduction in awareness 
(p=0.465); and no children in either group were reported to have a reduction in 
responsiveness. O f the total 39 children who were reported as having improved 
alertness, 26 (67%) had over 50% reduction in baseline seizure numbers at this time 
point; of the total 39 children who were reported as having improved awareness, 25 
(64%) had over 50% reduction in baseline seizure numbers at this time point; and of 
the total 39 children who were reported as having improved responsiveness, 26 (67%) 
had over 50% reduction in baseline seizure numbers at this time point.
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4.3.6 Other side effects, cholesterol and triglycerides
At the 3-month outpatient visit one classical diet child (infantile spasms, on 
topiramate, lamotrigine and clobazam) was found to have haematuria. A subsequent 
renal ultrasound detected debris, indicating risk of stone formation. Following 
treatment with potassium citrate, the child remained on the diet without any 
recurrence of the problem. Routine haematology and biochemistry at 3 months 
showed no significant abnormalities. Cholesterol and triglyceride levels were 
analyzed in detail, although data was not available at all time points from all children. 
General trends in levels over the 12-month period, subdivided by diet, are shown in 
Figures 4.1 and 4.2.
Figure 4.1 Serum cholesterol levels in classical and MCT diet 
children at baseline, 3, 6 and 12 months.
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Figure 4.2 Serum triglyceride levels in classical and M CT diet
children at baseline, 3, 6 and 12 months
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Table 4.8 shows the mean serum cholesterol levels before diet 
commencement, and at, 3, 6 and 12 months, for children on the classical and MCT 
diets. Numbers of children from whom data was available is also shown. Mean level 
increased from baseline to 3 months, but did not show a further increase (Figure 4.3). 
There were no significant differences between the two types of diet
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Table 4.8. Serum cholesterol levels at baseline and after 3, 6 and 12
months on the classical and MCT ketogenic diets
Mean (±SD) serum cholesterol 
(mmol/1) Mean 
difference 
between two 
diets
P value
Classical diet MCT diet
Baseline 4.20 (±0.88) 
(n=46)
4.43 (±0.95) 
(n=48)
0.23 0.220
3 mo 5.34 (±1.70) 
(n=41)
5.19 (±1.06) 
(n=42)
-0.15 0.621
6 mo 5.28 (±1.67) 
(n=37)
5.29 (±0.94) 
(n=35)
0.01 0.970
12 mo 5.24 (±1.69) 
(n=26)
4.92 (±0.87) 
(n=20)
-0.32 0.447
Figure 4.3. Serum cholesterol levels at baseline and after 3, 6 and 12 
months on the classical and MCT ketogenic diets
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Table 4.9 shows the mean serum triglyceride levels before diet 
commencement, and at, 3, 6 and 12 months, for children on the classical and MCT 
diets. Numbers of children from whom data was available is also shown. In the 
classical diet group, mean level increased from baseline to 3 months, and then stayed 
around this higher level, however the mean level in the MCT group fell to less than 
baseline during the 12-month period. This trend is illustrated in Figure 4.4; this plot 
also shows that there were a number of outlying children on both diets with very high 
triglyceride levels, this was particularly noticeable in the classical diet group. 
Whereas there was no significant difference in baseline mean triglyceride level 
between the two types of diet, after 3, 6 and 12 months this was lower in the MCT 
group, the difference was highly statistically significant.
Table 4.9. Serum triglyceride levels at baseline and after 3, 6 and 12 
months on the classical and MCT ketogenic diets
Mean (±SD) serum triglyceride 
(mmol/1)
(n = number providing data)
Mean 
difference 
between two 
diets
P value
Classical diet MCT diet
Baseline 1.07 (±0.57) 
(n=45)
1.16 (±0.71) 
(n=47)
0.09 0.497
3 months 2.20 (±1.38) 
(n=40)
1.15 (±0.77) 
(n=42)
-1.05 0.000*
6 months 2.08 (±1.09) 
(n=37)
0.96 (±0.46) 
(n=34)
-1.12 0.000*
12
months
1.98 (±0.88) 
(n=25)
0.87 (±0.33) 
(n=20)
-1.12 0.000*
* significant at P<0.001 level
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Figure 4.4. Serum triglyceride levels at baseline and after 3, 6 and 12
months on the classical and M CT ketogenic diets
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The mean within-person differences between baseline and 3, 6 and 12-month 
cholesterol and triglyceride levels were computed for children on the classical and 
MCT diets, and tested for significance. Results are shown in table 4.10. On both diets 
this significantly increased at all time points for cholesterol; this was also the case for 
triglycerides in the classical diet group. However the mean within-person difference 
in triglycerides in the MCT group decreased from baseline to 3, 6 and 12 months; this 
was just significant at 6 months only.
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Table 4.10 Within-person paired differences in serum cholesterol and 
triglyceride levels in children on classical and MCT diets
Classical diet MCT diet
Mean (±SD) 
difference (no. 
providing data)
P value Mean (±SD) 
difference (no. 
providing data)
P value
Cholesterol 
0 - 3  months
0 - 6  months
0-12 months
1.18 (±1.46) 
(n=41) 
0.97 (±1.28) 
(n=37) 
1.01 (±1.34) 
(n=26)
0.000**
0.000**
0.001**
0.80 (±0.85) 
(n=42) 
0.75 (±0.75) 
(n=35) 
0.42 (±0.87) 
(n=20)
0.000**
0.000**
0.046*
Triglycerides 
0 - 3  months
0 - 6  months
0-12 months
1.13 (±1.25) 
(n=40) 
1.05 (±1.06) 
(n=37) 
0.92 (±0.97) 
(n=25)
0.000**
0.000**
0.000**
-0.02 (±0.52) 
(n=42) 
-0.22 (±0.50) 
(n=34) 
-0.13 (±0.37) 
(n=20)
0.805
0.017*
0.118
* significant at P<0.05 level 
**significant at P<0.001 level
Tables 4.11 and 4.12 show the numbers of children at baseline and after 3, 6 and 12 
months on both diets that would be defined as having high serum cholesterol and 
triglyceride levels, being above the age-appropriate ranges. At baseline, more MCT 
diet children had raised cholesterol; numbers were similar in both diet groups for 
triglycerides. After 3, 6, and 12 months, there were no significant differences between 
the diets in numbers with raised cholesterol levels, both groups showing between 30- 
40% of children to have a high level at any time point. After 3, 6 and 12 months, there 
was a highly significant difference between the diets in numbers of children with 
raised triglyceride levels. Over half of the classical diet group had high levels by 3
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months; this increased to over two-thirds by 6 and 12 months. In contrast, numbers 
with high levels dropped during diet treatment in the MCT group.
Table 4.11. Numbers of children on classical and MCT diets with 
high serum cholesterol levels at baseline, 3, 6 and 12 months
Time Number o f children with high cholesterol level P value
Classical diet MCT diet
Baseline 5/46(11% ) 10/48 (21%) 0.262
3 months 16/41 (39%) 15/42 (36%) 0.823
6 months 14/37 (38%) 14/35 (40%) 1.000
12 months 9/26 (35%) 6/20 (30%) 1.000
Table 4.12. Numbers of children on classical and MCT diets with 
high serum triglyceride levels at baseline, 3, 6 and 12 months
Time Number of children with high triglyceride level P value
Classical diet MCT diet
Baseline 11/45 (24%) 11/47 (23%) 1.000
3 months 23/40 (57%) 6/42 (14%) 0.0001*
6 months 23/37 (62%) 2/34 (6%) 0.0001*
12 months 17/25 (68%) 1/20 (5%) 0.0001*
* significant at P<0.001 level
4.4 Discussion
The children in our study were able to start their diets at home, without a 
fasting period. This will have many advantages for the family. The inconvenience 
and disruption of a hospital admission can be avoided, as can the risk of potential 
adverse events caused by starvation. Since commencement o f our study, other groups 
have shown non-fasted children to have better tolerance and fewer adverse events, 
with no difference in efficacy (Kim et al, 2004; Berquist et al, 2005). However, 
advocates of hospital admission will argue that it allows a much closer monitoring of
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the initiation process. Five of our study children stopped the diet within the first week; 
two because of increased seizures, one due to extreme drowsiness, one vomiting and 
one diarrhoea. Could these early withdrawals have been avoided if the children were 
admitted to hospital, and therefore monitored more closely? In all cases, the families 
were in very close contact with the ketogenic diet team, and advice was given to try 
and alleviate the symptoms. It is unlikely that hospital admission would have made 
any difference to outcome. Indeed, the child who withdrew due to extreme drowsiness 
was actually at the residential centre for young people with epilepsy, and had round 
the clock nursing and medical care during this period. In their retrospective review of 
54 children, comparing in- and out-patient initiation groups, Vaisleb et al (2004) 
found no significant difference in adverse events or efficacy between the two groups. 
However, our study experience has shown that diets started at home do need to have a 
careful, stepwise fat increase: all classical diets were commenced at a 2:1 ratio, which 
was increased to 4:1 as tolerated, and the MCT in the MCT diets was also built up 
slowly.
The advocates of inpatient admission will also argue that it provides a setting 
for an intensive education program about the diet, including supervised practice in 
meal preparation. Although this may be the case in a few larger centres that have 
experience in the ketogenic diet and a well-established initiation program, it is only a 
theoretical ideal in many other UK hospitals. Many families have found inpatient 
admissions to be frustrating and lonely, with both ward staff and diet cooks 
unprepared for the complexities o f such a diet, and dietitians only able to give limited 
time to education due to multiple other work commitments that cannot be put on hold. 
All parents or carers of children starting the diet in out study were given a full day of 
teaching, and regular discussions over the phone to reinforce knowledge. Whereas a
1 3 4
teaching program over a longer period of time may have been an advantage, this was 
not possible due to the constraints of limited staff and bed availability. In most 
children, it is unlikely that this would have any impact on long-term success o f the 
diet, although in a very small number who have parents or carers who found the 
mathematical nature of the diet difficult to follow, it may have been an advantage.
During the early stages of the study, two study children did need to attend 
their local hospital, one requiring admission, due to problems with acidosis and excess 
ketosis, related to use o f the anti-epileptic medication topiramate. Both were 
following the classical diet; after these episodes, extra care was taken when 
commencing a child on topiramate onto the classical protocol, ensuring that they 
stayed on a 2:1 ratio diet for a few days without problems, before increasing the ratio 
gradually.
The diet was stopped before 3 months in 20 other children; three of these were 
due to increased seizure activity, two due to diarrhoea and one due to constipation. 
Although numbers were too small for statistical comparisons, it is of interest that four 
of the five withdrawals due to increased seizures were on the classical diet, and all 
three children with excessive diarrhoea were on the MCT diet. There was no obvious 
link between any of these side effects and either the child’s epilepsy syndrome, or 
anti-epileptic medications. Other withdrawals included problems with the food texture 
in one child and behavioural eating problems in 7 children; all of which were present 
prior to the child starting the diet, but worsened by this treatment Six other children 
were withdrawn from the study by parents who felt unhappy with the restrictions the 
diet imposed on their child. Following these results, our study group would 
recommend that in future the initial assessment and screening process should be even 
more comprehensive, with future inclusion criteria ensuring that children with pre­
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existing behavioural feeding problems have these appropriately treated before 
embarking on a restrictive dietary regimen. The willingness and full understanding of 
parents and all other important carers to comply with restrictions and monitoring, 
before commencing treatment, is also paramount, particularly in cases where care is 
shared between two or more individuals who live in separate locations.
After 3 months of treatment, the main reason for dietary withdrawal was 
limited efficacy. Although problems with tolerability were still reported, these were 
not considered severe enough to merit dietary withdrawal if seizure control had 
significantly improved. Tolerability was assessed by the reports of parents or carers, 
either over the telephone, or at clinic visits, and by a questionnaire. Although the use 
o f our non-validated questionnaire could be questioned, and obviously this assessment 
method could be subject to a degree of bias by its subjective nature, it did provide a 
useful way to serially assess the opinion o f parents or carers on tolerance or any side 
effects. There would be no advantage for any family to over or under report problems, 
and although questions were asked about any side effects from the diet in the 
outpatient clinic setting, the written responses to the questionnaire were not discussed 
at these visits.
The results of this questionnaire do not support the idea that the MCT diet has 
a worse profile of abdominal side effects. There do seem to be more reports o f 
diarrhoea associated with this protocol after 6 and 12 months, as seen in the early 
drop-outs. This was not seen at 3 months, and no difference was significant. Reports 
of abdominal pain were also higher in the MCT group at all time points, again not 
significant. No more than 20% of any group reported either of these problems at any 
time point. There was a higher incidence of vomiting; this was reported to have 
occurred in over one quarter of diet children at 3 and 6 months. By 12 months, the
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incidence of vomiting was significantly higher in the classical diet group; 45% of 
families reported that this had been a problem compared to only 13% of the MCT 
group. This may be due to the higher overall dietary fat content. Although our results 
for vomiting are similar to those reported by Kang et al (2004) in their large study o f 
classical diet children, our incidence of diarrhoea was lower. Other studies on the 
MCT diet (table 4.2) frequently report problems of diarrhoea, nausea, vomiting, and 
abdominal pain; with the exception of the modified MCT group in the study by 
Schwartz et al (1989a), all these studies were using 60% of energy from MCT in their 
diets. Although some children in our study did need this level of MCT to attain good 
ketosis and optimal seizure control, many others were able to achieve these goals on a 
lower amount. As discussed in chapter 2, diets were generally commenced on 45% 
energy as MCT, and this percentage increased as needed. This aimed to provide the 
best balance between optimal seizure control and acceptable tolerability.
In our study constipation was the most frequently reported side effect, present in 
39%, 44% and 42% of children at 3, 6 and 12 months respectively. At 3 months, this 
was more of a problem on the classical diet, as would be expected due to the reduced 
amount of carbohydrate and increased total fat content, however by 6 and 12 months, 
numbers were similar on both diets. This was a much higher incidence that that 
reported by Kang et al (2004); only 3% of their large group of classical diet children 
were reported to have this problem after 4 weeks; reasons for this difference are not 
clear. There are no other literature reports of constipation being a problem on the 
MCT diet; indeed, this type of fat is often advocated as being of benefit as a treatment 
for the condition. Our study has shown constipation to be a problem on both types of 
diet, although fluids were not strictly restricted and fruit and vegetables were 
encouraged as part of the limited carbohydrate intake wherever possible. Although
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constipation was only cited as a reason to stop the diet in the one withdrawal before 3 
months, approximately one third o f all children were on medication for this problem 
at any time point.
Other reported side effects in our questionnaire results were a lack of energy, 
hunger and taste problems. It is not clear why significantly more classical diet 
children were reported as having a lack o f energy at 3 months, with over a third of this 
diet group reported to have the problem, but this difference was not present later in 
the study. Hunger was a problem in 29% o f children at 3 months; this had fallen to 
21% by 6 and 12 months. As growth was monitored carefully during the study, and 
diet calorie content adjusted to ensure appropriate weight gain, it may be that much of 
the perceived hunger problem was due to the smaller, higher in fat, portion size rather 
than actual calorie deficit. There were more reports of taste problems with the 
classical diet at 3 months, but by 6 months, they were worse in the MCT diet group, 
with over one third reporting problems. However, the difference was not significant, 
and our overall results do not support the idea of the MCT diet being more 
unpalatable. By 12 months, the difference between the two protocols was less 
noticeable, and while a number of parents using the MCT diet did say that 
incorporating the MCT into the diet was their main challenge, the use o f a range of 
recipe ideas, and at times using MCT oil rather than the higher volume of Liquigen 
emulsion, seemed to help.
Our questionnaire additionally enquired about any changes in alertness, 
awareness and responsiveness on the diet. Results were remarkable: after 3 months, 
over 75% of children reported improvements in alertness, awareness and 
responsiveness, this increased to over 80% at 6 months, and over 90% at 12 months. 
A few children were reported to have a reduction of these skills; this was less than 5%
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of the total sample at any time point. There were no differences in changes in 
alertness, awareness and responsiveness between the two dietary protocols. Whereas 
it is appreciated that the subjective nature o f such a questionnaire may lead to an over­
reporting of dietary benefits, and that it was not a validated tool that took the age of 
the child into account, similar improvements have previously been documented. In 
2001, Pulsifer et al reported that mean developmental quotient was significantly 
improved in 34 children who had been on the classical ketogenic diet for a year, with 
significant behavioural improvements in attention and social functioning. In a study 
on parental expectations of dietary benefits, Farasat et al (2005) reviewed 100 
parental letters written during dietary initiation regarding their goals of treatment. 
They found the third most common goal, after seizure or anti-epileptic medication 
reduction, was improvement in cognition or alertness. O f the 63 families who 
expected this, 59% achieved their goal after 6 months, and cognitive improvement 
was found to be more important than either seizure or medication reduction in 
predicting the length of time a child remained on the diet.
Why would the ketogenic diet have such benefits? It is likely that this would be 
due, certainly in part, to seizures and/or medication dose being reduced, but this is 
difficult to asses, as children who do not show an improvement in seizure control do 
not usually continue on the diet for any significant length o f time. Animal studies 
have attempted to answer this question, but show conflicting results. Whereas Murphy 
et al (2004) found ketogenic diet-treated rats to be more mobile than controls, thus 
less ‘depressed’, Zhao et al (2005) found their group of diet-treated rats to have 
significantly impaired visual-spatial learning and memory compared to rats fed a 
regular diet. Our study did not set out to examine the association between changes in 
alertness, awareness or responsiveness and seizure control, however results show that
139
these three functions were reported to be greatly improved in the majority of children, 
including many who did not have significant improvement in seizure control, as 
measured by greater than 50% reduction in baseline seizures. This was particularly 
noticeable at 3 months.
Other side effects in our study group were rare. During 12 month follow up, only 
one child presented with renal debris, thought to be at high risk of subsequent stone 
formation; this was less than 1% of our total sample. This is lower than other 
literature reports (Hertzberg et al, 1990; Furth et al, 2000; Kossoff et al, 2002; 
Sampath et al, 2007), however, the long-term risk was not assessed in our study. 
Hertzberg et al (1990) found the average time on the diet before kidney stone 
formation to be 17 !/2 months; a longer follow up of our children may have increased 
the numbers seen with this side effect.
As a group, there were no significant abnormalities noted in the routine 
haematology or biochemistry. However, as found in many previous studies (Dekaban, 
1966; Chesney et al. 1999; Vining 1999; Delgado et al, 1996, Kwiterovich et al, 2003; 
Keene et al, 2006), there were increases in plasma lipid levels during diet treatment. 
After 3, 6 and 12 months, cholesterol levels rose significantly in both diet groups, 
with 30-40% of children having a serum cholesterol level above the recommended 
higher limit. This pattern was different for triglycerides: levels rose significantly in 
the classical diet group, but not in the MCT group, and by 3 months of treatment, 
there was a highly significant difference in mean levels between the groups, which 
continued throughout the study duration. Over half o f the classical group had a 
triglyceride level above the recommended higher limit at 3 months; this increased to 
over two thirds by 6 and 12 months. However, numbers with high levels in the MCT 
group fell during the study.
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So what is the significance o f these results? Our analysis would have been 
considerably improved if we had examined the lipoprotein fractions within the total 
cholesterol, as it is well known that raised very low density lipoprotein and low 
density lipoprotein cholesterol increase atherogenic risk, whereas raised high density 
lipoprotein has a protective influence. Kwiterovich et al (2003) did examine 
lipoproteins and apolipoproteins in ketogenic diet children, and found significant 
increases in the atherogenic lipoproteins and a decrease in the anti-atherogenic high 
density lipoprotein cholesterol. The question that is asked by not only scientific 
investigators, but also the parents and carers o f many children is, does this increase 
the long-term risk of cardiovascular problems? It is known that in the general 
paediatric population, raised serum lipids and lipoproteins in childhood do tend to 
track into later life (Webber et al, 1991), but the relevance o f this to our particular 
group with epilepsy is not known. An early case report suggested no evidence of 
adverse effects of the diet on cardiovascular function in adulthood (Livingstone,
1977), and a more recent study on long-term use o f the diet suggests that lipid levels 
may trend back towards normal after two years (Groesbeck et al, 2006). As alterations 
in fatty acid intakes have been shown to influence plasma levels (Dahlin et al, 2007), 
it is certainly important that ketogenic diet children are given advice to maximise their 
intake of long-chain polyunsaturated fatty acids and reduce saturated fat sources 
wherever possible within the constraints of such a high fat diet, to try and reduce 
cardiovascular risk.
It is worth noting that a considerable number o f our children had high levels of 
both cholesterol and triglycerides prior to starting dietary treatment. 11 % of the 
classical diet group and 21% of the MCT diet group had a baseline cholesterol level 
above the recommended higher limit; just under a quarter of both groups had a
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baseline triglyceride level above the recommended higher limit. Kwiterovich (2003) 
also found higher than average baseline triglyceride levels; this may be due to the ant- 
epileptic medications, and raises the question o f pre-existing cardiovascular risk that 
these children may be exposed to prior to diet commencement. Indeed, in the MCT 
group, the proportion of children with triglyceride levels above recommended higher 
limits fell progressively from 24% to only 5% by 12 months on the diet.
The relevance of the differing effect of the two diet protocols on triglyceride 
levels is not easy to elucidate. There will be faster metabolic clearance of triglycerides 
provided by a MCT diet due to their faster digestion and absorption, but it is not clear 
how much the difference in levels between the two diets is due just to these metabolic 
differences, and how much they could actually benefit a child in terms of their 
cardiovascular risk. This certainly warrants further study, with a more detailed 
examination of the effect that the two diets have on not just total lipid levels, but their 
lipoprotein fractions as well.
This uncertainty aside, the tolerability results of this study have shown no 
differences between the classical and MCT diets that would indicate any clinical 
advantages in using one protocol above the other. This adds further weight to the 
conclusion that both diets have their role in the treatment of children with drug- 
resistant epilepsy.
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APPENDIX -  PARENT/CARER QUESTIONNAIRE 
How are you doing on the ketogenic diet?
Name: Date:
Length of time on diet:
1. Has your child had any side effects on the diet, such as sickness, abdominal pain, 
diarrhoea, constipation or lack o f energy? (circle answer)
1. NO ------------► I f  answer is No, go to question 4
2. YES 
▼ 3.
(I f answer is Yes, please complete questions 2 and 3)
2. What side effects have you noticed? (circle answer)
1. DIARRHOEA
2. VOMITING
3. ABDOMINAL PAIN
4. CONSTIPATION
5. LACK OF ENERGY
6. OTHER - please specify
3. Do you feel these problems are caused by the prescribed food, or the special 
drinks? (circle answer)
1. FOOD
2. DRINKS
3. BOTH
4. If your child has been more constipated on the diet - have they needed any 
medicines for this?
1. NO
2. YES - please specify which medicines........................................................
5. Would you say that your child was more hungry on the ketogenic diet than he/she 
was before it was started? (circle answer)
1. NO
2. YES
6. Is your child able to finish all the food and drink that he/she has been prescribed? 
(circle answer)
1. NO
2. YES
7. Is your child having problems with the taste of the special drinks prescribed on 
his/her ketogenic diet? (circle answer)
1. NO
2. YES
143
8. Is your child having problems with the taste of the food prescribed on his/her 
ketogenic diet? (circle answer)
1. NO
2. YES
9. Have mistakes been made with your child's diet, for example, eating extra foods? 
(circle answer)
1. NO
2. YES
3. DON'T KNOW
10. Are you having any problems understanding and using the exchange system and 
recipes given to you? (circle answer)
1. NO
2. YES
(Ifyes, please specify the nature o f  the problem)
11. Since starting the diet, have you noticed any changes in your child's level of 
alertness? (circle answer)
1. MORE ALERT
2. LESS ALERT
3. NO CHANGE
12. Since starting the diet, have you noticed any changes in your child's awareness of 
his/her surroundings? (circle answer)
1. MORE AWARE
2. LESS AWARE
3. NO CHANGE
13. Since starting the diet, have you noticed any changes in your child's level of 
responsiveness? (circle answer)
1. MORE RESPONSIVE
2. LESS RESPONSIVE
3. NO CHANGE
14. Are there any other changes that you have noticed in your child since starting the 
ketogenic diet? (eg. mood changes, tasks and activities he/she is doing differently). 
Please specify below:
18. Overall, how do you feel that being on the diet has affected your child's quality of 
life? (circle answer)
1. IT HAS IMPROVED
2. IT HAS WORSENED
3. NO CHANGE
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19. Overall, how do you feel the ketogenic diet has affected your quality of life as a 
family? (circle answer)
1. IT HAS IMPROVED
2. IT HAS WORSENED
3. NO CHANGE
Thank you for your help
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CHAPTER 5 
GROWTH OF CHILDREN ON THE KETOGENIC DIET
Contents
5.1 Introduction
5.2 Subjects and methods
5.3 Results
5.4 Discussion
5.1 Introduction
Feeding difficulties and poor growth are widespread amongst children with 
neurological problems. Studies on growth in epilepsy have provided conflicting 
results. Lower than average heights have been reported in children with epilepsy 
living in a residential school (Round, 1981; Robinson et al, 1983), but subsequent 
studies on children with epilepsy living at home did not find any deviations in linear 
growth patterns (Tada et al, 1986; MacArdle et al, 1987; Kurowski et al, 1993). At the 
outset of this study, the author conducted a cross-sectional growth survey of 124 
children and young adults living in the residential centre from which we were 
additionally recruiting into our trial. Many individuals had poor linear growth; this 
was a particular problem in females and those between 14-17.9 years of age (Neal et 
al, 2003). It was concerning that, despite improvements in management of childhood 
epilepsy, the findings were similar to those reported 20 years ago. Multiple drug 
usage may cause particular problems; in one group of children who were found to 
have lower than normal height centiles, the individuals on a combination o f two 
medications had greater deficits in height than children taking either o f the drugs
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separately (Guo et al, 2001). Other side effects of such medications can be weight 
changes. A problem in some children with epilepsy may be a tendency to obesity, 
which will be worsened by inactivity, poor diet and lack of exercise.
There have been concerns about the growth of children on the ketogenic diet. 
Many children trying this treatment will have severe epilepsy, with associated 
neurological problems that will increase risk of nutritional problems, even before a 
restricted diet is commenced. Five studies have reported growth data from children on 
the diet, all following the classical protocol; these are summarised in Table 5.1. Three 
of the five were retrospective reviews, and only one study (Vining et al, 2002) 
contained a reasonable number of children; after accounting for initial dropouts, all 
the others had less than 40 children in their sample. Although Couch et al, (1999) 
found children were able to maintain linear growth and weight percentiles after 6 
months on the ketogenic diet, other results were less encouraging. Liu et al (2003) 
reported a decrease in weight, but not height centiles after 4 months. Three studies 
reported compromised linear growth (Vining et al, 2002; Williams et al, 2002; 
Peterson et al, 2005); this appeared to be more of a problem in the younger age group 
and after a longer time period on the diet. Growth data on MCT diet children is very 
limited, and there are no studies that examine the relation between calorie and protein 
intake and growth.
As part of the current study, the growth of children on both classical and MCT 
diets was investigated, using weight and height measures, and the association between 
growth and calorie and protein intake examined.
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Table 5.1 Studies reporting growth o f children on the ketogenic diet
Authors No Age Diet Study design Measurements Results
Couch et 
al, 1999
21 2-11-
yrs
Classical Retrospective
review
Height & weight at baseline &
6 mo on diet (as centiles for 
age), calculation o f  weight-for- 
height percent standard (as a 
percentage o f  50th centile value)
•  Significant increase in weight and height over 6mo
•  No change mean weight and height centiles, no weight & 
height centiles lower than baseline at 6mo
•  No falling below 100% standard weight-for-height
Vining et 
al, 2002
237 (133 
on diet at 
1 yr, 76 
at 2 yrs)
2mo- 
9.8 yrs
Classical Prospective 
study o f  4 
age cohorts, 
excluded 
severe 
physical & 
cognitive 
impairments
Height & weight (as z-scores) 
at baseline, 3mo, 6mo, 1 yr, 2 
yrs & 3 yrs on diet. Change in 
Z-score analysed by 4 age 
groups, also whether above or 
below median for age at 
baseline, also whether ambulant 
or communicating.
•  W eight z-score - lower after 3 mo in all groups; stable 
after 3 mo if  below median at baseline; decreased after 3 mo 
if  above median at baseline (sig. difference).
•  Height z-score -  no problems up to 6 mo, then declined. 
Sig. d iff between groups above & below median at baseline.
•  No children lost more than 2 z-scores up to 2 yrs
•  More problems in younger age groups
•  Greater decline in weight z-scores if  non-ambulant or non 
communicating.
Williams 
et al, 
2002
21 1-15.5
yrs
Classical Retrospective
review
Height while on diet, for up to 2 
yrs at unspecified intervals (as 
centiles for age)
• Height centile fell from baseline while on diet in 18 
children (86%), by visit 1 in 15 (71%).
Liu et al, 
2003
25 1-16
yrs
14
classical. 
11 MCT
Prospective
study
W eight & height at baseline and 
4 mo on diet (as centiles for 
age),
• No change in height centiles after 4 mo on both diets
•  W eight centiles decreased by 10% on both diets after 4 
mo, change more significant on classical diet
Peterson 
et al, 
2005
57
(39 on 
diet at 6 
mo, 33 at 
12 mo)
11 mo- 
20 yrs
Classical Retrospective
review
Height & weight (as centiles for 
age & z-scores) at baseline, 6 
mo & 12mo on diet. Weight- 
for-height centiles if under 2 
yrs, BMI if over 2 yrs.
Analysed by seizure control & 
ketosis level.
•  W eight z-score -  no significant change
•  Height z-score — significant.decrease from baseline — 12 mo, 
greatest fall between 6 mo & 12 mo
• W eight-for-height centile - significant.decrease from baseline 
-  12 mo, BMI centile -n o  change
•  No relation between seizure control & growth
•  High ketosis group had lower weight & height z-scores at 6 & 
12 mo than moderate ketosis group
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5.2. Subjects and methods
All children enrolled into the ketogenic diet trial had weight and height 
measures performed at the initial screening visit, the diet initiation visit, and at each 
subsequent follow-up clinic visit. Hospital clinic nurses, under the supervision of the 
ketogenic diet study nurse, performed all growth measures. Although families were 
also encouraged to regularly weigh the children at home between clinic visits (weekly 
if possible) to monitor the appropriateness of the dietary prescription, only clinic 
growth data is used for this analysis. Weight was measured to the nearest 0.1kg, using 
digital scales that weighed the subject while seated. Children who were unable to sit 
unaided were weighed while held by a parent or carer; this person was then reweighed 
on the same scales without holding the child, and the difference between the two 
weights calculated to give the child’s weight. The same set of scales was used for 
most of the children at the main hospital centre (Great Ormond Street); occasionally a 
different clinic area had to be used, however the weighing scales were all regularly 
cross calibrated according to hospital protocol. Children seen at the other two centres 
were weighed in the same way on similarly accurate sitting scales available at those 
sites, the same set of scales being used for all measures
Height was measured to the nearest 1mm in children who were able to stand 
using a wall-mounted stadiometer. Shoes were removed before the measurement. 
Children stood upright, looking straight ahead, with feet together and both heels and 
backs touching the upright back o f the scale. Children who were unable to stand 
independently had their length measured. Three people were usually needed for this 
type o f measurement (clinic nurse, ketogenic diet nurse and dietitian). The child was 
positioned on a flat surface with the head held lightly. The legs and back were held 
straight with toes pointing vertically, and length measured with a flexible tape
150
measure. This method could only be used if the child was able to lie flat; it was not 
possible to accurately monitor linear growth in a few children with severe scoliosis.
Weights and heights were compared with reference values by using standard 
deviation scores (Z-scores), which express the difference between the measurement of 
an individual and the median value o f the reference population as a proportion of the 
standard deviation of the reference population. An excel add-on computer program, 
lmsgrowth, was used to convert the measures into Z-scores; (Cole TJ, Pan. H. 
lmsGrowth: an Excel add-in to convert measurements to Z-scores) this used British 
1990 reference data (Freeman et al, 1995). Body mass index (BMI) (weight in 
kilograms divided by the square o f height in metres) was calculated for all 
individuals. The expression of this index as a Z-score, using the same computer 
program, based on BMI reference curves for children and young adults (Cole et al, 
1995), allowed the use of this index to assess body shape in terms of fatness/thinness.
In children that completed 12 months of the study, mean calorie and protein 
intakes per kilogram (kg) body weight were calculated, using the average o f the 
values for calorie and protein that were prescribed for the child at each of four time 
points, diet initiation, 3 months, 6 months and 12 months. As detailed in chapter 2, a 
child would have an initial energy and protein prescription calculated at the outset of 
the study; this would then be adjusted as regularly as needed, depending on 
subsequent weight changes.
Statistical analysis: Statistical analyses were performed on the growth data 
as outlined below, in order to answer the following questions:
1. What change, i f  any, occurred in the weight, height and BMI Z-scores o f  the 
children during ketogenic diet treatment?
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Student’s paired t-tests were used to compare Z-scores for weight, height and BMI at 
diet initiation (Z-scoreO), and 3 months (Z-score3), 6 months (Z-score6) and 12 
months (Z-scorel2). In children who continued the diet for 12 months, linear 
regression was used in each child separately to determine the gradient of the line of 
best fit of their serial weight Z-scores. The resulting gradient value was used to 
represent the overall change in weight in that child over the 12-month period. This 
process was also repeated for both height and BMI Z-scores.
2. Did the sex, ambulatory status or age o f  the child influence growth?
The unpaired t-test was used to compare mean Z-scoreO values of girls and boys, and 
of the ambulant and non-ambulant groups (ambulant defined as being able to walk 
aided or unaided). Three age groups were defined, as for the initial randomization (2-6 
years, 7-11 years, 12-16 years): analysis o f variance was used to do the same baseline 
comparison between the three different age groups. The paired t-tests to examine 
differences in Z-scores for weight, height and BMI between initiation and 3, 6 and 12 
months were performed separately for girls and boys, for whether the child was 
ambulant or non-ambulant, and for each of the three age groups. In the children who 
completed 12 months of treatment, the unpaired t-test was used to compare the mean 
gradient of the line of best fit o f serial Z-scores for weight, height and BMI between 
girls and boys, and the ambulant and non-ambulant groups. Analysis of variance was 
used to do the same comparison between the three different age groups.
3. Was there any correlation between baseline weight, height or BMI, and 
subsequent growth?
The difference between Z-score values at initiation and 3, 6 and 12 months was 
computed for each child, for weight, height and BMI. Pearson correlation coefficient
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was used to examine correlation between initiation (Z-scoreO) values and these 
differences. In the children who completed 12 months of treatment only, Pearson 
correlation coefficient was used to examine correlation between initiation (Z-scoreO) 
values and the gradient of the line o f best fit o f their serial Z-scores for weight, height 
and BMI. Two data groups were created for both weight and height values: children 
with initiation weight or height above median for age (Z-scores > 0), and children 
with initiation weight or height below median for age (Z-score < 0). The unpaired t- 
test was used to compare mean Z-scoreO values between these two groups, and to 
compare the mean gradient of the line o f best fit o f serial Z-scores for weight, height 
and BMI between the two groups.
4. Was there any difference between classical and MCT diet children?
Mean Z-scoreO values were compared between the two diet groups, using the 
unpaired t-test. The paired t-tests to examine differences in Z-scores for weight, 
height and BMI between initiation and 3, 6 and 12 months were performed separately 
for the two diet groups. In the children who completed 12 months of treatment, the 
unpaired t-test was used to compare the mean gradient of the line of best fit o f serial 
Z-scores for weight, height and BMI between the two diet groups.
5. Was there any association between growth and energy or protein intake? 
This was examined for the children who completed 12 months of treatment only. The 
mean energy and protein per kg intake over the 12 months was compared between the 
two diets, using the unpaired t-test. Pearson correlation coefficient was used to 
examine the correlation between the mean energy and protein intake per kg o f a child, 
and the gradient of the line o f best fit o f their serial Z-scores for weight, height and 
BMI.
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SPSS software version 13 was used for all statistical analysis.
5.2 Results
A total of 75 children were included in the growth data analysis: 42 boys and 33 
girls. 50 of these children were defined as ambulant, and 25 non-ambulant. 40 were 
aged between 2-6 years; 25 between 7-11 years, and 10 between 12-16 years. 37 were 
following the classical ketogenic diet, 38 the MCT. The full data on each child is 
given in the appendix to chapter 5. As not all children continued on the diet beyond 3 
months, the number of children providing weight and height data at each time point 
fell as the study progressed. Accurate height/length measures were not possible in all 
children, and calculation of BMI was only possible where weight and height data 
were both present. Table 5.2 shows the number of children providing data at each 
time point, and summarizes Z-scores, with mean, standard deviation, maximum and 
minimum values.
Table 5.2. Children providing growth data at each time point, and 
summary Z-score values for weight, height and BMI
Time point Measure
No. o f  
children 
providing 
data
Minimum 
; Z-score
M aximum
Z-score
Mean Z- 
score
Std.
Deviation
Initiation Weight 75 1 -4.100 3.283 .17224 1.478935
visit (Z- Height 64 -3.690 2.890 -.10061 1.351129
scoreO) BMI 64 -3.370 3.001 .41112 1.346118
3-m onth Weight 74 ! -4.300 3.331 -.00885 1.340424
visit (Z- Height 61 -3.850 3.690 -.16032 1.383647
score3) BMI 61 -3.150 2.561 .17218 1.223200
6 -m onth Weight 59 -4.550 3.220 -.14419 1.372597
visit (Z- Height 43 -4.060 2.820 -.27330 1.388418
score6) BMI 43 -3.210 2.452 .15760 1.251040
12 m onth Weight 40 -5.240 2.570 -.18950 1.532253
v isit (Z- Height 32 -3.880 2.300 -.50212 1.491335
sc o re l2 ) BMI 32 i  -4.640 2.150 .26182 1.349311
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Changes in Z-score values for weight, height and BMI over the course of the study 
period were plotted for all children, to visualise any overall trends (figures 5.1 -  5.3).
Figure 5.1. Change in weight Z-score over time (n=75)
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Figure 5.2. Change in height Z-score over time (n=64)
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Figure 5.3. Change in BMI Z-score over time (n=64)
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There is a general trend of falling weight and height Z-score during the course of 
ketogenic diet treatment. Changes in BMI Z-score are influenced by both weight and 
height. An increase in mean BMI Z-score at 12 months would be due to the fall in 
mean height of the children, rather than an increase in weight.
To examine the significance of any changes, paired differences in Z-score 
between diet initiation and 3, 6 and 12 months were computed (see Table 5.3). There 
was a significant fall in weight Z-score between diet initiation and 3, 6 and 12 months. 
Height Z-score showed no change between initiation and 3 months, but by 6 months 
there was a highly significant fall, which continued at 12 months. The significant fall 
in BMI Z-score between initiation and 3 months would reflect the fall in weight; by 6 
and 12 months the height had also dropped, and BMI showed no significant change.
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Table 5.3 Analysis of paired differences in weight, height and BMI Z- 
score.
Paired difference p value 
(2 tailed)Mean Std Deviation
Weight Initiation -  3 months -0.154 0.466 0.006**
Initiation -  6 months -0.213 0.665 0.017*
Initiation -  12months -0.321 0.588 0.001**
Height Initiation -  3 months 0.004 0.415 0.947
Initiation -  6 months -0.187 0.303 0.000***
Initiation -  12months -0.506 0.343 0.000***
BMI Initiation -  3 months -0.221 0.753 0.027*
Initiation -  6 months -0.137 0.854 0.305
Initiation -  12months -0.033 0.920 0.838
*signiflcant at P<0.05 level 
**significant at P<0.01 level 
♦ ♦♦significant at P<0.001 level
The gradient of the lines of best fit o f serial Z-scores for weight, height and BMI were 
computed for all children who continued the diet for 12 months, and used to represent 
the change occurring over that time in an individual child. The mean gradient for 
weight (n=40) was -0.0280 (range -0.17-0.06), for height (n=32) was -0.0434 (range 
-0.10-0.02), and for BMI (n=32) was -0.0044 (range -0.22-0.16), again indicating an 
overall downward trend in all growth Z-scores.
Influence o f  sex
Mean initiation weight, height and BMI Z-score values showed boys as a group to be 
slightly heavier, shorter and fatter than girls (see Table 5.4), but the differences were 
not significant (p=0.748, p=0.748, p=0.861 for weight, height and BMI Z-score 
respectively).
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Table 5.4 Mean diet initiation Z-score values (Z-scoreO), subdivided 
by sex, ambulatory status, age group and diet.
Category Mean Z-scor 
Weight
eO value (no. provic 
Height
ing data) 
BMI
Girls
Boys
0.110 (n=33) 
0.221 (n=42)
-0.034 (n=26) 
-0.146 (n=38)
0.375 (n=26) 
0.436 (n=38)
Ambulant
Non-ambulant
0.357 (n=50) 
-0.198 (n=25)
-0.045 (n=48) 
-0.267 (n=16)
0.509 (n=48) 
0.116 (n=16)
Age 2-6 years 
Age 7-11 years 
Age 12-16 years
0.616 (n=40) 
-0.281 (n=25) 
-0.471 (n=10)
0.264 (n=36) 
-0.330 (n=19) 
-1.072 (n=9)
0.666 (n=36) 
0.087 (n=19) 
0.078 (n=9)
Classical diet 
MCT diet
-0.069 (n=37) 
0.407 (n=38)
-0.391 (n=32) 
0.190 (n=32)
0.330 (n=32) 
0.492 (n=32)
Analysis of the paired differences in Z-scores between initiation and 3, 6 and 12 
months separately for girls and boys showed the fall in weight Z-score between 
initiation and 3 months to be significant for boys (p=0.010) but not girls (p=0.206); 
this was also the case at 12 months (p=0.007 for boys and 0.068 for girls). Neither 
group had a significant change in height Z-score at 3 months. The fall in height Z- 
score between initiation and 6 months, although significant in both groups, appeared 
more marked in the boys (p=0.003) than the girls (p=0.037). This was also the case at 
12 months (p=0.000 for boys and 0.002 for girls).
The mean gradients of the lines of best fit for serial Z-scores for weight, height 
and BMI were plotted for each sex separately in children completing the 12-month 
study period (see Table 5.5). There was no significant difference in mean gradient 
between girls and boys for weight (p=0.920), height (p= 0.732) or BMI (p= 0.923).
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Table 5.5 Mean gradient of best-fit line values for weight, height and 
BMI Z-scores, in children completing 12 months of treatment.
Category Mean gradient of line of best fit (number providing 
data)
Weight Z-score Height Z-score BMI Z-score
Girls -0.0288 (n=18) -0.0414 (n=14) -0.0018 (n= 14)
Boys -0.0272 (n=22) -0.0449 (n=18) -0.0065 (n=18)
Ambulant -0.0306 (n=29) -0.0459 (n=24) -0.0070 (n=24)
Non-ambulant -0.0210 (n=l l ) -0.0358 (n=8) 0.0033 (n=8)
Age 2-6 years -0.0333 (n=23) -0.0512 (n=21) 0.0027 (n=21)
Age 7-11 years -0.0102 (n=12) -0.0352 (n=7) 0.0029 (n=7)
Age 12-16 years -0.0459 (n=5) -0.0160 (n=4) -0.0492 (n=4)
Classical diet -0.0323 (n=19) -0.0429 (n= 17) -0.0097 (n=17)
MCT diet -0.0241 (n=21) -0.0440 (n=15) 0.0015 (n=l 5)
Baseline weight Z-score<0 -0.0126 (n=18) * *
Baseline weight Z-score>0 -0.0405 (n=22) * *
Baseline height Z-score<0 * -0.0404 (n=16) *
Baseline height Z-score>0 * -0.0464 (n=16) *
Baseline BMI Z-score<0 * * 0.0121 (n=13)
Baseline BMI Z-score>0 * * -0.0146 (n=19)
Total -0.0280 (n=40) -0.0434 (n=32) -0.0044 (n=32)
Influence o f  ambulatory status
Ambulant children as a group were heavier, taller and fatter than their non-ambulant 
counterparts at baseline (see Table 5.4), but the differences in mean weight, height or 
BMI Z-scoreO were not significant (p=0.126, p=0.574, p=0.316 respectively). 
Analysis of the paired differences in Z-scores between initiation and 3, 6 and 12 
months separately for ambulant and non-ambulant groups showed the fall in weight 
Z-score between initiation and 3 months to be highly significant for the ambulatory 
group (p=0.000) but not the non-ambulatory group (p=0.334); this was also the case at
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6 months (p=0.000 for ambulatory and 0.505 for non-ambulatory), and at 12 months 
(p=0.001 for ambulatory and 0.406 for non-ambulatory). A similar pattern of 
difference was seen with height Z-score: neither group had a significant change at 3 
months, but by 6 months this fell significantly in the ambulatory group (p=0.000), but 
not in the non-ambulatory group (p=0.950). By 12 months, both groups had a 
significant drop in height Z-score, but this continued to be more marked in the 
ambulatory children (p=0.000 for ambulatory and 0.032 for non-ambulatory).
The mean gradients of the lines of best fit for serial Z-scores for weight, height 
and BMI were plotted for the ambulatory and non-ambulatory groups separately in 
children completing the 12-month study period (see Table 5.5). There was no 
significant difference in mean gradient between the two groups for weight (p=0.596), 
height (p= 0.386) or BMI (p= 0.777).
Influence o f  age
The children at diet initiation appeared as a group to get lighter, shorter and thinner 
with increasing age, with a progressive fall in mean Z-score for weight, height and 
BMI in the older groups (see Table 5.4). This difference was significant for both 
weight and height Z-score (p=0.018 for both), but not BMI Z-score (p=0.233). 
Analysis of the paired differences in Z-scores between initiation and 3, 6 and 12 
months separately for the three age groups showed the fall in weight Z-score between 
initiation and 3 months to be significant in the 2-6 year old children (p=0.015) but not 
the older groups (p=0.593 for 7-11 year group, p=0.065 for 12-16 year group); this 
was also the case at 6 months (p=0.026 for 2-6 year group, p=0.506 for 7-11 year 
group and p=0.336 for 12-16 year group), and 12 months (p=0.006 for 2-6 year group, 
p=0.535 for 7-11 year group and p=0.074 for 12-16 year group). No age group had a
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significant change in height Z-score at 3 months, but by 6 months this fell 
significantly in the 2-6 year group (p=0.016) and the 7-11 year group (p=0.024), but 
not in the 12-16 year group (p=0.099). Changes in height Z-score were similar at 12 
months: this fell significantly in the 2-6 year group (p=0.000) and the 7-11 year group 
(p=0.025), but not in the 12-16 year group (p=0.126).
The mean gradients of the lines o f best fit for serial Z-scores for weight, height 
and BMI were plotted for each age group separately in children completing the 12- 
month study period (see Table 5.5). There was no significant difference in mean 
gradient between the three age groups for either weight (p=0.305) or BMI (p=0.495), 
but this was significant for height (p= 0.044).
Influence o f  baseline weight, height and BMI
There was a highly significant negative correlation between weight Z-score at the 
initiation visit, and the subsequent difference between this value and the values for 
that child at 3 and 6 months; this correlation was still present at 12 months but not as 
significant (see Table 5.6). Therefore the higher the Z-score at baseline, the more 
likely a child was to have a lower, or more negative value for the change in Z-score, 
that is, to drop down the Z-scores with subsequent ketogenic diet treatment. This 
correlation was not present for height, however BMI showed a similar pattern as 
weight (see Table 5.6).
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Table 5.6 Correlation between baseline Z-scores and subsequent 
change in Z-score between baseline and 3, 6 and 12 months
Correlation 
and change i 
0 and
between Z-scoreO 
n Z-score between 
3 months
Correlation 
and change i 
0 ant
between Z-scoreO 
n Z-score between 
6 months
Correlation between Z-scoreO 
and change in Z-score 
between 0 and 12 months
Correlation
coefficient
No. p value Correlation
coefficient
No. p value Correlation
coefficient
No. p value
Weight -0.425 74 0.000*** -0.464 59 0.000*** -0.329 40 0.038*
Height -0.006 60 0.967 -0.155 42 0.328 -0.282 32 0.112
BMI -0.444 60 0.000*** -0.357 42 0.020* -0.467 32 0.006**
* significant at P<0.05 level 
**significant at P<0.01 level 
***significant at P<0.001 level
In children who completed 12 months of treatment, the correlation between weight Z- 
score at initiation visit, and the gradient of the line of best fit of serial weight Z-score 
values was not significant (see Table 5.7). This correlation was also non-significant 
for height, but just significant for BMI.
Table 5.7 Correlation between baseline Z-scores and gradient of line 
of best fit of serial Z-score values
Correlation between Z-scoreO and gradient of 
line of best fit of serial Z-score values
Correlation
coefficient
No. p value
Weight -0.291 40 0.068
Height -0.296 32 0.100
BMI -0.411 32 0.020*
*significant at P<0.05 level
Children were divided into two groups, those with Z-scores above and below zero at 
baseline. At initiation 33 children had a weight Z-score less than zero and 42 had a Z- 
score greater than zero. The mean gradient of the line of best fit for serial Z-scores for 
weight was plotted for each group separately in children completing the 12-month
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study period (see Table 5.5); there was no significant difference between the two 
groups (p=0.079). At initiation, 33 children had a height Z-score less than zero and 31 
had a Z-score greater than zero. The mean gradient of the line of best fit for serial Z- 
scores for height was plotted for each group separately in children completing the 12- 
month study period (see Table 5.5); there was no significant difference between the 
two groups (p= 0.551). At initiation, 24 children had a BMI Z-score less than zero and 
40 had a Z-score greater than zero. The mean gradient of the line of best fit for serial 
Z-scores for BMI was plotted for each group separately in children completing the 12- 
month study period (see Table 5.5); there was again no significant difference between 
the two groups (p= 0.358).
Differences between classical and M CT diet children
At diet initiation, the children randomized to start the MCT diet appeared as a group 
to be heavier, taller and fatter than the classical diet group (see Table 5.4), however 
differences in mean Z-scoreO values were not significant for weight (p=0.165), height 
(p=0.085), or BMI (p=0.635). The changes in Z-score values over the course of the 
study period were plotted for the two diets separately (figures 5.4 -  5.6).
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Figure 5.4. Change in weight Z-score over time in children on the
MCT and classical ketogenic diets
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Figure 5.5. Change in height Z-score over time in children on the 
MCT and classical ketogenic diets
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Figure 5.6. Change in BMI Z-score over time in children on the MCT
and classical ketogenic diets
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These figures show a general downward trend in all Z-scores on both diets. This can 
be seen more clearly in the group who provided data at all of the four measurement 
time points. Weight Z-score data at all time points was available from 19 classical diet 
and 20 MCT diet children; the MCT diet group showed a progressive drop in mean 
weight Z-score throughout treatment, whereas this initially increased after 3 months in 
the classical diet group, followed by a drop at 6 and 12 months (see Figure 5.7). 
Height Z-score data at all time points was available from 14 classical diet and 13 
MCT diet children. Mean height Z-score had fallen slightly by 3 months in the MCT 
group only; both groups showed a progressive drop in mean height Z-score after 6 and 
12 months of treatment (see Figure 5.8). Changes in mean BMI Z-score are again
165
difficult to interpret due to the influence of both weight and height; the classical group 
appeared to become thinner over the 12-month period, while the MCT group became 
fatter (see Figure 5.9).
Figure 5.7 Change in mean weight Z-score while on classical (n=19) 
and MCT (n=20) diet treatment in children who provided data at all 
time points
06
04
0.2
<D
8 °  (0 »
N
c
s  -0 2 
2
Initiation 3 mo 6 mo 12 mo
-04
-06
-08
Time
■Classical diet 
•MCT diet
166
Figure 5.8 Change in mean height Z-score while on classical (n=14) 
and MCT (n=13) diet treatment in children who provided data at all 
time points
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Figure 5.9 Change in mean BMI Z-score while on classical (n=14) 
and MCT (n=13) diet treatment in children who provided data at all 
time points
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Analysis of the paired differences in Z-scores between initiation and 3, 6 and 12 
months separately for the two diet groups showed the fall in weight Z-score between 
initiation and 3 months to be significant for the MCT group (p=0.014) but there was 
no significant change in the classical group (p=0.146); this was also the case at 6 
months (p=0.014 for MCT and 0.332 for classical). By 12 months there was a 
significant fall in weight Z-score in both diet groups (p=0.014 for MCT and 0.041 for 
classical). Neither diet group had a significant change in height Z-score at 3 months, 
but by 6 months this fell significantly in both MCT (p=0.003) and classical (p=0.029) 
groups. By 12 months, the fall in height Z-score was highly significant for both diet 
groups (p=0.000 for MCT and classical). There were no significant changes in BMI 
Z-score on either diet.
The mean gradients of the lines of best fit for serial Z-scores for weight, height 
and BMI were plotted for each diet separately in children completing the 12-month 
study period (see Table 5.5). There was no significant difference in mean gradient 
between the two diet groups for weight (p=0.611), height (p=0.912) or BMI 
(p=0.748).
Association between growth and calorie or protein intake
The mean energy and protein intake of the 40 children on classical and MCT 
ketogenic diets who completed the study period is shown in Table 5.8.
Table 5.8. Mean energy and protein intakes over 12 months
Diet Mean intake over 12 months
Energy (kcals per kg) Protein (g per kg)
MCT (n=21) 63.2 1.67
Classical (n=19) 61.1 1.13
P value 0.651 0.000
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There was no significant difference in mean energy intake over the 12 months 
between the two diets, but the MCT group had a significantly higher protein intake. 
There were no significant correlations between the mean energy or protein intake per 
kg o f a child, and the gradients o f the lines of best fit o f their serial Z-scores for 
weight, height or BMI (see Table 5.9).
Table 5.9 Correlation between energy and protein intakes and 
gradient of line of best fit of serial Z-score values
Correlation between mean energy 
intake (kcals /kg) and gradient of line 
of best fit of serial Z-score values
Correlation between mean protein 
intake (g/kg) and gradient of line of 
best fit of serial Z-score values
Correlation
coefficient
No. p value Correlation
coefficient
No. p value
Weight 0.050 40 0.760 0.029 40 0.858
Height 0.448 32 0.108 -0.219 32 0.453
BMI -0.206 32 0.479 -0.191 32 0.514
5.4. Discussion
The Z-score results for weight, height and BMI in these children on two 
ketogenic diets range widely, from below -3  to above 3; they are clearly a group of 
varying size and shape, who span the whole centile range. Although the use o f mean 
Z-scores at each time point may be limited by differing numbers included at each 
point, they do indicate a downward trend in both weight and height during the course 
of the study. The paired differences show the fall in weight Z-score to be significant at 
all time points, and height highly significant by 6 and 12 months.
These results add further weight to the growing body of evidence that the 
ketogenic diet does appear to impact adversely on growth. Although some of the 
previous study results appear conflicting (see Table 5.1), a large part o f the
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discrepancy may be due to differing follow up measurement periods. Couch et al 
(1999) found no problems with either weight or height in their group of children after 
6 months on the diet, and Liu et al (2003) found no height change after 4 months, but 
weight to decrease by 10%. These are short time frames within which to assess 
growth trends; any negative impact on longitudinal height gain will not usually be 
noticed until after a few months. In contrast, Williams et al (2002) reported height 
centiles to fall from baseline in 86% of their children after 24 months on the diet, and 
Peterson et al (2005) found height Z-score to show a significant decrease from 
baseline by 12 months, with the greatest fall between 6 and 12 months. No significant 
change was found in weight Z-score. Vining et al (2002), also reported height Z-score 
to show no problems up to 6 months, then to decline. It is clear that the more long­
term the measurement period, the more accurately a conclusion can be reached about 
the impact of ketogenic diet treatment on growth.
Changes in BMI Z-score are more difficult to interpret; this is influenced by 
weight and height, changes in either resulting in a change in BMI. An overall fall in 
an individual’s weight and height would be likely to manifest as no change in a BMI 
Z-score. Therefore there appeared to be no significant changes in BMI over the study 
period, similar results to Peterson et al (2005), who also reported using BMI centiles, 
and found no change after 12 months. The importance of BMI in dietary efficacy has 
been questioned: a recent study has shown no correlation between changes in BMI 
and seizure control in children on a ketogenic diet (Hamdy et al, 2007).
The use of a gradient o f line of best fit of serial measures in children who 
completed 12 months of dietary treatment is recommended as the appropriate 
statistical methodology for this type of data (Matthews et al, 1990). This enables a 
mean gradient to be obtained for subgroups of children on the diet, which allows a
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statistical comparison between these groups. Initially the fall in weight and height 
appeared more marked in boys, in the ambulant group, and in the younger children. 
When a mean gradient was obtained for each of these sub-groups, no significant 
differences were found between the sexes, or non-ambulant and ambulant groups. The 
three age groups had a significantly different height gradient, which fell with 
increasing age, indicating more o f a fall in Z-score; this significance was not seen for 
weight. Vining et al (2002) also examined age and ambulatory status as variables. 
They reported similar problems in younger age groups, however found a greater 
decline in weight Z-scores if non-ambulant. This discrepancy in results may have 
been due to our ambulant group being heavier than their non-ambulant counterparts at 
baseline, thus having a lower calorie prescription at the outset.
It would certainly seem expected that changes in weight Z-score could be 
influenced by baseline weight. The correlation between weight and BMI Z-scores at 
initiation and subsequent changes in Z-score seen in our results would not be 
surprising; the heavier and fatter a child initially, the more likely a diet would be 
designed with less calories, so child would be expected to have poorer weight gain. 
When growth trends in our study were examined in the group completing 12 months, 
by gradients of the line of best fit of serial measures, there were no significant 
difference in mean gradients for any of the three Z-scores between groups above and 
below median at baseline for the respective growth indicator. This is in contrast to 
results reported by Vining et al (2002) who found that weight Z score remained stable 
after 3 months if weight was below median at baseline, but continued to decrease if 
weight was above median at baseline; this difference was significant. The differing 
results are likely to be due to our considerably smaller sample size. Vining et al 
(2002) had 133 children remaining on the diet at 12 months out of an initial 237. A
similar drop out rate occurred in our sample, with only 40 children providing weight 
data and 32 height data by 12 months. This is a clear limitation of our study, as sub­
groups for statistical comparisons were small. It is likely that the difference in mean 
weight Z-score gradient would achieve significance with a larger sample. Indeed, the 
correlation between baseline weight Z-score and the gradient of the line o f best fit o f 
serial weight Z-score values was significant for BMI, and only just below significance 
for weight.
The use of a randomization process should equal out the two diet groups, so it 
was surprising to find the MCT group considerably heavier, taller and fatter than the 
classical group at initiation, even if this difference was not statistically significant. 
This difference may be responsible in part for the differing pattern of weight Z-score 
between children on the two diets. Weight Z-score appeared to initially increase in the 
classical diet group, the subsequent decline was not significant until 12 months on the 
diet; however it showed a significant fall at all time points in the MCT diet group. 
This was the opposite of results reported by Liu (2003) who found more problems 
with the classical diet group after 4 months. Early weight changes between the two 
diets would be expected, due to the differing nature of the initiation process. As 
detailed in chapter 2, MCT fat in our study is built up over a week or two, resulting in 
reduced calories, whereas the classical diet was commenced on a full energy 
prescription if tolerated. Details of dietary prescriptions used by Liu et al (2003) are 
not available: it may be they were more generous in calories on the MCT diet, with a 
quicker increase to full prescription. It has also been suggested that the differing 
metabolic pathways and energy costs of MCT metabolism may lead to enhanced 
thermogenesis, as compared to their long chain counterparts (Papamandjaris et al, 
1998). If so, this would affect energy balance by increasing energy expenditure and
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reducing weight gain in the MCT group A statistical comparison of weight Z-score 
between the two diet groups in children completing our study, using the mean 
gradients of line of best fit, showed no significant difference between the classical and 
MCT diet children. The pattern o f change in height Z-score was very similar for the 
two diets, both showing significant decline by 6 and 12 months; again there was no 
significant difference between the mean gradients for height Z-score. There were no 
significant changes in BMI on either diet.
A limitation of our methodology was that the study did not collect data on 
pubertal staging. Although only 10 children were aged between 12-16 years old, a 
small number of this group may have gone through puberty, and this could be a 
potential confounder in the results that we have been unable to control for.
The mean energy intakes over 12 months in the group of 40 children who 
completed the study were not significantly different between the two diet groups, 
however, as would be expected from the differing nature of the dietary prescriptions, 
the MCT group had a significantly higher mean protein intake per kg body weight. 
Despite suggestions that a low protein intake may be a factor in poor growth on a 
ketogenic diet, the more generous protein allowance of the MCT diet in this study 
clearly did not improve outcome; growth was not significantly different between 
classical and MCT diet children. There also appeared to be no correlation between 
either the energy or protein intake of a child and the gradient of their lines o f best fit 
for weight, height or BMI. This would throw into question the importance of a role 
that either of these two nutrients would have in determining the long-term growth 
outcome of a child on this diet, and raises the question of what else might be causing 
the problems. Could it be persistent high ketones, or some other, as yet unknown 
process having an influence? The question must also be asked -  what would the
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growth of this group be like had they not been on a ketogenic diet? The nature of 
epilepsy, frequent seizures, and anti-epileptic medications, all are known to adversely 
affect growth, and whereas the ketogenic diet clearly does play a part, without a much 
larger trial, designed to answer this question specifically, the extent will be unknown.
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APPENDIX. Table A 5 .1. Growth data for all children
:udy Diet Sex Ambulant Z-scoreO Z-score3 Z-score6
No. Wt Ht BMI Wt Ht BMI Wt Ht
1 2 F No -1 995 -1 188 -1 138
2 2 M Yes 3 283 2881 2 324 3 331 2 715 2 561 3220 2693
3 1 F Yes -0 260 0650 -1 040 0030 0680 -0 610 0430 0 400
4 2 M Yes 1 035 0877 0 747 1 434 0679 1 482 1 313 0 734
5 1 M No -0 195 -0 001 -0 345 0.279 0 520 0413
6 2 F Yes -0212 -0 998 0 383 -0 174 -0 968 0409 -0 377 -0 828
7 1 M Yes -1.487 -1 511 -0 906 -1 281 -1 483 -0 620 -1 024 -1 646
10 2 F Yes 0676 0 399 0673 0 371 0 528 0277 0030 0 350
11 1 M Yes 1 550 1.461 0750 1 302 1 338 0 550 1 824 0 932
16 1 F Yes -1 133 -1 050 -0 603 -0 922 -1.176 -0 226 -1 060 -1 320
17 1 M No -1 092 -1.177 -0 363 -1 344 -1 423 -0 468 -1 605
19 1 M Yes -2 694 -2 399 -1 548 -2.038 -2653 -0 406 -2 750 -2 080
20 2 F No 0 411 0 036 0610 0 190 0 350
21 1 M Yes 0 782 0745 0 515 0 867 0 357 0942 0 780 0 030
22 2 F No 1 732 1 500
23 2 M Yes 0 374 -0 613 1 183 0.267 -0 690 1.108 0.490 -1 120
25 2 M Yes -1 310 -0 842 -1 212 -1.828 -0 914 -1 936 -2 180 -1 020
26 1 M No 0 384 0 209
30 2 M Yes -1 047 -1 887 0 563 -1 640 -2 280 0.190
31 1 M Yes -1 570 -2030 -0 560 -1.710 -1 900 -0 880
33 1 M Yes 1 317 0 677 1 220 0890 0.380 0 920
35 2 M No 2.829 1 074 3001 0750 1 700 -0 680 0200
36 2 M Yes -0 040 -0 760 0.560 -0 390 -0 640 -0.040
37 2 F Yes -1 190 -1 240 -0 430 -1.200 -1 380 -0 310 -1 030 -1 310
38 2 F Yes 0.050 -0 550
Zscore12 Age Z-scoreO Slope of Slope of Slope of Mean kcals Mean g
Wt Ht BMI group* Wt Ht BMI best fit line best fit tine best fit line per kg** protein
for weight** for height*** for BMI*** per kg**
2 <>0
2 570 2 300 1 880 1 >0 >0 >0 -0 06 -0 05 -0 04 71 7 1 8
1
OAV >0 <0
1.180 0 350 1 370 1 >0 >0 >0 0 00 -0 04 0 0 4 45.4 1.5
-0 590 -0 450 -0 450 1 <>o <0 <0 -0 04 -0 04 -0 01 76 0 12
2 <>0 <0 >0
-1.410 -1 830 -0 480 3
OA <0 <0 001 -0 03 00 4 46.2 1.0
-0.170 0460 -0.190 3 >0 >0 >0 -007 0 0 0 -0 07 33 9 0 9
1.770 0390 2.150 1 >0 >0 >0 0 03 -0 09 0.13 74.0 1 1
-1.580 -1 300 -0.860 3
OAV <0 <0 -0 04 -0 02 -003 41 7 0 9
-1 920 -1.660 -1 090 1 <>o <0 <0 -0 07 -0 04 -0 06 68 2 1 4
-3030 -2 940 -1.530 2 <>0 <0 <0 -0 05 -0.04 -0 04 80 1 1 4
-0 460 1 >0 >0 >0 -007 744 1.9
0630 0000 0 880 2 >0 >0 >0 -0 02 -0 06 0.02 60 5 1.0
2 >0
-0 360 -1 290 0810 1 >0 <0 >0 -0 06 -0 06 -0.02 7 9 4 2 0
2 <>0 <0 <0
1 >0
1 A V o <0 >0
3
OA <0 <0
1 >0 >0 >0
1 >0 >0 >0
2 <>0 <0 >0
-1.450 -1 770 -0370 1 A V O <0 <0 -0 02 -0 04 0.00 764 19
3 >0
BMI
2452
0240
1 283
0 331
0020
-0.067
0 260
1.708
-0.260
-2 160
1 050
1 810
-2 360
-0 180
175
!udy Diet Sex Ambulant Z-scoreO Z-score3 Z-score6
No. Wt Ht BMI Wt Ht BMI Wt Ht
39 2 F Yes 0 310 0 480 -0020 0.120 0 320 -0 160 -0 300 0.100
40 1 M Yes -0 940 -1 750 0370 -1.120 -1.410 -0240 -1.160 -2.100
43 1 M Yes 2220 1 700 1 520 1.770 0 590 1.890
45 1 F No 1 540 -0 260 2210 1.260 -0 600 2.180
48 1 F Yes 1 840 0 550 2 040 1.500 0630 1.570 1.230 0 590
49 2 F No -0 110 -0 390
50 1 F No -0810 -1.590 0 190 -0.950 -1 420 -0.140 -1.270 -1 650
51 1 M Yes -4 100 -3690 -3020 -4 300 -3850 -3.150 -4.550 -4 060
52 2 M Yes 0 580 -0 290 1.040 0240 -0.510 0 760 0 390 -0 550
53 2 F Yes 0410 -0 300 0900 0280 -0 040 0450 0.110 -0 090
55 1 M No -0 570 -0490 -0 440
57 1 F No 1 660 0010 2.220 1.390 0600 1.440 -0 050 0640
59 1 F No -2680 -1 890 -2 530 -1.960 -1.790 -1.500 -1.640
60 1 M Yes 0 090 -1 250 1 120 -0 190 -0 900 0470
61 1 F Yes 2 220 0 770 2 270 1.970 0620 2.100 1.620 0 220
62 1 M Yes 0310 -1 120 1 250 0.110 -0 840 0 800 0.190 -1.190
64 2 M Yes -0 630 -0 570 -0470 -0 550 -0 730 -0210 -0 630
66 2 M Yes 2.660 1 040 2 900 2 050 0970 2 210 1.930
67 2 F Yes -0 230 -1 500 0 760 -0 220 -1.500 0 760 -0 660 -1 340
71 1 M Yes 0650 0080 0880 0 390 -0 080 0 650 0 700 -0 060
73 2 M Yes 0420 1.020 -0.210 0070 1.020 -0 810 0.140 0 850
75 1 F Yes 1 090 2220 -0 280 1.330 2 300 0050 1.020 1.960
76 2 M Yes -1 260 -1 350 -0 950 -1.400 -1.390 -0.820 -1.660 -1.630
79 1 M No -0 810 -0 150 -1.180 -1.350 -0670 -1 420
80 1 F No 1 050 0950 0 750 1.700 1.290 1.390 1.390 0460
82 2 M Yes 2.320 0750 2 540 2.150 1.030 2.120 1.650 0 850
83 2 M Yes -0 790 0 160 -1.560 -0 530 1.080 -2.330 -1.430 -0 740
Z-score12 Age Z-scoreO Slope of Slope of Slope of Mean kcals Mean g
Wt Ht BMI group* Wt Ht BMI best fit line best fit line best fit line per kg‘* protein
for weight** for height*** for BMI*** per kg**
-0.120 -0 260 0 000 2 >0 >0 <0 -0 04 -0 06 0 0 0 6 7 2 1 7
-1.260 -2.550 0600 1 <>0 <0 >0 -0 02 -0 08 00 4 7 56 12
1 >0 >0 >0
1 >0 <0 >0
1.090 0220 1.320 1 >0 >0 >0 -0 06 -0 03 -0.06 522 1.1
2 <>0
-0210 -2 070 1.210 1 <>0 <0 >0 0 0 5 -0 05 0 09 71.0 1.1
-5 240 -3.880 -4 640 3 <>0 <0 <0 -0 10 -0 02 -0 14 83.2 15
0200 -1.010 1.060 1 >0 <0 >0 -0 02 -0 06 001 79.0 1 9
0.240 -0.540 0 750 1 >0 <0 >0 -001 -0 03 -001 60.6 17
-0 620 2 <>0 -001 47 1 10
-0210 0050 -0 300 1 >0 >0 >0 -0 17 -001 -0 22 50 5 11
-1.910 -1 690 -1.550 2 <>0 <0 <0 0 06 0 0 2 0.06 532 1.0
2 >0 <0 >0
0690 -0410 1.350 1 >0 >0 >0 -0 13 -0 10 -0 08 55 8 1 0
3 >0 <0 >0
-0 430 2
oA <0 <0 001 58.6 14
1.170 0460 1.330 2 >0 >0 >0 -0 12 -0 05 -0.12 49 1 1.2
-0470 3 A V O <0 >0 -0 02 31 6 0 9
3 >0 >0 >0
0590 0700 0.340 2 >0 >0 <0 0 02 -0 03 00 6 59.9 1.5
1.420 1 640 0750 1 >0 >0 <0 002 -0.05 00 8 6 5 0 12
-1.450 -1.610 -0 710 2 A V O <0 <0 -0 02 -0 02 0.02 65.5 17
1 <>0 <0 <0
1.040 0810 0 790 1 >0 >0 >0 -0 02 -0.03 -001 54 0 1 0
1.170 0.570 1.190 1 >0 >0 >0 -0 10 -0 02 -0 11 71 2 2 0
1 <>0 >0 <0
BMI
-0 460
0 360
1 240
-0 350
-3210
0980
0230
-0 660
1 990
1 180
0220
1 030
-0 530
-0 170
-0 980
1 550
1.610
-1 470
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Study Diet Sex Ambulant Z-scoreO Z-score3 Z-score6 Z-ecore12 Age Z-scoreO Slope of Slope of Slope of Mean kcals Mean g
No. Wt Ht BMI Wt Ht BMI Wt Ht BMI Wt Ht BMI group* Wt Ht BMI best fit line 
for weight**
best fit line 
for height***
best fit line 
for BMI***
per kg** protein 
per kg**
84 1 M Yes 1 420 1 200 1 270 1 270 0850 1 260 0 940 0610 1.140 1 260 0.410 1.480 2 >0 >0 >0 -001 -0 06 002 53 5 1.1
85 2 F Yes 0 220 0220 0 170 0.250 -0 040 0450 0 480 -0.270 0 940 0200 1 >0 >0 >0 0 0 0 62 9 1.7
86 2 M No 0 510 0 970 -0 310 0 510 0430 0 280 1 >0 >0 <0
88 1 M Yes 1 730 0 140 2 240 1 100 0 150 1 410 1 >0 >0 >0
89 2 F No -2280 -0 190 -3 370 -2 100 -0 640 -2490 -1 740 -0.660 -1 890 -1 830 -1.270 -1.370 1 <>0 <0 <0 0 04 -0 08 0.16 93 5 2.5
91 2 F Yes -0 730 -0 910 -0 290 -0 860 -0.770 -0 600 -0 950 -0 980 -0 570 -0700 2 <>0 <0 <0 0 0 0 69 8 1.7
92 1 F No 2 080 2.230 1 500 1.440 3690 -0 410 0 990 2 >0 >0 >0
93 2 F Yes 2 150 2890 0510 1 140 2 820 -0 970 1.730 1.760 0.980 1 >0 >0 >0 -0 04 -0 09 00 4 68 2 2.1
94 2 M No -0410 -0 330 -0.330 -0970 0 300 0010 2 <>0 0 03 38 7 1.1
95 2 M Yes 2 400 2 460 1 150 1 940 2250 0670 2 630 2 330 1 680 2.540 2.170 1.740 1 >0 >0 >0 0 03 -0 02 007 697 18
97 1 M No -1 180 -1 530 -0 040 -1 210 -1 870 0 310 -1 380 -1 660 -2 330 0.200 1 <>0 <0 <0 -0 04 -0 06 001 53 1 1.1
98 1 F Yes -0 020 -1 750 1 150 -0 540 -1 950 0670 -0610 -2 110 0 700 2 <>0 <0 >0
99 2 F No 0 860 0 510 0 300 1 >0
too 2 M Yes 0 750 1 300 -0 080 0 700 1 160 0 000 1 >0 >0 <0
101 1 F No -0 310 -1 550 1.010 -2 310 -1 780 -1 490 -2 070 -1 500 -1 440 1 <>0 <0 >0
103 2 F Yes 1.020 1 270 0620 0 860 1 440 0280 0820 1 230 0 340 2 >0 >0 >0
104 1 M Yes 0940 0400 0 140 0450 0.100 1 >0
108 1 F No -0 610 -0 650 -0 590 1 <>0
110 2 M Yes 2 130 0.770 2 230 1 480 3 >0 >0 >0
111 2 F Yes 0090 -0 340 0 350 -0.140 -0 450 0.110 -0470 -0 740 -0 140 2 >0 <0 >0
112 1 M No -1 740 -1 200 -1.490 -1 150 0.210 -2 140 -0.630 2 <>0 <0 <0
118 1 F No -3 220 -2.700 -2 160 2 <>0
119 2 M Yes 0480 -0.730 1 430 0 840 -0 190 1 420 0450 1 >0 <0 >0
* 1 = 2-6yrs, 2 = 7-11 yrs, 3 = 12-16 yrs
** Only included i f  provided 12 month data for w eight Z-score
*** Only included if  provided 12 month data for height Z-score
1 7 7
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6.1. What have we achieved?
This study is an exciting contribution to the ketogenic diet literature. It is the 
first randomized controlled trial that has been conducted on this treatment, and is 
therefore the strongest scientific study to date and an extremely important milestone 
in the history of the diet. It is clear evidence that the diet does work, and should be 
routinely included in the treatments available for all children with intractable epilepsy. 
Although the classical diet may induce greater ketosis in children, there does not 
appear to be any significant advantage o f using either the classical or MCT diet 
protocols in terms of either efficacy or tolerability. The impact of the diet on growth 
trajectories over the 12 months is also not significantly different between the two 
protocols. It is clear from these results that both ways of doing the diet have their 
place in the treatment of this group of children.
The achievements of the study are not limited to these results alone. Over the 
past six years, there has been a considerable change in awareness of the ketogenic diet 
in the UK. Publicity about the trial, both among health professionals and the media, 
has increased knowledge of the treatment. The development of a ketogenic diet 
charity by a mother of one of our study children has also made a significant 
contribution to the demand for this treatment. The charity, set up to provide support,
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information, and dietary accessibility for families throughout the UK, has seen a huge 
growth over the past two years, and has been able to provide funding for some 
individual children to do the ketogenic diet, grants to enable more dietetic hours in 
certain hospitals, and for further research. The electronic ketogenic diet calculator 
(EKM) that was developed by the author in conjunction with a computer programmer 
has also contributed to these changes taking place. By allowing dietitians to calculate 
recipes at a fraction of the speed of hand calculations, and by also empowering many 
families with the freedom to calculate their own meals, this has released considerable 
dietetic time, enabling more children to be given the chance to try the diet. In 
addition, the Ketogenic Diet Professional Advisory Group (ketoPAG) of the UK has 
seen expansion of both numbers and activities, the latter including organisation of two 
national and a recent international conference. These far-reaching effects of our study 
have been very encouraging
6.2. Where do we go from  here?
So what is the way forward? This will be in two main areas -  research and 
education. There are a number of areas where future research would be very 
beneficial. The current study has only assessed children up to 12 months on treatment. 
After this, they were transferred to their local centres for on-going follow-up. It was 
not possible to continue diet monitoring o f all children at the main study centre due to 
lack of NHS resources; this transfer was agreed with local centres prior to any child 
starting a ketogenic diet. As the most important outcome when measuring efficacy 
will be prolonged periods of seizure remission (Chadwick, 1997), an obvious follow- 
on to this study would be the research review of children at 24 months post diet 
initiation, and at further time points beyond then if  possible. Other studies have shown
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continued favourable outcome after 12 months, both in children who continued the 
diet for 12 months (Hemingway et al, 2001), and those who discontinued it earlier 
(Marsh et al, 2006). Although similar success rates in our children were hoped for, 
there is concern that many children have not done so well if transferred to a local 
centre with limited ketogenic diet experience. Some have actually discontinued 
successful diet treatment due to a lack of support from their local team. The extent of 
any problems in this area do need to be examined, to ensure no unnecessary loss o f 
the benefits that many children have obtained from their first year on the diet. 
However it is not possible from our study to recommend an ideal length o f time that a 
child should continue on the diet. Whereas some children who have become seizure 
free will be able to discontinue treatment after a couple of years without any 
recurrence of problems, many other children will need to stay on the diet for much 
longer to sustain the benefits. Further research into this area will help answer these 
questions.
Our study only included children over 2 years of age. It has already been 
speculated that the exclusion of younger children may have gone some way to explain 
differences in our results from some other published studies. The diet has been shown 
to be extremely successful in infants (Nordli et al 2001, Kossoff et al 2006), and it 
would be important to include this group in future randomized controlled trials.
Since commencing this study, there have been reports of different types of 
‘ketogenic style’ diets, without such strict dietary regimens, that may also be of 
benefit for seizure control in children with intractable epilepsy. A modified Atkins 
diet, very low in carbohydrate, but without calorie, protein or fluid restriction has 
been shown to be effective (Kossoff et al, 2006; Kang et al, 2007). A low-glycaemic 
index treatment, with more liberal total carbohydrate but restricted to the low
180
glycaemic index varieties, has also been successful in 20 patients (Pfeifer & Thiele, 
2006). It is likely that different types o f diet will suit different types o f patient, 
depending on age, food preferences, feeding method and family circumstances. Future 
research on these other types of dietary treatments for epilepsy, as compared to the 
two more established classical and MCT ketogenic diets, will enable more patient 
choice and tailoring to individual needs.
The education of relevant health professionals, mainly dietitians and 
paediatricians or paediatric neurologists, is essential to increase both acceptability and 
availability of the ketogenic diet, and thus meet the demand for this treatment. The 
education of dietitians is of particular concern to the author. There is very scarce 
literature that provides a practical guide to how to implement the ketogenic diet in 
practice. This is limited to a chapter in the dietitian’s paediatric handbook (Neal & 
MacGrath, 2007), and an American handbook (Freeman, Freeman & Kelly, 2000), the 
latter based only on the classical diet and using American food values. The lack of 
information on the MCT diet is especially worrying. Identifying the importance o f a 
stricter approach to management o f this protocol, alongside a more flexible approach 
to its fine-tuning, especially with adjustments to the proportion of energy provided 
from the MCT fat, has already been discussed. The author strongly believes that this 
will contribute to maximizing both efficacy and tolerability of this version o f the 
ketogenic diet.
The concern about the lack of support that some ketogenic diet children have 
received when transferred to their local hospital has been highlighted. There are also 
many children across the UK who have been unable to try the treatment, or who have 
seen long delays in initiating it, due to the lack of resources and education o f local 
teams. It is hoped that the development of national educational resources related to the
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implementation of both types of ketogenic diet in the UK will be a follow on from this 
work. There is a need to develop best practice protocols for diet calculation, initiation, 
maintenance, and monitoring. Questions to be addressed include who should do the 
diet, and where? Should this treatment be available only in specialist centres, or more 
widely across the country? The vision is that this educational work will be done in 
conjunction with both the parents charity and ketoPAG, and will include the regional 
training of dietitians and other health professionals where needed. This study has 
been just the beginning of what is an exciting time in the history of the ketogenic diet 
in the UK, and has provided a stepping-stone from which it can now continue to move 
forward in many directions.
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